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Abstract 
Glomerular filtration rate (GFR) is regarded as the best measure of kidney function. It can 
either be measured or estimated. This dissertation aims to provide a better understanding of 
GFR measurement in order to improve its performance and interpretation. It also aims to 
validate GFR estimation in local populations and to demonstrate the utility of simple 
adaptations of existing equations to improve estimation. 
On completion of a GFR measurement, various quality control (QC) checks are performed to 
ensure the accuracy of the result. However, this requires comparison with clearly defined 
reference ranges. In a study of healthy, potential kidney donors, reference data for two QC 
parameters were defined. 
In a study analysing the effect of measurement errors on GFR, the single-sample method was 
found to be the most robust technique overall, although for all methods measurement error was 
generally insignificant compared to expected biological variation in GFR. However, at low 
GFR values measurement errors were shown to affect all methods significantly. Errors in 
measurement of the doses were found to have the greatest impact on accuracy.  
Using nuclear medicine techniques 51Cr-ethylenediaminetetra-acetic acid (51Cr-EDTA) is the 
most commonly used and widely studied exogenous filtration marker. However, 99mTc-
diethylenetriaminepenta-acetic acid (99mTc-DTPA) is gaining favour because of a few technical 
advantages it has over 51Cr-EDTA, its lower cost, and recent issues with the availability of 
51Cr-EDTA. In response to a systematic review suggesting that GFR measurement from the 
plasma clearance of 99mTc-DTPA was inaccurate, a mini meta-analysis was performed that 
demonstrated excellent agreement between 51Cr-EDTA and 99mTc-DTPA clearance, thus 
supporting the use of 99mTc-DTPA as a reliable alternative.  
Where GFR cannot be routinely measured, it is frequently estimated using a creatinine-based 
equation. The use of any equation first requires validation in the population in which it will be 
used. In a study evaluating the Modification of Diet in Renal Disease (MDRD) and Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equations in non-cancer, mixed 
ancestry adults, both equations were found to perform well. However, in a study that evaluated 
equations in adults with cancer, the GFR estimates were found to be biased and imprecise. This 
study highlighted the limitations of using estimated GFR for guiding management decisions in 
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cancer patients. A further study evaluated 11 estimating equations in non-cancer and cancer 
populations of South African children. The accuracy of all estimates was poor, particularly in 
the cancer group. Given the extensive use of GFR estimates in South Africa, these findings 
have profound implications for their use in the management of children and adults with cancer 
in this country. 
Developing new equations for a specific population requires large datasets and incurs costs that 
are impractical in most middle- or low-income countries. A simpler alternative is to adapt 
existing equations. This work demonstrates the application of a relatively simple approach to 
adapt existing equations, using modest amounts of data and a readily available Microsoft® 
Excel-based tool. While this approach is simple and likely to require further refinement, its 
utility was demonstrated in paediatric and adult cancer populations. 
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Opsomming 
 
Glomerulêre filtrasiespoed (GFS) word as die beste maatstaf van nierfunksie beskou. Dit kan 
gemeet of geskat word. Hierdie proefskrif se doel is om ‘n beter begrip van GFS meting te 
bewerkstellig teneinde die metode se verrigting en interpretasie te verbeter. Verder word 
gepoog om GFS skatting in plaaslike populasies te valideer en om die nut van eenvoudige 
aanpassings van bestaande vergelykings om skatting te verbeter, te demonstreer.   
Na voltooide GFS meting word verskeie gehaltetoetse gedoen om die akkuraatheid van die 
resultaat te verseker. Dit verg egter vergelyking met duidelik gedefinieerde 
verwysingswaardes. Verwysingsdata vir twee gehalteparameters is in ’n studie van gesonde 
moontlike nierskenkers daargestel.  
In ‘n studie wat die effek van metingsfoute op GFS ontleed, is bevind dat die enkel-monster 
metode algeheel die mees robuste tegniek is, alhoewel metingsfout vir alle metodes oor die 
algemeen vergeleke met verwagte biologiese variasie in GFS nie betekenisvol was nie. By lae 
GFS waardes is egter aangetoon dat metingsfoute alle metodes betekenisvol beïnvloed. Daar 
is getoon dat foute in meting van die dosis die grootste impak op die akkuraatheid het.  
51Cr-etileendiamientetra-asynsuur (51Cr-EDTA) is die mees algemeen gebruikte en bes 
nagevorste eksogeene filtrasiemerker in kerngeneeskundige tegnieke om GFS te bepaal.  99mTc-
di-etileentriamienpenta-asynsuur (99mTc-DTPA) wen egter veld weens ‘n aantal tegniese 
voordele wat dit bo 51Cr-EDTA het, soos laer koste en meer onlangse probleme met die 
beskikbaarheid van 51Cr-EDTA. In antwoord op ‘n sistematiese oorsig wat daarop dui dat GFS 
meting gebaseer op plasma opruiming van 99mTc-DTPA onakkuraat sou wees, is ‘n mini meta-
analise gedoen wat uitstekende ooreenkoms tussen 51Cr-EDTA en 99mTc-DTPA opruiming 
getoon het, en sodoende die gebruik van 99mTc-DTPA as betroubare alternatief ondersteun.  
Waar GFS nie roetinegewys gemeet kan word nie, word dit dikwels geskat met behulp van ‘n 
kreatinien-gebaseerde vergelyking. Die gebruik van enige vergelyking vereis eers validasie in 
die populasie waarin dit gebruik gaan word. ‘n Studie waarin die sogenaamde Modification of 
Diet in Renal Disease (MDRD) en Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) vergelykings in kankervrye volwssenes van gemengde afkoms evalueer is, het 
bevind dat beide vergelykings goed doen. ‘n Ondersoek wat die vergelykings in volwassenes 
met kanker evalueer het, is egter bevind date GFS skattings sydig en nie presies was nie. 
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Hierdie studie het die beperkings van die gebruik van GFS skattings om oor kliniese hantering 
van kankerpasiënte te besluit, uitgelig.  ‘n Verdere ondersoek het 11 skattings-vergelykings in 
populasies van Suid-Afrikaanse kinders met en sonder kanker evalueer. Die akkuraatheid van 
alle skattings was swak, veral in die groep met kanker. In die lig van die wye gebruik van GFS 
skattings in Suid-Afrika, het hierdie bevindings verregaande implikasies vir hul gebruik in die 
hantering van kinders en volwassenes met kanker in hierdie land.  
Die ontwikkeling van nuwe vergelykings vir spesifieke populasies vereis groot datastelle en 
koste wat in die meeste middle- en lae-inkomste lande onprakties is. Aanpassing van bestaande 
vergelykings is ‘n eenvoudiger alternatief.  Hierdie werk toon die toepassing van ‘n redelik 
eenvoudige benadering om bestaande vergelykings aan te pas met behulp van matige 
hoeveelhede data en geredelik beskikbare Microsoft® Excel-gebaseerde nutsprogrammatuur. 
Alhoewel die benadering eenvoudig is en waarskynlik verdere verfyning gaan vereis, is die nut 
daarvan in volwasse kanker- en pediatriese populasies getoon.    
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Introduction 
Background 
Glomerular filtration rate (GFR), defined as the rate at which the kidneys filter plasma, is 
widely regarded as the best measure of kidney function (Brenner and Levine 2008). In a young, 
healthy adult the average GFR is 120-130 ml/min, decreasing with age (Sherwood 2007). By 
convention, GFR measurements are scaled to body surface area (BSA) to allow comparison 
between individuals of different body sizes (Peters et al. 2000).  
GFR determination is essential in many clinical scenarios. Foremost, it is used in patients with 
chronic kidney disease (CKD) for diagnosis, staging, and predicting prognosis (KDIGO 2013). 
GFR measurement is also required for the assessment of live kidney donors. Local practice, 
which is based on international guidelines, requires a GFR of  ≥ 80 ml/min/1.73 m2 for kidney 
donation (Sawinski and Locke 2018; BTS 2018). GFR determination is frequently required for 
evaluation of kidney function in patients with complex urological problems or prior to renal 
surgery (Burniston 2018). In cancer patients who will be treated with nephrotoxic 
chemotherapy, GFR is used to determine baseline kidney function and to monitor kidney 
function during treatment (Launay-Vacher et al. 2008). The GFR requirements differ 
depending on the type of chemotherapy, but in most instances a GFR of < 60 ml/min/1 73m2 
will either preclude the use of the drug or will necessitate a reduction in dose (UCLH 2009). 
For cancer patients being treated with carboplatin, GFR is used for the calculation of individual 
doses (Calvert 1989)..  
As no test exists that can measure GFR directly, it requires an indirect approach, by measuring 
the urinary or plasma clearance and/or plasma concentration of another substance (Levey and 
Inker 2016). Urinary inulin clearance is regarded as the gold standard technique because inulin 
possesses characteristics closest to a perfect filtration marker, rendering its clearance closest to 
‘true’ GFR (Brenner and Levine 2008). However, its measurement is complex as it requires a 
continuous intravenous infusion to maintain a constant plasma concentration, with carefully 
timed urine and blood collections (Sherwood 2007). For this reason, it is seldom used in the 
clinical setting and is generally reserved for research. 
Measurement of the urinary or plasma clearance of other exogenous filtration markers provides 
an accurate, yet simpler alternative. The filtration marker is administered as an intravenous or 
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subcutaneous bolus, obviating the need for a steady-state infusion. The most commonly used 
exogeneous filtration markers are 51Cr-ethylenediaminetetra-acetic acid (51Cr-EDTA), 99mTc-
diethylenetriaminepenta-acetic acid (99mTc-DTPA), 125I-iothalamate, non-radioactive 
iothalamate, and iohexol (Stevens and Levey 2009). Small systematic differences in the 
clearance of these markers and urinary inulin clearance exist, but provided standardized 
protocols are adhered to, the accuracy of all of these methods is good (Stevens and Levey 2009; 
Soveri et al. 2014). The choice of filtration marker and technique used largely depends on 
availability, cost and experience. British Nuclear Medicine Society (BNMS) and European 
Association of Nuclear Medicine (EANM) GFR guidelines recommend the use of either 51Cr-
EDTA or 99mTc-DTPA (Piepsz et al. 2001; Fleming et al. 2004; Burniston 2018) and 
consequently, these have become the preferred filtration markers in Europe. As South African 
nuclear medicine departments frequently base their practice on European guidelines, most also 
use these tracers. 
Despite being methodologically simpler than urinary inulin clearance, measurement of the 
clearance of alternative exogenous filtration markers remains unavailable in many centres for 
a variety of reasons including lack of local expertise and its relatively time- and labour-
intensive nature. It is thus not feasible to measure GFR in all patients. Generally, GFR 
measurement is reserved for the patient groups in which high accuracy is required, e.g. potential 
kidney donors. In the majority, however, an estimation of GFR is widely used. 
The serum creatinine concentration provides an estimate of GFR because in the steady state it 
is related to the reciprocal of GFR (Stevens et al. 2006). The appeal of estimated GFR is that it 
only requires serum creatinine (Scr) measurement and is therefore simple, cheap and widely 
available. However, the Scr concentration is also affected by many non-GFR determinants 
including age, sex, ethnicity, body habitus, chronic illness, diet and certain medications 
(Stevens and Levey 2009). Various equations have been described to correct the Scr 
concentration for some of these factors, thus improving the accuracy of the GFR estimate. 
Despite this, few adaptations exist for the many different patient populations. This may be 
related to the resources required and relative complexity of developing these equations.  
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Research objectives  
The intention of any GFR measurement or estimation is to provide a value that is as close to 
the true GFR as possible, and thereby an accurate reflection of kidney function. The research 
objectives were thus: 
• to increase our knowledge of specific aspects of GFR measurement in order to improve 
its performance and interpretation.  
• to validate GFR estimation in South African populations and, where applicable, to 
develop tools to adapt existing equations in order to improve GFR estimation.  
Significance and motivation 
Many important clinical management decisions are based on GFR. For example, GFR must be 
above a certain level for a person to donate a kidney or to receive potentially curative but 
nephrotoxic chemotherapy for cancer. Certain patients, such as those with complex urological 
problems or on life-long immunosuppressive therapy, require long-term, serial GFR 
measurements to ensure timely detection of a deterioration in kidney function. GFR is also 
required to calculate individualised doses of certain chemotherapy drugs. In these challenging 
clinical scenarios, it is essential that GFR is measured as accurately as possible.  
The 2004 BNMS GFR guideline (Fleming et al. 2004), which was in effect until 2018, 
considered the volume of distribution and clearance half-time of the injected 
radiopharmaceutical to be important quality assurance tools to ensure the reliability of results 
of GFR measurement studies. However, the reference ranges provided for these parameters in 
the guideline were vague. This work sets out to better define them.     
Interpretation of a GFR measurement requires comparison with reference data. However, most 
published reference ranges for GFR are based on the clearance of 51Cr-EDTA, inulin, iohexol 
or iothalamate. Normative data for the plasma clearance of 99mTc-DTPA is scant. This has 
recently become significant as many departments have been compelled to change over to 99mTc-
DTPA due to the global unavailability of 51Cr-EDTA.  
Genetically, socioeconomically and frequently also in terms of diet and pathology, local South 
African populations differ from the predominantly White northern hemisphere populations 
from which most GFR literature originates. There are also no locally derived formulae for 
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estimating GFR, compounded by a paucity of studies that have validated GFR estimation in 
South African populations. Consequently, clinicians are frequently left with no alternative but 
to utilize existing estimation equations that are likely to be unsuitable for other patient 
populations. 
Thesis, delineation, research questions 
This dissertation has been compiled in one of the accepted hybrid formats, comprising both 
published and unpublished articles. Two articles describe prospective work, three describe 
retrospective work, and one is a letter to the editor containing a mini meta-analysis in response 
to a recently published review. The first two studies and letter address issues around GFR 
measurement. The latter three studies are more clinical and focus on GFR estimation in three 
different clinical populations. All studies were approved by the Stellenbosch University Health 
Research Ethics Committee. Approval from the University of Cape Town Human Research 
Ethics Committee was also obtained for the study that was conducted at the Red Cross War 
Memorial Children’s Hospital.  
The studies were designed around the following research questions: 
• Are published reference ranges for GFR and two of its quality assurance parameters 
that were described for 51Cr-EDTA valid for 99mTc-DTPA?  
• Is the plasma clearance of 99mTc-DTPA a sufficiently accurate method to measure 
GFR? 
• What is the statistical and clinical effect of measurement errors on GFR? Which 
measurement errors have the greatest effect? And which GFR calculation method is 
least sensitive to measurement errors?  
• How accurate are published GFR estimation equations in a number of patient 
populations: 
o adult patients of mixed ancestry with and without chronic kidney disease 
o adult cancer patients 
o children with pathology 
• In any of these populations, can the performance of the estimating equations be 
improved by adapting the equations to better fit the data? 
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Definitions, assumptions and limitations 
True GFR cannot be measured, so irrespective of the method used, the value obtained is an 
estimate of the true value (Levey and Inker 2016). However, for the purpose of clarity, in this 
dissertation ‘measured GFR’ or ‘GFR measurement’ refers to the measurement of the clearance 
of an exogenous filtration marker, specifically in this work the plasma clearance of 99mTc-
DTPA or 51Cr-EDTA. ‘Estimated GFR’ or ‘GFR estimation’ refers to the use of an empiric 
equation to estimate GFR from the serum creatinine concentration and sometimes additional 
patient-specific characteristics. These have been abbreviated mGFR and eGFR respectively. 
In certain papers, the terms ‘tracer’ and/or ‘radiopharmaceutical’ have been used in place of 
‘exogenous filtration marker’. 
The abbreviations ‘2-point SI-GFR’ and ‘3-point SI-GFR’ refer to GFR that is calculated using 
the slope-intercept method using 2 or 3 blood samples respectively. 
The P30 of an estimated GFR equation is a measure of its accuracy and is defined as the 
proportion of estimates that are within 30% of the measured GFR (Stevens et al. 2006). 
For the purposes of this dissertation, good accuracy has been defined as P30 > 80%, moderate 
accuracy P30 of 60-80%, and poor accuracy P30 < 60%. 
Measurement of creatinine clearance is an established technique to estimate GFR (Sherwood 
2007). However, because it systematically overestimates GFR, and is frequently erroneous due 
to incomplete urine collections, it has been superseded by more robust methods and its 
measurement is largely historical (Perrone et al. 1992; Stevens et al. 2006). It has thus not been 
addressed in this dissertation. 
The serum concentration of cystatin-C provides an additional method for estimating GFR 
(Stevens et al. 2006), but at present, there are no laboratories in South Africa than have the 
facilities to measure it. It was thus also not included in this work. 
A general limitation of four of the studies is that, being based on populations that are 
demographically representative of the population of the Western Cape province, the results 
may not be generalizable to other South African or international populations.  
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Theory base, general literature review 
Using nuclear medicine techniques, GFR is usually measured from the plasma clearance of 
either 99mTc-DTPA or 51Cr-EDTA. Both tracers are considered acceptable in current BNMS 
and EANM GFR guidelines (Piepsz et al. 2001; Burniston 2018). Interpretation of a GFR 
measurement requires comparison with normative data and for this purpose the previous 
BNMS guideline cited a 51Cr-EDTA reference range described by Granerus and Aurell 
(Granerus and Aurell 1981; Fleming et al. 2004). Subsequently, 51Cr-EDTA reference ranges 
have been described in many other larger populations (Hamilton et al. 2000; Grewal and Blake 
2005; Peters et al. 2012b; Soares et al. 2013; Blake et al. 2013). However, reference ranges for 
99mTc-DTPA are lacking. In a 2014 systematic review, which compared the plasma and urinary 
clearance of various tracers to urinary inulin clearance, some doubt was cast over the use of 
99mTc-DTPA. Its plasma clearance was concluded to be too inaccurate for routine use whereas 
plasma clearance of 51Cr-EDTA was found to be sufficiently accurate (Soveri et al. 2014). 
These results contradicted the finding of good agreement between 99mTc-DTPA and 51Cr-
EDTA in earlier studies (Rehling et al. 1984; Fleming et al. 1991; Biggi et al. 1995). This was 
the motivation for the letter and mini meta-analysis in chapter 2. 
When measuring the plasma clearance of 99mTc-DTPA or 51Cr-EDTA, calculation of the area 
under the full (bi-exponential) clearance curve provides optimal accuracy. However, this is 
labour-intensive and invasive as it requires at least 10 blood samples to be taken from the 
patient (Fleming et al. 2004). Its complexity led to the development of simpler alternatives. Of 
these, the slope-intercept (Chantler et al. 1969), single-sample  and slope-only methods (Peters 
1992) are most commonly used. Using the slope-intercept method, only the terminal 
exponential of the plasma clearance curve is measured. Two to four blood samples are taken at 
timed intervals after equilibration of the tracer. The counts of each sample are first expressed 
in terms of the standard counts. Then, the natural logarithms of these values are plotted against 
time, linear regression is used to fit the points to a single curve, and the area under the curve is 
calculated. Finally, a correction is made to account for the missing early exponential (Fleming 
et al. 2004).  
Single-sample GFR uses an equation to calculate GFR from a single plasma sample that is 
taken, in most cases, between 3 and 4 hours after administration of the tracer. It is based on the 
premise that at any fixed time point, there is an inverse relationship between GFR and the 
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plasma concentration of the tracer (Fleming et al. 2004). Consequently, many single-sample 
equations have been described with varying degrees of accuracy (McMeekin et al. 2016a).  
The slope of the terminal exponential of the plasma clearance curve represents the rate at which 
glomerular filtration turns over the extracellular fluid (Peters 1992). Using the slope-only 
method, only this rate constant (α2) is measured, and GFR is thus expressed in terms of 
extracellular fluid volume rather than BSA. At least 3 plasma samples are required, all taken 
after equilibration of the tracer. The natural logarithms of the background-corrected plasma 
counts are plotted against time, and linear regression is used to fit the points to a single curve 
(Peters 1992).  
International and the current BNMS guidelines recommend a single-sample method (Blaufox 
et al. 1996; Burniston 2018). Single-sample GFR has the advantage of requiring only one blood 
sample, which makes it the least invasive of the three methods and requires the least time in 
the department for the patient. Furthermore, strong recent evidence supports its routine use 
(McMeekin et al. 2016 a; McMeekin et al. 2016b). The slope-only method has many 
proponents as it has various physiological and technical advantages over the other methods 
(Peters 1992). The methodology is fairly straightforward as preparation of a standard is not 
required,  and  it does not express GFR in terms of BSA. Height and weight measurement, 
which may be challenging in certain patients e.g. amputees, are also not required. (Peters et al. 
2000).  
In contrast, the slope-intercept method is the most complex technically, requiring many 
measurements. The patient is first weighed and his/her height is measured. After the 
radiopharmaceutical has been prepared, patient and standard doses are drawn up from the vial. 
These doses require accurate calibration by measuring their mass, activity or volume, both 
before and after administration. The technique used by departments to prepare the standard 
varies, but in our unit the tracer is added to a half-filled 100 ml volumetric flask, which is then 
filled with distilled water to the 100 ml mark. Two 1 ml aliquots are pipetted from this flask 
into a second half-filled volumetric flask, which is then filled to the 100 ml mark. After mixing, 
2 x 1 ml samples are pipetted into counting tubes. The exact times of administration of the 
tracer to the patient and times of blood sampling are recorded. Once the blood samples have 
been centrifuged, duplicate plasma samples are pipetted into counting tubes. All samples 
(standard and plasma) are counted in a gamma well counter (Fleming et al. 2004). Errors in 
any of these measurements will affect the final GFR value. 
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Studies that have attempted to quantify the effect of measurement errors on GFR are limited. 
In a simulation study, De Sadeleer et al (De Sadeleer et al. 2000) found that after introducing 
errors to the blood sampling times and activity measurements, errors in slope-only GFR were 
greater than slope-intercept GFR. A subsequent study by the same group found that these 
measurement errors had a smaller effect on single-sample GFR than slope-intercept GFR (De 
Sadeleer et al. 2001). However, these studies were criticized as they did not assess the impact 
of errors in other important measurements (Watson 2000; Peters 2001).  
The previous BNMS GFR guideline recommended the slope-intercept method and described 
its methodology in detail (Fleming et al. 2004). Consequently, this became the preferred 
method in many departments around the world. More recently, literature has emerged showing 
the single-sample method to be as accurate as the slope-intercept method and the slope-
intercept method to have no additional advantage in terms of quality assurance (McMeekin et 
al. 2016a; McMeekin et al. 2016b). For these reasons, combined with the convenience and 
comfort it confers to patients, the single-sample method has replaced the slope-intercept 
method in the current BNMS guideline (Burniston 2018). A more thorough comparison of the 
methods in terms of their sensitivity to measurement error will provide further evidence to 
inform this change in practice.  
On completion of a GFR measurement study, a number of quality control (QC) checks are 
performed (Fleming et al. 2004; Burniston 2018). Comparing the volume of distribution (VD) 
of the administered tracer and the half-time (T½) of its clearance to published reference data 
are two such checks that were considered important in the previous BNMS guideline (Fleming 
et al. 2004). An abnormality in either of these biological parameters alerts the nuclear physician 
to a potential problem with the GFR measurement. However, in addition to the vague origins 
of the reference data for these two parameters, a limitation to their widespread use is that the 
reference data was based on 51Cr-EDTA clearance in predominantly White, British populations 
(Fleming et al. 2004; Fleming et al. 2009). It is not known whether the reference ranges are (i) 
applicable for 99mTc-DTPA  and (ii) applicable in local populations who differ ethnically and 
genetically to British populations. 
The value of QC parameters such as VD has been challenged recently. In a systematic review, 
McMeekin et al (McMeekin et al. 2016b) classified errors that can occur during GFR 
measurement into 3 categories: model failure (type 1); errors that affect the whole clearance 
curve (type 2); and individual point measurement errors (type 3). They found most 
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conventional QA parameters to be insensitive for detecting type 1 errors, a conclusion that was 
subsequently supported by Klein et al (Klein et al. 2019). However, conventional QA 
parameters are thought to have some utility in the detection of type 2 and type 3 errors, but the 
design of the systematic review did not enable it to assess these adequately. 
In centres where GFR cannot be measured, or where the requirement for GFR measurement 
exceeds the department’s capacity, clinicians are compelled to rely on a GFR estimate. In adults 
the Modification of Diet in Renal Disease (MDRD) (Levey et al. 2007) and Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) (Levey et al. 2009) equations are most 
commonly used, with the CKD-EPI equation being recommended in international and local 
CKD guidelines (KDIGO 2013; SARS 2015). Both equations were developed in North 
American, predominantly White populations (Levey et al. 1999; Levey et al. 2009). Results of 
a more recent systematic review suggest that ethnicity has an effect on the performance of the 
equations, finding neither the MDRD nor CKD-EPI equation to perform as well in African or 
Asian populations as it did in North American and European populations (Earley et al. 2012). 
In African-American individuals an ethnicity factor needs to be applied to the equations as this 
population has higher average Scr levels due to genetic differences in creatinine generation 
(Worrall et al. 1990; Jones et al. 1998). A systematic overestimation of GFR by the MDRD 
equation in a Japanese population suggests that this population has lower Scr levels on average 
(Imai et al. 2007). There are a few studies that have evaluated the equations in Black and Indian 
South African adults (van Deventer et al. 2008; van Deventer et al. 2011; Stevens et al. 2011; 
Madala et al. 2011; Moodley et al. 2018). Their results varied substantially, but in general, the 
accuracy of the equations was poor. It is not known how the estimating equations will perform 
in individuals of mixed ancestry considering this population’s genetic diversity (de Wit et al. 
2010). 
In children multiple GFR estimating equations have been described. The older equations were 
developed prior to routine standardization of Scr assays (Counahan et al. 1976; Schwartz et al. 
1976; Morris et al. 1982; Léger et al. 2002; Mattman et al. 2006). A few are adult equations 
that have been adapted for paediatric use (Biörk et al. 2007). Others were developed in cancer 
populations (Cole et al. 2004; Brandt et al. 2006; Millisor et al. 2017), whereas the majority 
were developed in CKD populations (Schwartz et al. 2009; Pottel et al. 2010; Gao et al. 2012; 
Pottel et al. 2012; Schwartz et al. 2012; De Souza et al. 2012; Hoste et al. 2013; Pottel et al. 
2016). The most well-known of these, the Schwartz formula (Schwartz et al. 2009), was used 
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in the large Chronic Kidney Disease in Children (CKiD) study (Wong et al. 2012). The results 
of subsequent validation studies in CKD populations are discrepant, some showing excellent 
agreement with the measured GFR, others showing unacceptably low accuracy (Pottel et al. 
2010; Staples et al. 2010; Bacchetta et al. 2011; Gao et al. 2012; Pottel et al. 2012; Selistre et 
al. 2012; De Souza et al. 2012; Blufpand et al. 2013; Hoste et al. 2013; Uemura et al. 2014; 
Deng et al. 2015; Pottel et al. 2016). Fewer studies exist that have tested the equations in 
children with cancer, but in general, estimated GFR has been found to be less accurate in this 
group (Blufpand et al. 2011; Bernhardt et al. 2015; Millisor et al. 2017; Llanos-Paez et al. 
2018). The large number of equations that have been developed together with their varying 
performance in validation studies, suggests that the equations are largely population specific.  
Due to the nephrotoxicity of certain chemotherapy drugs, e.g. the platinum-based agents, 
cancer patients form a large proportion of the patients requiring GFR measurement. The GFR 
is used in one of three main settings: (i) determining whether kidney function is adequate prior 
to starting nephrotoxic chemotherapy, (ii) serial monitoring of kidney function during 
treatment, and (iii) calculation of the dose of certain drugs e.g. carboplatin (Calvert et al. 1989; 
Launay-Vacher et al. 2008). CKD-based estimating equations have been found to be biased 
and imprecise in patients with cancer (Wright et al. 2001; Poole et al. 2002; Marx et al. 2004; 
Verhave et al. 2005; de Lemos et al. 2006; Barraclough et al. 2008; Ainsworth et al. 2011; 
Hartlev et al. 2012; Lauritsen et al. 2014), and the number of equations developed in cancer 
populations is limited (Jelliffe 1973; Martin et al. 1998; Wright et al. 2001; Janowitz et al. 
2017). Those available were developed in European or American populations (Jelliffe 1973; 
Martin et al. 1998; Wright et al. 2001; Janowitz et al. 2017). It is thus required to test the CKD 
and cancer GFR estimating equations in a local cancer population in which differences in 
ethnicity, diet and pathology exist. 
Brief paper overviews 
Paper 1  (p. 1) is an original article that derived reference data for VD and T½, two parameters 
that are frequently used for quality assurance of GFR studies. It also derived reference data for 
GFR using 99mTc-DTPA. This paper was published in Nuclear Medicine Communications 
(Holness et al. 2013).  
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Paper 2 (p. 22) is a letter to the editor containing a mini meta-analysis, supporting the use of 
the plasma clearance of 99mTc-DTPA to measure GFR. It was published in American Journal 
of Kidney Diseases (Holness et al. 2015). 
Paper 3 (p. 26) is an original article analyzing the effect of measurement errors on GFR. It 
compares their impact on the slope-intercept, single-sample and slope-only methods, and it 
performs a sensitivity analysis to the various sources of measurement error. It allows 
conclusions to be made about the clinical impact of the resultant error in GFR and provides 
recommendations for minimizing measurement error. This paper was published in Nuclear 
Medicine Communications (Holness et al. 2019). 
Paper 4 (p. 48) is a prospective study evaluating the performance of the MDRD and CKD-EPI 
GFR estimating equations in a mixed ancestry, adult population. This paper has been accepted 
for publication in the South African Medical Journal (July 2019). 
Paper 5 (p. 64) is a retrospective evaluation of GFR estimating equations in a largely non-
White adult cancer population. The parameters of the equations are adapted, and the 
performance of the adapted equations is compared to that of the original equations. This 
manuscript is currently being finalised for submission.  
Paper 6 (p. 83) is a combined prospective/retrospective study evaluating the performance of 
11 GFR estimating equations in a Western Cape paediatric population. In order to improve 
their accuracy, it also examines the adaptation of the parameters of four of the equations and 
compares the performance with the original equations. This manuscript is currently being 
finalised for submission.  
Candidate’s role in the PhD 
Retrospective studies (papers 1, 3 and 5) 
Dr Holness developed the protocols for each of these studies. She reviewed the records of all 
participants. This entailed accessing the original GFR measurements from nuclear medicine 
records, obtaining additional clinical management from the Tygerberg Hospital Enterprise 
Content Management (ECM) system, and laboratory values from the National Health 
Laboratory Service (NHLS). Dr Holness was responsible for all data capture, and performed 
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the data analysis with assistance from Prof James Warwick (papers 1, 3 and 5), Prof John 
Fleming (papers 1 and 3) and two biostatisticians, Justin Harvey and Maxwell Chirehwa 
(papers 1 and 3 respectively). Dr Holness was responsible for the writing of all three 
manuscripts, and all co-authors reviewed their respective manuscripts.  
Prospective studies (papers 4 and 6) 
Dr Holness developed the protocols for these studies. This included the development of the 
patient consent forms, participant check lists, and data capture forms. Screening and 
recruitment of participants was performed by Dr Karla Bezuidenhout in the Tygerberg Hospital 
Nephrology outpatient clinic (paper 4) and Dr Anita Brink in the Nuclear Medicine Division, 
Red Cross Children’s Hospital (paper 6). The GFR measurements for paper 4 were performed 
by a research assistant who is experienced in GFR measurement. As the participants in paper 
6 were all referred for GFR measurement as part of their clinical management, the actual 
measurements were performed by the radiography staff of the Nuclear Medicine Division, Red 
Cross Children’s Hospital. The blood samples that were sent for creatinine measurement were 
taken by the research assistant/staff member performing the GFR study. Dr Holness was 
responsible for data capture. Data analysis was performed by Dr Holness with assistance from 
Prof James Warwick. Dr Holness wrote both manuscripts, and these were reviewed by all co-
authors.  
Letter to the editor (paper 2) 
The data was analysed by Dr Holness with assistance from Prof James Warwick. Dr Holness 
wrote the letter and this was reviewed by the co-authors.  
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Abstract 
 
Background and aim: Assessment of volume of distribution (VD) and half-life (T½) values 
during glomerular filtration rate (GFR) investigations is a useful quality control check. The aim 
of this study was to derive reference data for VD and T½ and also to provide reference data for 
GFR from studies performed using 99mTc-diethylenetriaminepentaacetic acid (99mTc-DTPA).  
Methods: This was a retrospective study of 126 healthy potential kidney donors (age range 18-
59 years). GFR was evaluated from 99mTc-DTPA plasma clearance using the 2004 British 
Nuclear Medicine Society guidelines. The association between VD and body surface area 
(BSA) was assessed. T½ was correlated with age and with GFR. The correlation between 
Bröchner-Mortensen-corrected GFR (BM-GFRCorr) and age was evaluated.  
Results: Uncorrected VD (L) was (10.1*BSA) ± 40.6% (p<0.01). Corrected VD (L) was 
(8.19*BSA) ± 34.4% (p<0.01). In individuals under the age of 40 years mean T½ was 95.0 min 
± 36.2%. In individuals 40 years and older, T½ increased at a rate of 0.49 min/year (p=0.04). 
T½ (min) was [9480*(1/BM-GFRCorr)] ± 35.1% (p<0.01). In individuals younger than 40 years 
the correlation of BM-GFRCorr and age was not statistically significant (p=0.45) and mean GFR 
was 108 ml.min-1.(1.73 m2)-1 ± 27.5%. In individuals 40 years and older BM-GFRCorr was [170 
- (1.55*age)] [ml.min-1.(1.73 m2)-1] ± 36.7% (p<0.001).  
Conclusion: Well defined reference data for VD and T½ can be used as quality control checks 
in GFR investigations. In addition to these, reference data for GFR using 99mTc-DTPA have 
been defined. This will enhance the interpretation of adult 99mTc-DTPA GFR measurements.  
 
Keywords: 99mTc-DTPA, volume of distribution, half-life, glomerular filtration rate, reference 
ranges 
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Introduction 
Glomerular filtration rate (GFR) is a standard measure of renal function. Although measuring 
plasma inulin clearance remains the gold standard for determining GFR, this technique is rarely 
used because it is time-consuming and difficult to perform (Blaufox et al. 1996; Fleming et al. 
2004). An estimate of GFR can be obtained by measuring creatinine clearance; however, this 
technique is inaccurate, especially in cases of poor renal function (Bröchner-Mortensen and 
Rödbro 1976; Sawyer et al. 1982). Measurement of GFR using Nuclear Medicine techniques 
is considered a suitable alternative with clearance of 51Cr-ethylenediaminetetraacetic acid 
(51Cr-EDTA) having been shown to be similar to that of inulin (Garnett et al. 1967; Bröchner-
Mortensen et al. 1969). 
99mTc-diethylenetriaminepentaacetic acid (99mTc-DTPA) is considered an acceptable 
alternative to 51Cr-EDTA (Blaufox et al. 1996; Fleming et al. 2004). It has the advantages of 
being inexpensive, widely available and the radiation dose to the patient is low. It is also 
suitable for gamma camera imaging, allowing simultaneous acquisition of a renogram for 
calculation of differential renal function. Clearance of 99mTc-DTPA has been shown to 
correlate well with 51Cr-EDTA clearance (Hilson et al. 1976).  
In 2004 the British Nuclear Medicine Society (BNMS) published guidelines for the 
measurement of GFR (Fleming et al. 2004). The authors recommended measuring the plasma 
clearance of either 51Cr-EDTA or 99mTc-DTPA using the slope-intercept method with 
Bröchner-Mortensen correction (Bröchner-Mortensen 1972; Fleming et al. 2004). In the 
clinical context this method provides a good compromise between accuracy and simplicity. 
Nevertheless, careful attention to technique is warranted since methodological errors can be 
introduced at a number of stages (Bird et al. 2007). These include, amongst others, errors in 
height or weight measurement, drawing up and injection of the patient dose, preparation or 
measurement of the standard, and preparation or measurement of the plasma samples. 
The slope-intercept method does, however, offer a number of opportunities for quality control 
of the procedure (Fleming et al. 2004). Two parameters obtained during the calculation of GFR 
using the slope-intercept method are the volume of distribution (VD) and the half-life (T½) of 
the injected radiopharmaceutical (Bröchner-Mortensen 1972). While being of limited value for 
predicting the GFR in isolation, these values can be valuable to check for underlying 
methodological errors (Piepsz et al. 2001; Fleming et al. 2004; Piepsz et al. 2005). Using VD 
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and T½ for this purpose requires clearly defined reference ranges for each of these parameters. 
The BNMS guidelines  provide a reference range for the uncorrected VD (L) as being linearly 
related to body surface area (BSA) (m2) by the equation (Fleming et al. 2004): 
VD (uncorrected) = (8*BSA) ± 25% (2 SD)                   (1)    
This range for VD was obtained using 
51Cr-EDTA. It applies to an uncorrected value for VD, 
calculated using the formula: 
VD (uncorrected) = A/C                      (2)    
where A is the administered activity and C the intercept at zero time obtained by back 
extrapolation of the terminal exponential of the curve of activity per unit volume versus time 
((Waller et al. 1987), Personal communication: G. Blake, King’s College London, UK).  
The Medical Physics Department of University Hospital Southampton NHS Foundation Trust, 
UK, found the corrected VD for 
99mTc-DTPA to be related to BSA by the equation (Fleming et 
al. 2009): 
VD (corrected) = (6.61*BSA
1.218) ± 32% (2 SD)           (3) 
The values for VD were calculated using the equation: 
VD (corrected) = BM-GFR / k              (4)  
where BM-GFR is the Bröchner-Mortensen-corrected GFR (Bröchner-Mortensen 1972) and k 
is the slope of the terminal exponential.  
Equation 2 leads to an overestimation of the volume of distribution as it takes into account only 
the terminal exponential of the plasma clearance curve after mixing has taken place between 
the vascular and extravascular compartments (Waller et al. 1987). The degree of overestimation 
is similar to that found when calculating GFR by the slope-intercept method without Bröchner-
Mortensen correction. The corrected volume of distribution, VD (corrected) (equation 4), although 
still an approximation since it assumes k is the terminal exponential, tries to correct for the 
overestimation.   
A technique of measuring extracellular fluid volume (ECV) using a combination of the slope-
only and slope intercept methods has been described and validated (Peters 1992; Bird et al. 
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2009). Using this technique, reference data for ECV have recently been described by Peters et 
al in a large multi-centre study in the UK (Peters et al. 2012b). 
In the BNMS guidelines T½ is described as being “typically in the range” of 100-120 min in 
adults (Fleming et al. 2004). However, to the authors’ knowledge no data has been published 
supporting the use of the above or other reference ranges for VD and T½. Specifically, there is 
a lack of published data for normal values of VD and T½ that have been determined using 
99mTc-
DTPA (Fleming et al. 2006).  
Reference data for GFR have been well-defined by Granerus (Granerus and Aurell 1981), 
Hamilton et al (Hamilton et al. 2000), Grewal and Blake (Grewal and Blake 2005), as well as 
by Peters et al (Peters et al. 2012b). Although previous studies have shown only a small 
difference in GFR values obtained using 51Cr-EDTA and 99mTc-DTPA (Fleming et al. 1991; 
Biggi et al. 1995), there are no published reference ranges for GFR using 99mTc-DTPA.   
The aim of this study was to determine reference values for VD and T½ from GFR studies using 
99mTc-DTPA in a healthy population. In addition, reference data for GFR using 99mTc-DTPA 
have been defined for the study population.  
Methods 
Patient population 
This retrospective study included the GFR studies of all potential kidney donors referred to the 
Nuclear Medicine Department of Tygerberg Hospital, Cape Town, South Africa, between 
February 2007 and September 2012. In total 128 GFR studies were performed and 126 of these 
were included in the study (69 females, 57 males; age range 18-59 years). Two studies were 
excluded; one due to discrepancies with weight measurements and one as it was performed 
using 51Cr-EDTA. In 113 subjects a renogram was performed in combination with the GFR 
study, while in 13 subjects the GFR study was performed on a different day to the renogram. 
All potential donors underwent a screening process by the hospital’s Renal Unit. Subjects were 
excluded if they had chronic diseases that could potentially affect renal function or that placed 
them in a high-risk surgical category. Hypertension, diabetes mellitus and psychiatric illness 
were considered absolute contraindications to kidney donation. The initial blood tests included 
haematological and biochemical parameters (urea, creatinine, full blood count, liver function, 
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sodium, potassium, chloride, calcium, magnesium, inorganic phosphate, uric acid, glucose), as 
well as serology for HIV, syphilis, hepatitis A, hepatitis B, hepatitis C, and cytomegalovirus. 
If these tests were normal and the subject was considered a match based on ABO compatibility 
and T-cell cross-matching, more specific renal screening was performed. GFR was estimated 
from a plasma creatinine sample using either the Modification of Diet in Renal Disease 
(MDRD) (Levey et al. 2007) or Cockcroft-Gault formula (Cockcroft and Gault 1976). In 
addition, creatinine clearance was calculated from a 24-hour urine collection, 24-hour urinary 
protein excretion was determined, and a spot urine sample was collected to determine the 
protein-to-creatinine ratio. Only if the results of all tests were normal were subjects referred to 
the Nuclear Medicine department for a renogram and GFR study. 
This work was approved by the Stellenbosch University Health Research Ethics Committee; 
study number N10/05/177.  
Measurement of GFR, VD and T½ 
All GFR studies were performed based on the protocol described in the BNMS guidelines 
(Fleming et al. 2004). The subjects’ heights and weights were recorded and the BSA calculated 
using the Haycock formula (Haycock et al. 1978). 99mTc-DTPA (TechneScan® DTPA, 
Covidien) was injected intravenously. Labelling efficiency was greater than 90% in all cases. 
The injection site was imaged to exclude extravasation. The dose was approximately 40 MBq 
when only the GFR study was performed on that visit, and about 400 MBq when the GFR study 
was combined with a renogram. The patient and standard doses were accurately calibrated by 
weighing the syringes pre- and post-injection on a Precisa 620 C balance, without flushing the 
syringes or removing the needles. Three 8 ml venous blood samples were drawn from the 
contralateral arm at 2, 3 and 4 hours respectively. The exact time of injection and the time of 
drawing each sample were recorded to the nearest minute. Samples were centrifuged 
immediately after being drawn. A standard was prepared by withdrawing a similar dose of 
99mTc-DTPA from the same kit and adding it to a half-filled 100 ml flask, which was 
subsequently filled to the 100 ml mark with distilled water and mixed. Two millilitres of this 
solution was pipetted into a second 100 ml flask that was filled and mixed in a similar manner. 
The dilution volume of the standard was thus equivalent to 5 litres. Duplicate 1 ml aliquots of 
plasma samples and standard were pipetted into counting tubes. Background counts were 
recorded, followed by the counting of each sample in a Picker NaI(Tl) well counter. All 
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samples were counted sequentially in one sitting. Linearity of the well counter was checked 
routinely and was acceptable, specifically at high count rates.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
The GFR was calculated using the slope-intercept method as described in the 2004 BNMS 
guidelines (Fleming et al. 2004). The natural logarithm of the plasma 99mTc-DTPA 
concentrations were plotted against time. Linear regression analysis was used to determine the 
half-life (T½) and VD (uncorrected). The slope-intercept GFR (SI-GFR) was calculated using the 
equation (Fleming et al. 2004): 
SI-GFR = VD (Uncorrected) x (0.693/T½)             (5) 
The SI-GFR was then corrected for body surface area: 
SI-GFRCorr = SI-GFR x (1.73/BSA m
2)           (6) 
Subsequently, the mean Bröchner-Mortensen (BM) equation was applied to correct for the 
missing area under the curve from the fast exponential (Fleming et al. 2004): 
BM-GFRCorr = 1.0004 x SI-GFRCorr – 0.00146 x SI-GFR2Corr         (7) 
The coefficients used in this equation are an average of those in the adult (Bröchner-Mortensen 
1972) and paediatric equations (Bröchner-Mortensen et al. 1974). 
The absolute GFR was calculated by reversing the BSA correction: 
BM-GFR = BM-GFRCorr x (BSA m
2/1.73)           (8) 
For each GFR study the uncorrected VD was calculated using equation 2 and the corrected VD 
was calculated using equation 4. 
Using the methodology previously described (Peters 1992; Bird et al. 2009; Peters et al. 2012b), 
ECV-BSA (extracellular volume corrected to a BSA of 1.73 m2) was calculated for each 
individual. Correction for BSA was reversed by multiplication of ECV-BSA with BSA/1.73 
m2 to give ECV (Peters et al. 2012b). 
Defining reference ranges 
Values for VD, both uncorrected and corrected, were plotted against BSA. Using linear 
regression analysis the correlation was determined between VD and BSA. Variability was 
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defined by calculating the standard error of the estimate of the regression analysis.  This gives 
the standard deviation of estimating VD from BSA. In this report the 95% confidence limits, or 
two standard deviations, are expressed as a percentage relative to the mean VD value. These 
results were compared to the accepted reference ranges described earlier (equations 1 and 3) 
(Fleming et al. 2004; Fleming et al. 2009) and to the ECV-BSA data described by Peters et al 
(Peters et al. 2012b). 
In order to define reference data for T½, the correlations of T½ and age as well as T½ and 1/BM-
GFRCorr were determined. Similarly, the association between BM-GFRCorr and age was 
investigated using linear regression. Variability for these parameters was also described by the 
relative two standard deviation, expressed as a percentage. The results of the BM-GFRCorr vs. 
age correlation were compared to 51Cr-EDTA reference ranges described by Granerus 
(Granerus and Aurell 1981), Hamilton (Hamilton et al. 2000) and Grewal and Blake (Grewal 
and Blake 2005) and to the mean values for GFR described by Peters et al (Peters et al. 2012b).  
Deviations from BNMS guidelines 
The protocol used in this study deviated from the BNMS guidelines in two aspects and steps 
were taken to assess their impact on the calculated GFR and VD. Firstly, in 70 of the 126 studies, 
low counts were recorded for some of the samples. The BNMS guidelines state that, where 
practical, a minimum of 10 000 counts should be obtained from each sample in order to reduce 
statistical error (Fleming et al. 2004). The effect of this factor on the accuracy of the GFR and 
VD was assessed by introducing simulated random error into the counts that were obtained from 
all samples in all 126 studies. This was repeated 10 times and GFR and VD were calculated in 
each instance. From this data, systematic, random and total error was estimated.  
A second deviation from the BNMS guidelines was that no correction was performed for decay 
of 99mTc during the counting process. In order to quantify the error introduced by not correcting 
for radioactivity decay, an independent set of 26 GFR studies was evaluated. Counts obtained 
from all samples in these studies were higher than 10 000 and the exact time at which each 
sample was counted was recorded. GFR and VD were then calculated for each study, with and 
without decay correction. From this set of data the systematic, random and combined errors 
were computed. 
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Results 
The scatter graphs of the uncorrected VD (L) and corrected VD (L) as a function of the BSA 
(m2) are shown in Fig. 1.1 and Fig. 1.2 respectively with trendlines representing ± 2 SD.  
The correlation between VD (L), both uncorrected and corrected, and BSA (m
2) was significant 
(p < 0.001 for both correlations). Both were best described using linear functions: 
VD (Uncorrected) = (10.1 * BSA) L ± 40.6% (2 SD)       (9) 
(RMSE = 3.70 L; 95% CI for the coefficient: 9.79 to 10.5 L).  
VD (Corrected) = (8.19 * BSA) L ± 34.4% (2 SD)                 (10) 
(RMSE = 2.53 L; 95% CI for the coefficient: 7.95 to 8.44 L).  
In Fig. 1.1 the trendlines representing the upper and lower limits of the range described in the 
BNMS guidelines (equation 1) (Fleming et al. 2004) are displayed. Similarly, the trendlines 
representing the upper and lower limits of the range described by University Hospital 
Southampton NHS Foundation Trust, UK (Fleming et al. 2009) are displayed in Fig. 1.2. 
Mean ECV normalised for BSA (ECV-BSA) was 12.7 ± 4.4 (2 SD) L/1.73 m2. ECV-BSA in 
men was 13.5 ± 4.9 (2 SD) L/1.73 m2 and in women 12.0 ± 3.5 (2 SD) L/1.73 m2. 
The association between T½ (min) and age (years) was not statistically significant (p = 0.16), 
nor was the association between T½ (min) and age (years) in subjects under the age of 40 years 
(p = 0.65). In this subgroup (< 40 years) the mean T½ was 95.0 ± 36.2% (2 SD). In subjects 40 
years and older the association between T½ and age was statistically significant (p = 0.046). 
This bi-linear fit is illustrated in Fig. 1.3. Using linear regression the following equation 
describes the association in subjects 40 years and older: 
 T½ = [(0.49*age) + 75.9] min ± 30% (2 SD)                 (11) 
The association between T½ (min) and 1/BM-GFRCorr (min.(1.73 m
2).ml-1) was statistically 
significant (p < 0.001) and it is illustrated in the scatter graph in Fig. 1.4. Using linear regression 
it was best described using the equation: 
T½ = 9480*(1/BM-GFRCorr) min ± 35.1% (2 SD)                 (12) 
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Fig. 1.5 is the scatter graph of BM-GFRCorr [ml.min
-1.(1.73 m2)-1] plotted as a function of age 
(years). In individuals younger than 40 years the correlation was not statistically significant (p 
= 0.45). The mean GFR in this group was 108 ml.min-1.(1.73 m2)-1 ± 27.5% (2 SD). In 
individuals 40 years and older the correlation between GFR and age was statistically significant 
(p < 0.001). The following equation describes this association: 
BM-GFRCorr = 170 – (1.55*age) [ml.min-1.(1.73 m2)-1] ± 36.7% (2 SD)                        (13) 
Mean BM-GFRCorr in men was 107 ± 29.8 (2 SD) [ml.min
-1.(1.73 m2)-1] and in women 100.7 
± 35.8 (2 SD) [ml.min-1.(1.73 m2)-1]. This difference was statistically significant (p = 0.04), 
however, men were significantly younger than women, mean age 30.5 vs. 36.4 years (p = 
0.003). 
Considering all 126 studies, the systematic and random errors (1 SD) introduced to GFR data 
through statistical noise were -0.19% and 2.97% respectively, and for VD, 0.64% and 10.19% 
respectively. In the prospective series of 26 studies the systematic and random errors (1 SD) 
introduced to GFR data through not correcting for radioactivity decay were -0.12% and 1.81% 
respectively, and for VD, -0.22% and 2.37% respectively. In this series the counting of all 
samples was completed within 14 minutes (range 6 – 14 min, mean 9 min).  
Discussion 
In this study reference ranges for a South African adult population were determined for VD, T½ 
and GFR using 99mTc-DTPA and the slope-intercept method as described in the BNMS 
Guidelines (Fleming et al. 2004). The slope-intercept method remains prone to methodological 
errors (Garnett et al. 1967; Bröchner-Mortensen et al. 1969) and various quality control checks 
have been proposed: the fit of the counts to a single exponential can be assessed, either 
graphically or by checking that the correlation coefficient is greater than 0.985 (Fleming et al. 
2004). Alternatively, slope-intercept GFR measurements can be checked using single-sample 
estimates (Fleming et al. 2005a; Fleming et al. 2005b) or using the slope-only technique (Peters 
1992; Bird et al. 2007). 
VD and T½ are two quantities that are obtained during calculation of GFR using the slope-
intercept method. The BNMS guidelines recommend reviewing these quantities as an 
additional quality control check (Fleming et al. 2004). For this purpose it is necessary to 
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compare values to normal values for VD and T½ defined for the patient population and for the 
radiopharmaceutical used. 
In the present study a reference range for uncorrected VD in litres was identified as (10.1 * 
BSA) ± 40.6% (2 SD). These values are systematically higher and show greater variability than 
those described in the BNMS guidelines (equation 1, Fig. 1.1) (Fleming et al. 2004). Although 
the values for VD in the BNMS guidelines were derived from GFR measurements using 
51Cr-
EDTA, previous studies demonstrated no significant difference in VD between 
51Cr-EDTA and 
99mTc-DTPA (Rehling et al. 1984; Fleming et al. 1991). Therefore, it is believed that it is 
unlikely that the radiopharmaceutical justifies for the differences between the BNMS range 
and the values in the current study.  
In this study the reference range for corrected VD in litres was found to be (8.19 * BSA) ± 
34.4% (2 SD). The variability for corrected VD (34.4%) is noted to be lower than for 
uncorrected VD (40.6%). This is expected because uncorrected VD is overestimated relative to 
the true value and the degree of overestimation depends on GFR. Thus a subject of a given size 
will have a higher value for uncorrected VD if GFR is normal than if it is reduced. This GFR-
related variability of VD is reduced by applying a Bröchner-Mortensen correction. 
In this study the values for corrected VD are systematically higher than those reported by 
University Hospital Southampton NHS Foundation Trust (equation 3, Fig. 1.2) (Fleming et al. 
2009). For example, for a BSA of 1.73 m2, the corrected VD using the Southampton equation 
would be 12.9 L whilst it would be 14.2 L using equation 11, leading to a 9% higher value. 
However, considering that the 2 SD error for the Southampton data is 32% and for the data in 
the current study it is 34.4%, the difference in variability between the two centres is within the 
estimated error on the VD. 
Radiopharmaceutical factors are even less likely to account for the differences in corrected VD 
between this centre and Southampton University Hospitals NHS Trust. In fact, both centres 
used TechneScan® DTPA, Covidien. This specifically excludes differences in protein binding 
of different DTPA preparations as a cause for the higher values or greater variability seen in 
VD. The study populations in the two centres differ. The Southampton data was obtained from 
a general clinical GFR population, which included normal and abnormal GFRs and both 
children and adults, while the data in this study was obtained from a carefully selected normal 
adult population. This will affect the uncorrected values of VD. The overestimation of 
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uncorrected VD will be higher in the normal group compared to the mixed population as the 
GFR will on average be higher. In terms of environmental and ethnic factors, the population in 
this study is likely to be more diverse than a population originating from Southampton. The 
current study population is heterogeneous, with roughly equal numbers of subjects of 
Caucasian, African and mixed ancestry. It has been shown in previous studies that there are 
differences in muscle mass amongst different ethnic groups and this may translate to 
differences in VD (Cohn et al. 1977; Harsha et al. 1978; Worrall et al. 1990). 
An additional factor contributing to the variability in the results for VD might have been 
experimental error due to low counts; however, this is thought to play a minor role and it will 
be discussed later in this section. 
Using the technique described by Peters et al ECV-BSA was calculated for each subject (Peters 
1992; Bird et al. 2009; Peters et al. 2012b). The mean ECV-BSA was 12.7 ± 4.4 (2 SD) L/1.73 
m2, whilst for males it was 13.5 ± 4.9 (2 SD) L/1.73 m2 and females 12.0 ± 3.5 (2 SD) L/1.73 
m2. These GFR values were corrected for the one-pool assumption using the mean Bröchner-
Mortensen correction as recommended in the BNMS guidelines (Fleming et al. 2004). When 
corrected using the adult Bröchner-Mortensen equation (Bröchner-Mortensen 1972), 
ECV/BSA in males was 13.9 ± 5.1 (2 SD) L/1.73 m2 and in females 12.3 ± 3.7 (2 SD) L/1.73 
m2. These values for ECV-BSA agree reasonably well with those described by Peters et al in 
their recent multi-centre UK-based study (Peters et al. 2012b). 
The mean value for ECV in this study is 27% lower than the mean value for uncorrected VD. 
This is in close agreement with previous work in which a difference of 30% was described 
(Peters et al. 2000). The mean value for ECV-BSA in the current study is, however, also 
approximately 10% lower than the mean value for corrected VD normalized for BSA. This is 
due to the approximation used in this study that the slope of the second exponential is equal to 
the clearance constant. The work of Bird et al (Bird et al. 2009) shows that the slope 
systematically underestimates the constant by about 10% leading to an overestimate in the 
volume of distribution.  
Calculation of T½ may be used as a quality control check by comparing it against the value 
expected for the subject’s GFR. The association between T½ (min) and 1/BM-GFRCorr 
[min.(1.73 m2).ml-1] was statistically significant (p < 0.001) and T½ (min) was found to be 
[9480*(1/BM-GFRCorr)] ± 35.1%. 
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In the study by Grewal and Blake, the authors noted that it was apparent that there was a break 
in the age dependence of GFR at approximately 40 years (Grewal and Blake 2005). They found 
no statistically significant correlation between GFR and age for individuals under the age of 40 
years, while there was a statistically significant decrease in GFR from the age of 40 years 
onward. In this study a cut-off of 40-years was used based on this work and it supports that 
conclusion: for individuals under the age of 40, the correlation between GFR and age was not 
statistically significant (p = 0.45), while it was significant (p < 0.001) in individuals 40 years 
and older. In individuals younger than 40 years the mean BM-GFRCorr was 108 ml.min
-1.(1.73 
m2)-1. This is the same as the 108 ml.min-1.(1.73 m2)-1 reported by Hamilton et al (Hamilton et 
al. 2000), but higher than the 103 ml.min-1.(1.73 m2)-1 reported by Grewal and Blake (Grewal 
and Blake 2005) and the 105 ml.min-1.(1.73 m2)-1 reported by Granerus and Aurell (Granerus 
and Aurell 1981). The slightly higher GFR is expected for DTPA compared to EDTA (Fleming 
et al. 1991; Biggi et al. 1995). In individuals 40 years and older, BM-GFRCorr was expressed 
by the linear relation 170 – (1.55*age) [ml.min-1.(1.73 m2)-1] ± 36.7% (2 SD). In this study the 
reference curve predicts a mean GFR at age 50 years of 93 ml.min-1.(1.73 m2)-1. This is in good 
agreement with the mean of 94 ml.min-1.(1.73 m2)-1 found by Grewal and Blake (Grewal and 
Blake 2005), but lower than the 98 ml.min-1.(1.73 m2)-1 in the Granerus and Aurell study 
(Granerus and Aurell 1981). The data in the subgroup 40 years and older has to be interpreted 
with caution, however, as it comprised only 44 individuals and covered a relatively limited age 
range compared to the other studies. 
The results of Granerus and Aurell (Granerus and Aurell 1981) and Hamilton et al (Hamilton 
et al. 2000) are not directly comparable due to small differences in methodology. On the other 
hand, the current study is based on the protocol described in the BNMS guidelines (Fleming et 
al. 2004), as was the study by Grewal and Blake (Grewal and Blake 2005), making it more 
appropriate for comparison.  
It is accepted that GFR declines with age, although a cut-off age for the start of the decline is 
difficult to establish as recently shown by Peters et al (Peters et al. 2012b). No clear age cut-
off could be identified in the current study, however a threshold of 40 years of age was chosen 
in accordance with the cut-off age used in a previous study (Grewal and Blake 2005). Due to a 
relatively small study sample, individuals were not divided into groups based on gender, 
however, mean BM-GFRCorr was 107.0 ± 14.9 (1SD) ml.min
-1.(1.73 m2)-1 in men vs. 100.7 ± 
17.9 (1 SD) ml.min-1.(1.73 m2)-1 in women. The difference was statistically significant (p = 
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0.04), however, the difference might be explained by the fact that the male cohort was 
significantly younger than the female cohort (mean age 30.5 versus 36.4 years, p = 0.002). 
These mean values for GFR in men and women are higher than those described in the multi-
centre UK study (Peters et al. 2012b), but this can be explained by two factors: firstly, the 
majority of GFR measurements (1783 of 1878) in the multi-centre study were performed using 
51Cr-EDTA and secondly, the mean age of subjects in all the individual centres was higher than 
the mean age of subjects in the current study. Due to the relatively small study population, 
individuals in the current study could not be sub-divided into groups based on other factors 
such as obesity as was done in the multi-centre study (Peters et al. 2012b). 
In another study by the same authors the coefficient of variation (CV) of ECV-BSA in normal 
subjects was found to be useful in assessing departmental performance as it reflects the 
‘technical robustness’ with which the department performs the GFR measurements (Peters et 
al. 2012a). The authors suggest a range of 10-20% as acceptable. The CV for ECV-BSA in this 
study (using the adult Bröchner-Mortensen correction equation (Bröchner-Mortensen 1972)) 
was 15%. 
The BNMS guidelines state that, where practical, a minimum of 10 000 counts should be 
obtained for each sample in order to reduce statistical errors (Fleming et al. 2004). In this study, 
70 of the 126 GFR studies contained samples with fewer than 10 000 counts. The systematic 
error (1 SD) in GFR and VD values due to counting error was found to be low (0.19% and 
0.64% respectively). As expected, the random error (1 SD) was higher (GFR 2.97% and VD 
10.19%). Another deviation from the BNMS guidelines was that no correction was made for 
the decay of Tc-99m. The resultant systematic error (1 SD) was negligible in all cases (GFR -
0.12% and VD -0.22%) therefore it was ignored in further calculations. The random error (1 
SD) was larger (GFR 1.81% and VD 2.37%). By assuming that the error measured in the 26 
cases represented the error introduced through not correcting for decay in all 126 studies, the 
combined random error of noise and lack of decay correction could be calculated. This resulted 
in 3.5% for GFR and 10.5% for VD (1 SD). 
The components of the relatively high combined random error in VD were assessed further. In 
the correlation of uncorrected VD against BSA, a 1 SD error expressed as a percentage of the 
mean VD is 20.3% (equation 9). Part of this variation will be genuine variability of VD with 
BSA, y%, and part due to experimental error. The two components add in quadrature: 
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20.32 = y2 + 10.52                     (14) 
The real standard deviation variation of uncorrected VD with BSA, y, is therefore 17.4%. 
Similarly, for corrected VD, a 1SD error expressed as a percentage of the mean is 17.2% 
(equation 10) and the real standard deviation variation with BSA is 13.6%. These results show 
that, because the error in VD is relatively large, the contribution of low counts and lack of decay 
correction to this variability is small.  
It is worth mentioning that a cohort of 126 studies is relatively small, therefore further larger 
studies are recommended to better define reference data for GFR using 99mTc-DTPA. Secondly, 
the age of all individuals fell between 18 and 59 years, with few over the age of 50, as these 
were the subjects being considered as kidney donors. Ideally, a study of this nature should 
include subjects over a wider range of ages, including individuals over the age of 60 years as 
these are often the patients referred for GFR studies. Moreover, although the hospital’s 
screening process for kidney donors is intensive, it may not have been rigorous enough to 
exclude all subjects with mild renal pathology.  
Having defined the variation of volume of distribution with body surface area and its expected 
variation, this data may be used for quality control. Studies in which the value of VD lies outside 
the expected limits for the subject’s BSA may be deemed fail the quality control (QC) test. 
Considering the corrected VD data shown in Fig. 1.2, two of the studies lie well away from the 
2 SD limits and therefore may be considered to fail the QC requirements. Using 2 SD limits, 
5% of the studies will lie outside the limits due to natural statistical variation, therefore in 
practical use wider limits might be used e.g. 2.5 or 3 SD. Several different methods of 
calculating volume of distribution exist and it is therefore important that in using this parameter 
in quality control values must be compared to the corresponding normal range for that 
particular estimation of the volume. A similar test may be applied to the measured T½. This is 
compared to the expected limits of T½ for the subject’s normalized GFR and if it lies outside 
these, then the study is deemed to fail the QC test (Fig. 1.4). One limitation of the current data 
in this respect is that it only contains data from control subjects. To obtain a better fit for low 
GFR further data is required. 
 
Stellenbosch University https://scholar.sun.ac.za
 16 
 
Conclusion 
This study has defined reference data for GFR, VD and T½ from GFR studies using 
99mTc-
DTPA in a healthy South African adult population. VD and T½ values can provide useful quality 
control checks for GFR studies performed using the slope-intercept method as described in the 
BNMS guidelines (Fleming et al. 2004). Reference data for GFR will enhance the interpretation 
of adult 99mTc-DTPA GFR measurements. The small difference in normal values for GFR in 
comparison to previous studies using 51Cr-EDTA is in agreement with previous publications. 
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Tables and figures 
Fig. 1.1 Scatter graph of VD (uncorrected) vs. body surface area 
 
Scatter graph of the uncorrected values of volume of distribution [VD (uncorrected)] in litres plotted 
as a function of body surface area. The central line represents equation 9, the upper and lower 
lines (dashes) represent ± 2 SD (± 40.6%). The faint dotted lines represent the upper and lower 
limits of the reference range described in the British Nuclear Medicine Society guidelines 
(8*BSA ± 25%) (2 SD) (Fleming et al. 2004). There is overlap of the two lines representing – 
2 SD.  
Abbreviations: VD, volume of distribution; BSA, body surface area; SD, standard deviation; 
BNMS, British Nuclear Medicine Society. 
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Fig. 1.2 Scatter graph of VD (corrected) vs. body surface area 
 
Scatter graph of corrected values of volume of distribution [VD (corrected)] in litres plotted as a 
function of body surface area. The central line represents equation 10, the upper and lower lines 
(dashes) are ± 2 SD (± 34.4%). The faint dotted lines represent the upper and lower limits of 
the reference range determined by University Hospital Southampton (6.61*BSA1.218) ± 32% (2 
SD) (Fleming et al. 2009). 
Abbreviations: VD, volume of distribution; BSA, body surface area; SD, standard deviation. 
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Fig. 1.3 Scatter graph of T½ vs. age 
 
Scatter graph of T½ (min) plotted as a function of age (years). The central line represents the 
mean in individuals under the age of 40 years and the equation-predicted-mean in individuals 
40 years and older (equation 11). The upper and lower lines are ± 2 SD (± 36.2% in individuals 
< 40 years and ± 36.7% in individuals ≥ 40 years). 
Abbreviations: SD, standard deviation 
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Fig. 1.4 Scatter graph of T½ vs. (1/BM-GFRCorr) 
 
Scatter graph of T½ (min) plotted as a function of (1/BM-GFRCorr) [min.(1.73 m
2).ml-1)]. The 
central line represents T½ fitted to equation 12 and the upper and lower lines represent ± 2 SD 
(± 35.1%). 
Abbreviations: BM-GFRCorr, corrected Bröchner-Mortensen glomerular filtration rate; SD, 
standard deviation. 
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Fig. 1.5 Scatter graph of BM-GFRCorr vs. age 
 
Scatter graph of BM-GFRCorr [ml.min
-1.(1.73 m2)-1] as a function of age (18-59 years) in 126 
potential kidney donors. GFR values were corrected for body surface area and using the mean 
Bröchner-Mortensen equation (Bröchner-Mortensen 1972; Fleming et al. 2004). The central 
line represents the mean GFR in individuals under the age of 40 years and the mean fitted to 
equation 13 in individuals 40 years and older. The upper and lower lines represent ± 2 SD (± 
27.5% in individuals under the age of 40 years and 36.7% in individuals older than 40). 
Abbreviations: BM-GFRCorr, corrected Bröchner-Mortensen glomerular filtration rate; GFR, 
glomerular filtration rate; SD, standard deviation. 
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To the editor: 
A recent systematic review (Soveri et al. 2014) concluded that plasma clearance of 99mTc-
diethylenetriaminepentaacetic acid (99mTc-DTPA) is inaccurate for measuring glomerular 
filtration rate (GFR). This was based on data from two studies with poor results (Shemesh et 
al. 1985; Dai et al. 2011), that are incompatible with a number of publications that demonstrate 
the suitability of DTPA plasma clearance. 51Cr-ethylenediaminetetraacetic acid (51Cr-EDTA) 
plasma clearance has been demonstrated to be comparable to renal inulin clearance (P30 value 
of 86%; bias 8%) (Soveri et al. 2014) and may thus be considered a secondary standard against 
which other techniques can be compared. Several publications compare plasma clearance of 
99mTc-DTPA to 51Cr-EDTA, and all demonstrate good overall precision and minimal bias 
(median bias <1%; P30=93%; P10=72%) (Tables and figures 
Fig. 2.1) (Rehling et al. 1984; Fleming et al. 1991; Biggi et al. 1995). 
In both included studies (Shemesh et al. 1985; Dai et al. 2011) the bias was large (14% and 
24.8%), and in the paper by Shemesh et al (Shemesh et al. 1985), there was very poor 
correlation between plasma 99mTc-DTPA clearance and renal inulin clearance (r = 0.694). 
Given subsequently published data, the measurements obtained in these studies are likely to be 
fundamentally flawed. Likely reasons include inadequate correction of the slope-intercept GFR 
(Shemesh et al. 1985; Dai et al. 2011),  unusual methodology to measure renal inulin clearance 
(Dai et al. 2011), and probable use of a poor quality DTPA preparation as was common in the 
earlier days of DTPA usage (Carlsen et al. 1980; Shemesh et al. 1985). 
The recent review (Soveri et al. 2014) provides a valuable comparison of a number of 
techniques to measure GFR. However, we believe the authors have erred in advising against 
the use of 99mTc-DTPA plasma clearance based on data from two questionable studies. We are 
firmly of the view that there is sufficient evidence in the literature supporting its use. 
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Tables and figures 
Fig. 2.1 Comparison of 99mTc-DTPA and 51Cr-EDTA plasma clearance 
 
 
(A) Comparison of simultaneous plasma 99mTc-DTPA and 51Cr-EDTA clearance; data derived 
from three studies (Rehling et al. 1984; Fleming et al. 1991; Biggi et al. 1995). (B) A Bland-
Altman-like diagram of the difference between 99mTc-DTPA and 51Cr-EDTA clearance plotted 
against 51Cr-EDTA clearance. The solid lines show the proportion of 99mTc-DTPA 
measurements that were within 30% of the 51Cr-EDTA values (P30), and the dashed lines show 
the P10 limit. 
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Abstract 
 
Background: Measurement errors occurring during glomerular filtration rate (GFR) studies 
propagate to an error in the calculated GFR. Previous work has modelled measurement errors 
for slope-intercept (SI-GFR), single-sample (SS-GFR) and slope-only (SO-GFR) methods. In 
this study we have extended these models. The primary aims were to 1) compare measurement 
errors in 2-sample SI-GFR, 3-sample SI-GFR, SS-GFR and SO-GFR, and 2) determine the 
sensitivity of GFR to errors arising from different measurements. 
Methods: This study expanded on previous models of GFR measurement error incorporating 
biological data from 786 patients, and realistic measurement errors. GFR median absolute error 
(MAE) and the coefficient of variation (CV) were calculated for each method.  A sensitivity 
analysis was performed for individual measurement errors.  
Results: MAE ranged between 1.2 and 2.3 ml/min/1.73 m2, lowest for SS-GFR (4 h) and 
highest for SO-GFR. At higher rates of clearance, CV was < 5% for all methods. CV increased 
rapidly when GFR dropped below a threshold ranging between 34 and 56 ml/min/1.73 m2, 
lowest for 3-point SI-GFR and highest for SO-GFR. SI-GFR and SS-GFR are most sensitive 
to injected activity quantification, but less sensitive to other measurement errors. 
Conclusion: Measurement errors are probably insignificant relative to biological variation for 
GFR > 60 ml/min/1.73 m2 but become significant regardless of biological variation at lower 
GFR, particularly in serial studies when GFR < 25 ml/min/1.73 m2. Limits of precision 
recommended in the 2018 British Nuclear Medicine Society guideline are appropriate for once-
off GFR measurement, whereas slightly more stringent limits are proposed for serial studies. 
 
Keywords: glomerular filtration rate, adult, humans, radiopharmaceuticals, quality control 
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Introduction  
Using nuclear medicine techniques, glomerular filtration rate (GFR) is measured from the 
plasma clearance of 51Cr-EDTA or 99mTc-DTPA with either the slope-intercept method (SI-
GFR) (Chantler et al. 1969), a single sample technique (SS-GFR) (Fleming et al. 2004), or the 
slope-only method (SO-GFR) (Peters 1992; Bird et al. 2009). Regardless of the method, 
multiple measurements are required, and errors are introduced with every measurement. These 
errors propagate, leading to an error in the final GFR value. Previous work has shown that the 
magnitude of the resultant errors differs according to the method (De Sadeleer et al. 2000; De 
Sadeleer et al. 2001), but it can be argued that these analyses may not provide a complete and/or 
realistic reflection of the measurement errors likely to occur in a busy clinical department, 
particularly within a training hospital where staff are frequently inexperienced (Watson 2000; 
Peters 2001). In addition, while the magnitude of errors was well quantified in these analyses, 
their clinical significance was not addressed (Watson 2000). Patients are frequently referred 
for serial GFR measurements to detect deterioration in kidney function; however, GFR must 
change by at least 20% before it can be regarded as significant (Fleming et al. 2004). This is 
high because of the high coefficients of variation (CV) of repeat GFR measurements that have 
been found previously (Bröchner-Mortensen and Rödbro 1976; Wilkinson et al. 1990; Blake 
et al. 1997; Grewal and Blake 2005; Delanaye et al. 2008a; Bird et al. 2008). Measurement 
errors and biological fluctuations are the two sources of this variability (Blake et al. 1997), but 
the exact contribution of each is not known. This knowledge would be useful as many of the 
measurement errors can be controlled and minimised. Efforts to minimise measurement errors 
would be justified if this would appreciably reduce the variability of GFR measurements. 
Many centres adopted SI-GFR after publication of the 2004 British Nuclear Medicine Society 
(BNMS) guideline (Fleming et al. 2004), and there are many proponents of SO-GFR. However, 
following a study that showed SS-GFR, using the technique described by Fleming et al 
(Fleming et al. 2005a), to have an accuracy comparable to that of SI-GFR, SS-GFR has become 
the recommended method in the 2018 updated BNMS guideline (McMeekin et al. 2016a; 
Burniston 2018). The current study therefore aims to model measurement error in adult GFR 
as accurately as possible by introducing realistic errors to as many measurements/sources as 
possible. The objectives were (i) to compare measurement errors in SI-GFR, SS-GFR, and SO-
GFR; (ii) to estimate the magnitude of measurement errors relative to biological variation in 
GFR; (iii) to perform a sensitivity analysis of individual measurement errors; and (iv) to make 
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practical recommendations to minimize errors in the context of a typical clinical unit. 
Methods 
Calculation of actual slope, intercept, and half-life  
The demographic and original count data was extracted from the folders of all adults (≥ 18 
years) who underwent GFR determination in the Tygerberg Hospital Nuclear Medicine 
Division between January 2008 and March 2016. The data was included only if 3 or more blood 
samples had been taken and if all information was complete. 
GFR was measured using the slope-intercept method, with corrections for body surface area 
(BSA) and the missing first exponential, adhering to the methodology and calculations in the 
2004 BNMS guideline (Fleming et al. 2004). After recording patient height and weight, 99mTc-
DTPA (Technescan®DTPA, Mallinckrodt, Netherlands) was administered through an 
indwelling intravenous cannula. In the majority of patients the dose was 40 MBq, while in 
cases where simultaneous renography was performed, 400 MBq was administered. Both 
patient and standard doses were weighed before and after administration of the dose on a 
Precisa 620 C balance (Precisa Balances Ltd, Milton Keynes, United Kingdom), without 
flushing the syringe or changing needles or needle caps. Three venous blood samples were 
taken from the opposite arm at approximately 2, 3, and 4h. The exact times were recorded to 
the nearest minute. Blood samples were immediately centrifuged (1000 g for 10 min) and then 
duplicate 1 ml plasma samples were pipetted into counting tubes. A standard was prepared 
using a similar dose of 99mTc-DTPA obtained from the same vial. To avoid excessively high 
count rates, a double dilution of the standard was performed, resulting in an effective volume 
of 5 litres. The count rates of duplicate 1 ml standard samples, the plasma samples, and 
background samples were determined using a Picker NaI(Tl) well counter (Picker International 
Inc, Cleveland, Ohio, United States).  
The natural logarithm of the plasma concentration of 99mTc-DTPA was plotted against time for 
each time point, and a linear curve fitted to the data points. From this curve, the slope (-k) and 
intercept (loge P0) were obtained. The half-life (T½) was calculated using the equation: 
T½ = -0.693/k 
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Modelling of measurement errors 
To be as realistic as possible measurement errors were generated based on actual errors from 
our unit, and real patient data was used to reflect patient variation. The model is described in 
three steps described below: 
1. Generation of idealised starting values 
Based on the original patient data and assuming values for the count rate of the standard 
samples (counts/min/ml; CPM/ml), P0 and k represented the “ground truth”, idealised starting 
values were derived for the standard dose (CPM) and for plasma concentration (CPM/ml) at 2, 
3 and 4 hours. Masses of the standard and patient dose syringes, pre- and post-administration, 
as well as the patients’ heights and weights were also assumed to represent “ground truth” 
starting values. Background counts were initially set to a fixed value of 400 for all patients 
(typical background counts in our unit). Finally, in order to model minimum requirements of 
the 2004 BNMS guideline (Fleming et al. 2004), the average counts of the latest sample for 
each patient was scaled to a value of 10 000, with the same scaling factor being applied to all 
counts in that patient’s study. Each step in the preparation of the standard was modelled. In our 
unit where a double dilution of the standard is performed, the following steps were modelled: 
(i) filling of flask 1 to 100 ml (after adding the dose), (ii) pipetting of 2 x 1 ml aliquots from 
flask 1 into flask 2, (iii) filling of flask 2 to 100 ml. 
2. Calculation of reference GFR  
Without the introduction of any measurement errors, the idealised starting values were used to 
calculate reference GFR values for the three methods.  
SI-GFR was calculated using the equation (Fleming et al. 2004): 
SI-GFR = VD x (0.693/T½), where VD = 100/P0 
The SI-GFR value was corrected for BSA (m2), which was calculated using the Haycock 
formula (Haycock et al. 1978): 
SI-GFRCorr = SI-GFR x (1.73/BSA) 
Thereafter, the mean Bröchner-Mortensen equation (Bröchner-Mortensen 1972; Bröchner-
Mortensen et al. 1974; Fleming et al. 2004) was applied to correct for the missing fast 
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exponential: 
 BM-GFRCorr = (1.0004 x SI-GFRCorr) – 0.00146 x (SI-GFRCorr2) 
All three plasma samples were used to generate a three-point SI-GFR [3pt SI-GFR (2, 3, 4 h)]. 
In addition, two-point SI-GFR values were calculated using the 2 and 3 h samples [2pt SI-GFR 
(2, 3 h)], the 3 and 4 h samples [2pt SI-GFR (3, 4 h)], and the 2 and 4 h samples [2pt SI-GFR 
(2, 4 h)]. While these create identical reference values, the SI-GFR error is expected to differ 
for each of the 4 methods. 
SS-GFR was calculated from both 3 h [SS-GFR (3 h)] and 4 h [SS-GFR (4 h)] samples using 
the technique described by Fleming et al (Fleming et al. 2005a):  
SS-GFRt = {[-11297 – (4883xBSA) – 41.9t] + [5862 + (1282xBSA)15.5t] + ln[Vapp(t)]}/t 
where BSA is the body surface area in square metres, t is sampling time in minutes and Vapp 
is the apparent volume of distribution in litres/1.73 m2. 
Vapp (t) = [A x 1.73]/[p(t) x BSA] 
where A is the total activity injected and p(t) the plasma activity concentration at time t. 
The units for SI-GFR and SS-GFR are ml/min/1.73 m2. 
SO-GFR was calculated using the equation described by Bird et al (Bird et al. 2009): 
SO-GFR = α2 + [15.4 x (α22)] 
where α2 is the rate constant of terminal exponential. SO-GFR is expressed in ml/min/L.  
For purposes of comparison with SI-GFR and SS-GFR, all values for SO-GFR were multiplied 
by the extracellular fluid volume of the standard person (12.5 L/1.73 m2) (Peters et al. 2000).  
3. Introduction of error 
Each method of GFR determination was modelled using realistic, normally distributed, random 
errors introduced to all measurements. The magnitude of error for each measurement was based 
on what has been observed within our institution. Table 3.1 lists the measurements, the one 
standard deviation (SD) error that was introduced to each, and the method used to determine 
the error. The calculated GFR values were compared to the reference values for each method. 
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Modelling of real GFR measurements was performed using in-house software written in R (The 
R-project for statistical computing; version 3.4.3, The R foundation, Vienna, Austria, 2018). 
One thousand simulations were performed per patient.  
Statistical analysis 
The median absolute error was calculated for each patient. Subsequently, the median absolute 
error was calculated across all patients. This was performed for all 7 methods/variations: 3pt 
SI-GFR (2, 3, 4 h), 2pt SI-GFR (2, 3 h), 2pt SI-GFR (3, 4 h), 2pt SI-GFR (2, 4 h), SS-GFR (3 
h), SS-GFR (4 h), and SO-GFR. CV was calculated for each patient and plotted against 
reference GFR. The 7 methods/variations were compared qualitatively as significance is 
expected due to the use of a large number of simulations. 
Sensitivity analysis 
In a second experiment, the sensitivity of each method to individual measurement errors was 
assessed. All measurement errors, other than the one being evaluated, were held at their realistic 
values. The standard deviation of the error in question was then varied between 0 and a value 
large enough to result in a mean error in GFR of 5 ml/min/1.73 m2.  Error in GFR was plotted 
against the SD of the evaluated measurement. 
For counting errors, where the standard deviation of the error is a function of counts, the 
minimum counts were varied between 10 000 and a value small enough to result in a mean 
error in GFR of 5 ml/min/1.73 m2. Error in GFR was plotted against the CV of counts. This 
was performed with background counts set to 400 and was repeated with background counts 
of 1500 and 3000, to reflect situations where lower count rates are expected (e.g. centres using 
51Cr-EDTA). 
Ethical approval was obtained from the Stellenbosch University Health Research Ethics 
Committee (Protocol S14/08/166). 
Results 
GFR studies of 786 adults (512 female) were included in the error model. Mean (SD) GFR was 
83.2 (26.7) ml/min/1.73 m2 (range 10 to 158 ml/min/1.73 m2). The diagnoses of the patients 
referred for GFR determination were cancer (536), chronic kidney disease (40) or urological 
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problems (14), and a further 196 individuals were healthy potential kidney donors. 
The resultant errors in GFR are summarised in Table 3.2 and the box-and-whisker plots (Fig. 
3.1). Median absolute error (MAE) ranged between 1.2 and 2.3 ml/min/1.73 m2, lowest for SS-
GFR (4 h) and highest for SO-GFR. The relative error ranged between 1.3% and 2.7%. The 
proportion with errors in GFR greater than 5% ranged between 0% for SS-GFR (4 h) and 6.2% 
for 2pt SI-GFR (2, 3 h). Figure 2 displays the CV as a function of GFR. At higher rates of 
clearance the CV was relatively low and independent of GFR for all methods, but as GFR 
decreased, the CV started increasing exponentially. The CV crossed a threshold of 5% at 
clearance values ranging between 34 and 56 ml/min/1.73 m2, lowest for 3pt SI-GFR (2, 3, 4 h) 
and highest for SO-GFR (Table 3.2).  
The sensitivity analyses of the individual measurements are displayed in Fig. 3.3. Only 3pt SI-
GFR (2, 3, 4 h), SS-GFR (3 h) and SO-GFR are presented for the sake of brevity, however 
similar results were obtained for all methods. Using 3pt SI-GFR (2, 3, 4 h) and SS-GFR (3 h) 
an absolute error in GFR of 5 ml/min/1.73 m2 was reached when the measurement errors 
exceeded the following values: weight 12 kg, height 40 cm, time 25 min, flask volume 6%, 
pipette volume 8%, balance 0.05 g, and CV of counts 4.3%. Using SO-GFR an absolute error 
in GFR of 5 ml/min/1.73 m2 was induced when measurement errors exceeded the following 
values: time 6 min, pipette volume 6% and counts 3.4%.  
Discussion 
In this study we found that after introduction of realistic, random errors to all measurements, 
the resultant median absolute error (MAE) in GFR was low for all methods, ranging between 
1.2 and 2.3 ml/min/1.73 m2 (Table 3.2). Consistent with previous studies (De Sadeleer et al. 
2000; Watson 2000; De Sadeleer et al. 2001), the error was lowest for SS-GFR (4 h) and highest 
for SO-GFR. SS-GFR (4 h) was also the most precise method (97.5th percentile 1.4 ml/min/1.73 
m2). Interestingly, 2pt SI-GFR (3, 4 h) was least precise (97.5th percentile 4.1 ml/min/1.73 m2), 
while the precision of SO-GFR and the other SI-GFR variations was similar. A single median 
absolute value across all patients is useful as it is relatively independent of GFR, whereas 
expressing the error as a coefficient of variation (CV) allows for comparison with previous 
studies as well as estimation of the contribution of measurement error, as opposed to biological 
variation, to the variability of repeat GFR measurements. CV was highly dependent on GFR 
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for all methods, rising sharply when the GFR fell below 60 ml/min/1.73 m2 (Fig. 3.2). This is 
expected as the error remains stable in absolute terms even when the GFR becomes low. While 
the mean CV of SS-GFR was lower than the other methods at normal and higher rates of 
clearance, for GFR values < 50 ml/min/1.73 m2, the mean CVs of 3pt SI-GFR (2, 3, 4 h) and 
2pt SI-GFR (2, 4 h) were the lowest.  
The differences in sensitivity of the methods to measurement errors can, in part, be explained 
by the methodology. SI-GFR, the method recommended in the 2004 British Nuclear Medicine 
Society (BNMS) guideline (Fleming et al. 2004), calculates GFR from the area under the 
second (slower) exponential of the plasma clearance curve, assuming a single compartment 
(Chantler et al. 1969). It requires at least two plasma samples taken after equilibration of the 
radiopharmaceutical with interstitial fluid. A disadvantage of SI-GFR is the procedure’s 
relative complexity. However, SI-GFR is protected from measurement errors by an inherent 
robustness:  errors that affect the slope have a reciprocal effect on the volume of distribution 
(VD), and because SI-GFR is the product of the slope and VD, resultant errors in GFR tend to 
be buffered (Blake et al. 1997; Peters 2001). SI-GFR is further stabilized by taking more than 
the minimum of two blood samples, as an increase in the number of samples leads to a better 
estimation of both slope and intercept, thus improving the precision of the GFR. 
Single-sample methods use an empiric equation to estimate GFR from the apparent volume of 
distribution, calculated from the tracer concentration in the plasma sample at a specific time 
(Fleming et al. 2004). SS-GFR is more convenient and comfortable for patients, and, because 
it requires fewer measurements, the potential for measurement error may be reduced. SO-GFR 
calculates GFR purely from the slope of the second (slower) exponential, expressing GFR in 
terms of extracellular fluid volume (Peters 1992). Of the three methods, SO-GFR is the most 
straightforward to perform. It does not require preparation of a standard, and measurement of 
the doses, patient height and patient weight are not necessary. Although SO-GFR requires 
fewer measurements, it is generally more sensitive to these errors than SI-GFR, most likely 
because it lacks the buffering mechanism intrinsic to SI-GFR. Surprisingly, while the same 
disadvantage may be expected for SS-GFR, it was found to be generally more robust than SI-
GFR. This may be due to the fact that the equation for the single sample is dependent on an 
estimate of the volume of distribution of tracer (Fleming et al. 2005a). This is proportional to 
the reciprocal of the intercept of the plasma clearance and so effectively provides an estimate 
of the intercept. This means that the single sample equation may contain some inherent 
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buffering, which is sufficient to keep it robust against experimental errors. 
In summary, for GFR values > 60 ml/min/1.73 m2, the mean CV was found to be < 5% for all 
methods. At a GFR of 50 ml/min/1.73 m2, the CV ranged between 3.7% and 5.8%, while at a 
GFR of 25 ml/min/1.73 m2, the CV ranged between 6.2% and 9.3% (Fig. 3.2). These findings 
are consistent with the results reported by De Sadeleer et al (De Sadeleer et al. 2000; De 
Sadeleer et al. 2001) and Watson (Watson 2000). De Sadeleer et al used a Monte Carlo 
simulation to compare the magnitude of error in SI-GFR and SO-GFR after introducing 
normally distributed random errors to sampling time and activity measurement (De Sadeleer et 
al. 2000). From the data of this study, using minimum counts of 10 000, background counts of 
400, pipetting error of 2%, and modelling determination of sample activity as the average of 
two samples, the activity measurement had a CV of 1.5 – 1.6%. Applying this and a timing 
error of 2 minutes to de Sadeleer’s model resulted in an uncorrected GFR CV that was on 
average almost 2% lower than those generated by the model used in this study for GFR between 
40 and 80 ml/min (data not shown), suggesting that additional errors from measurement of the 
standard dose, modelling the preparation of the standard, and counting of standard samples 
contribute significantly to GFR CV. This is consistent with the significant increases found by 
Watson et al (Watson 2000).  
The model used in this study further incorporated errors in the measurement of weight and 
height to model error propagation in Bröchner-Mortensen corrected SI-GFR, and single sample 
techniques. It has built on existing models of measurement error as accurately as possible using 
errors that can be expected in a busy clinical unit. Furthermore, the model used in this study 
generated simulations based on ground truth characteristics derived from a large and diverse 
population of real patients. This approach is supported by plots of individual patient CV values, 
which still show significant inter-patient variation for a given GFR despite the use of 1000 
simulations per patient (Fig. 3.2).  
Patients with chronic kidney disease or those being treated with nephrotoxic drugs frequently 
require serial GFR measurements. For the nephrologist/oncologist, timely identification of a 
deterioration in kidney function is essential. The CV for repeat GFR measurements has been 
shown to be high, ranging between 7.5% and 12.2% (Bröchner-Mortensen and Rödbro 1976; 
Wilkinson et al. 1990; Blake et al. 1997; Grewal and Blake 2005; Delanaye et al. 2008a; Bird 
et al. 2008). Consequently, a large (> 20%) drop in GFR is required before the change can be 
considered significant (Fleming et al. 2004). It is useful to estimate the relative contribution of 
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measurement error as these errors can, to a certain extent, be controlled. The CV of the biologic 
variation (CVBV) and the CV of measurement errors (CVME), added in quadrature, will give the 
CV of repeat measurements (CVRM):  
(CVBV)
2 + (CVME)
2 = (CVRM)
2 
After matching the populations and methodology as closely as possible, the CVME for each of 
the previous studies was estimated and subsequently the CVBV could be calculated. CVBV was 
found to range between 2.8% and 11%. This wide range is likely due to heterogeneity of both 
study populations and study conditions. The population with the highest CVBV had low mean 
GFR (45 ml/min) and the subjects were allowed free exercise during the study (Wilkinson et 
al. 1990), while the population with the lowest CVBV had a higher mean GFR (79 ml/min) and 
were studied under conditions of strict bedrest (Bröchner-Mortensen and Rödbro 1976). It is 
difficult to postulate where within this range the CVBV of the current study’s population would 
lie, but assuming a value of 6.8% (median across the previous studies), in cases of normal 
clearance (GFR > 60 ml/min/1.73 m2) where the CVME is consistently 3% - 4%, the CVRM 
would be < 8%. In this scenario CVME is small in relation to CVBV and reducing measurement 
errors further will have little impact on CVRM. Interestingly data from the previous studies 
suggests that differences in patient preparation (i.e. exercise vs. bedrest and fasting vs. non-
fasting) may have a greater impact on the CVRM than measurement errors alone (Bröchner-
Mortensen and Rödbro 1976; Wilkinson et al. 1990). At lower rates of clearance where CVME 
is large, its relationship relative to CVBV is uncertain. There is little data on CVRM at low GFR, 
but given the rapid rise in CVME, it is expected that CVRM would increase similarly. The 
resultant high CVRM is likely to render the investigation unusable. For example, even assuming 
a constant CVBV of 6.8%, at a GFR of 20 ml/min/1.73 m
2, the CVME of 3pt SI-GFR (3, 4 h) is 
approximately 8.5% (Fig. 3.2) and therefore CVRM will equal 13%. This means that GFR would 
have to drop by over 35% (2.8 x CV) before any change can be, with 95% confidence, regarded 
as significant (Fleming et al. 2004).  
Error is inherent to every measurement and these errors propagate, resulting in an error in the 
final GFR value. The sources of the errors vary: counting error is statistical; some measurement 
errors arise due to finite equipment precision (e.g. patient scale, balance for weighing doses); 
others from user imprecision due to inexpert use of equipment (e.g. pipetting volume, recording 
of time). While equipment imprecision and lack of expertise are seldom problems in a research 
setting, they are more common in a busy clinical department, particularly in a training hospital 
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where junior staff may be inexperienced. The second part of this paper has attempted to assess 
the sensitivity of GFR to individual measurement errors. SO-GFR is independent of many 
measurements (height, weight, flask volume and dose), yet it is more sensitive than SI-GFR 
and SS-GFR to errors in time and pipetting volume. Measurement errors had a similar effect 
on 3pt SI-GFR (2, 3, 4 h) and SS-GFR (3 h), both being relatively insensitive to errors in 
pipetting volume and flask volume, thus supporting the conclusions of De Sadeleer et al (De 
Sadeleer et al. 2001). Similarly, errors in height, weight and time measurement must be gross 
before the effect on GFR becomes clinically significant. Measurements performed based on 
the accuracy/precision requirements of the 2018 guideline (height 2 cm, weight 1 kg, time 1 
minute) are expected to have minimal impact on GFR variability. Indeed even “suboptimal” 
measurements of these parameters e.g. using simple measuring devices without attention being 
given to whether shoes or coats are removed, or using unsynchronized clocks, are unlikely to 
have a major impact. This may be particularly relevant in patients who are difficult to measure 
due to being bedbound or wheelchair bound. 
The measuring of dose syringes is however of greater importance.  The precision of the balance 
in our unit is 0.005 g. After adding this error to the pre-administration syringe mass, and to the 
mass of the post-administration syringe, the error on the administered dose will be 0.007 g (i.e. 
√(0.0052 + 0.0052),  equivalent to 0.7% of the 1 g dose used in our department for both standard 
and patient doses. If the administered dose volume was halved (i.e. 0.5 g), the error would 
double (1.4%). It must also be noted that if the standard and patient dose volumes differ, their 
error will differ. The 2018 guideline (Burniston 2018) recommends an accuracy/precision of 
2% on the difference of the pre- and post-administration syringe masses. Assuming balance 
precision of 0.005 g, the error on the administered dose exceeds the 2% threshold for doses < 
0.35 g. If a less precise balance were to be used, the mass of the administered dose would need 
to be higher to achieve 2% accuracy e.g. for a balance with precision of 0.01 g, the minimum 
administered mass would need to be 0.7 g. The same principles apply to centres that measure 
their doses by volume or activity. It is suggested that individual centres determine the error on 
their full and empty syringe masses, for both patient and standard doses, based on the specific 
methodology and instruments used. 
This study modelled the standard dilution protocol used in our institution. Different dilution 
protocols, both in terms of procedure and actual dilution, are expected to alter GFR error by 
altering the error of standard counts and altering the impact of flask volume error and pipetting 
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errors. In our department we estimated an error of 0.5 ml on flask volume, which is 0.5% for 
the 100 ml flasks used, whereas a 0.5 ml error on a 1 L flask (i.e. 0.05%) would result in a 
smaller error in GFR. Similarly, the impact of a 2% pipetting error is greater for higher 
concentrations of activity i.e. when smaller flask volumes are used or when higher doses of 
activity are added to the standard. In our department a double dilution of the standard is 
performed resulting in an effective volume of 5 L. This will reduce the impact of pipetting 
error; however, this is likely negated by the additional steps required in preparation of the 
second dilution, together with the use of low-volume (100 ml) flasks.  
 An unexpected observation is the relative robustness of GFR to low counts. In the 2004 
guideline (Fleming et al. 2004) it is stated that in order to minimize statistical counting error, a 
minimum of 10 000 counts is required for all samples. In this study it was found that total 
counts could reach surprisingly low levels before the error in GFR became significant (Fig. 
3.3). The CV of counts is dependent on both sample and background counts. Obtaining 
sufficient counts is not a problem for centres using 99mTc-DTPA, as counts frequently exceed 
10 000 after just a few minutes of counting with background counts that are low, resulting in a 
count CV of ~1%. However, this finding is reassuring to centres using 51Cr-EDTA  where 
lower doses of activity are administered. Here the prescribed minimum of 10 000 counts may 
be impossible to achieve despite much longer counting times, and this is compounded by 
background counts which are consequently higher.  The results of this study suggest that a less 
strict minimum number of counts may be adhered to without significantly affecting GFR 
measurement precision. The 2018 guideline recommends precision better than 2% for sample 
counts (Burniston 2018). A simple approach to meet this would be for all count measurements 
to have counts >2500+background. In the 3 background scenarios modelled here count 
precision would vary from 1.3-1.9% with minimal impact on GFR variability. 
How precise should individual measurements be? There is not a single, straightforward answer 
to this question as it depends on the indication for the study, the actual GFR, and the method 
used for GFR calculation. If using SO-GFR, precision is important. Time measurements should 
be kept accurate to within 1 minute and the error on pipetting volume should be < 1%. For a 
once-off GFR measurement using SS-GFR or SI-GFR extreme precision is not required and, 
as set out above, the equipment precision limits listed in the appendix of the 2018 BNMS 
guideline (Burniston 2018) are appropriate. Using these limits, median absolute errors would 
be < 2.3 ml/min/1.73 m2 and 1.8 ml/min/1.73 m2 for SI-GFR and SS-GFR respectively. 
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However, while the impact is finite, the greatest care realistically possible is required when 
serial GFRs are required, particularly when GFR < 60 ml/min/1.73 m2. In these cases, precision 
of every measurement is essential to keep CVME as low as possible. The problem is that one 
seldom knows at the outset which patients will require serial GFR measurement and which 
patients will have reduced kidney function. It is therefore reasonable to suggest that all 
measurements are kept as precise as possible. Table 3.3 lists the measurements, suggested 
maximum errors for each, and methods to adhere to these limits. Using these slightly stricter 
limits, median absolute errors would be < 1.3 ml/min/1.73 m2 and 1.0 ml/min/1.73 m2 for SI-
GFR and SS-GFR respectively. Values for minimum counts are based on the BNMS guideline 
recommendation of keeping counting error to < 2%, and this is appropriate for SI-GFR, SS-
GFR and SO-GFR.  
A recent meta-analysis of 1.7 million individuals with chronic kidney disease showed that a 
decline in estimated GFR of 30% was associated with a significantly increased risk of end stage 
renal disease (Coresh et al. 2014). In order to detect a 30% deterioration, CVME would have to 
be kept to < 8.3% (assuming a median CVBV of 6.8%). Although the exact GFR at which CVME 
reaches 8.3% varies, it seems reasonable to suggest a single cut-off of 25 ml/min/1.73 m2 for 
all methods, below which CVME becomes too high to meaningfully interpret serial GFR 
measurements. Should a referring clinician require detection of a 20% deterioration, CVME 
would have to be kept to approximately 2%, but this is only realistically achievable when GFR 
> 60 ml/min/1.73 m2 and meticulous care is paid to precision.  
The 2018 BNMS guideline (Burniston 2018) provides a list of quality control checks that 
should be routinely implemented when measuring GFR. One of the recommendations is that 
the difference in counts between duplicate samples should be less than expected levels when 
pipetting accuracy and counting error are both kept under 2%. It follows that the expected value 
would have to be determined for each centre as it is dependent on both minimum and 
background counts, which in turn, depends on the activity administered. In our unit, where 10 
000 counts are obtained within a few minutes of counting with background counts of < 400 
(due to higher doses of 99mTc-DTPA), the 95th percentile for the difference between duplicates 
is 3.5%. However, with background counts of 1500 and minimum counts are 4000, the 95th 
percentile for the difference between duplicates is 5.5%.  
This study has several limitations. Only adult GFR data has been evaluated. However, it is 
expected that most measurements, and their errors will be similar in children. Importantly, this 
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study did not specifically address the issue of gross human errors, e.g. inadvertent swapping of 
patients’ samples or misinjections; mishaps that frequently lead to grossly erroneous GFR 
results. While the results of this study may provide further evidence to support a transition from 
SI-GFR to SS-GFR, in line with the updated BNMS guideline (Burniston 2018), there remains 
a concern that these not uncommon but potentially catastrophic errors/mishaps may not be 
detected using SS-GFR due to a lack of QC opportunities. Using SS-GFR, the current guideline 
recommends later blood sampling in cases of lower GFR (6 h for GFR 25 to 50 ml/min/1.73 
m2 and 24 h for GFR < 25 ml/min/1.73 m2) (Burniston 2018). It is possible that CVME would 
be lower had the recommended time points been assessed, but this was not possible due to the 
lack of data at 6 h and 24 h. The approach taken for the sensitivity analysis of GFR to 
measurement errors represents a first order approximation as it focused on each error 
individually, thereby ignoring the possibility that errors may interact, either accentuating or 
attenuating each other. Radiopharmaceutical errors including small differences in protein 
binding between kits, or slight differences in the fraction of impurities (99mTcO4
- and 
hydrolysed reduced 99mTc) (Rehling et al. 2001)  were not included in our model, and their 
contribution is not known. It must also be noted that the intention of this study was to evaluate 
measurement errors only. Systematic errors arising from the use of simplified methods, as 
opposed to calculation of GFR from the area under the full plasma clearance curve, have been 
addressed elsewhere (Bird et al. 2007; McMeekin et al. 2016a). 
In conclusion, measurement errors that occur on a day-to-day basis in a busy nuclear medicine 
department are unlikely to result in clinically significant errors in GFR when it is measured 
once-off, irrespective of the method. However, due to the considerable intra-individual 
variation in GFR, measurement errors must be kept to a minimum when serial GFR studies are 
being performed, particularly when GFR is below 60 ml/min/1.73 m2. Serial measurements 
should not be performed when GFR < 25 ml/min/1.73 m2, as detecting a significant decline in 
GFR becomes increasingly difficult.   
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Tables and figures 
 
Table 3.1 Summary of the measurement errors introduced  
Measurement SD error Method to determine error 
Patient height 5 cm Departmental audit 
Patient weight 2.5 kg Estimation 
Sample times 2 min Estimation 
Standard flask volume 0.5% Departmental audit 
Pipetting volume 2% Departmental audit 
Syringe masses 0.005 g Precision of the balance 
Counts √counts Poisson distribution 
Abbreviations: SD, standard deviation 
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Table 3.2 A comparison of methods after introduction of realistic errors to all measurements 
Method 
Absolute error (ml/min/1.73 
m2) 
 
[median (2.5%; 97.5%)] 
Relative error 
(%) 
 
[median (2.5%; 97.5%)] 
Proportion with 
errors > 5% 
 
[% (95% CI)] 
GFR at which CV exceeded 
5% 
 
(ml/min/1.73 m2) 
3pt SI-GFR (2, 3, 4 h) 1.7 (0.9; 2.5) 2.0 (1.6; 4.4) 1.7 (0.8; 7.8) 34 
2pt SI-GFR (2, 3 h) 1.9 (1.4; 2.9) 2.2 (1.7; 8.3) 6.2 (4.5; 7.8) 52 
2pt SI-GFR (2, 4 h) 1.8 (0.9; 2.6) 2.1 (1.7; 4.4) 1.5 (0.7; 2.4) 34 
2pt SI-GFR (3, 4 h) 2.2 (1.1; 4.1) 2.6 (1.9; 6.9) 4.1 (2.7; 5.5) 42 
SO-GFR 2.3 (1.6; 3.2) 2.7 (2.1; 5.9) 4.0 (2.6; 5.4) 56 
SS-GFR (3 h) 1.6 (1.3; 1.8) 1.8 (1.2; 4.2) 0.8 (0.2; 1.4) 48 
SS-GFR (4 h) 1.2 (1.0; 1.4) 1.3 (0.9; 3.4) 0.0 (0.0; 0.0) 40 
Abbreviations: GFR, glomerular filtration rate; CV, coefficient of variation; SI-GFR, slope-intercept GFR; SO-GFR, slope-only GFR; SS-GFR, 
single-sample GFR 
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Fig. 3.1 Box-and-whisker plots comparing the seven methods of GFR calculation 
 
Box-and-whisker plots comparing the seven methods of GFR calculation: (a) absolute error 
(ml/min/1.73 m2) and (b) relative error (%). The solid lines represent the median values; the 
boxes represent the interquartile ranges; and the whiskers the 95% ranges.  
Abbreviations: GFR, glomerular filtration rate; SI-GFR, slope-intercept GFR; SO-GFR, 
slope-only GFR; SS-GFR, single sample GFR. 
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Fig. 3.2 Scatter plots of CV vs. GFR 
 
Scatter plots of CV vs. GFR after introduction of realistic errors to all measurements for the 7 
calculation methods/variations. The solid lines represent smoothed regression lines.  
Abbreviations: CV, coefficient of variation; GFR, glomerular filtration rate; SI-GFR, slope-
intercept GFR; SO-GFR, slope-only GFR; SS-GFR, single-sample GFR. 
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Fig. 3.3 Scatter plots of the error in GFR vs. error in each measurement 
 
Scatter plots of the error in GFR vs. a varying 1 SD error for each measurement (a-f), and 
error in GFR vs. the CV of the minimum counts obtained (g-i).   ̶ ̶ ̶̶ ̶ ̶ ̶ ̶ ̶ ̶  3pt SI-GFR (2, 3, 4 h); 
………..….SO-GFR; - - - - - -SS-GFR (3 h). The solid dots represent realistic values. SO-GFR 
values are plotted on a, b, d, and f for purposes of comparison only.  
 
Abbreviations: GFR, glomerular filtration rate; SD, standard deviation; CV, coefficient of 
variation; BG cts, background counts; SI-GFR, slope-intercept GFR; SO-GFR, slope-only 
GFR; SS-GFR, single-sample GFR.  
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Table 3.3 Suggested maximum allowable errors for all measurements and methods to achieve 
this 
Measurement Suggested maximum 
error 
Methods to minimize error or reduce its 
impact  
Height  2 cm Use of a single wall-mounted height rod 
Removal of shoes 
Weight 1 kg Use of a single scale 
Removal of bulky clothing, shoes and 
items in pockets 
Time 1 min Use of a single digital clock  
Synchronization of clocks if blood 
samples are taken outside the department  
(Important for SO-GFR) 
Volumetric 
flask volume 
0.5% Use of a larger volume flask 
Adequate training of technologists;  
Pipetting 
volume 
1% Adequate training of technologists 
Administered 
doses 
1% Measurement by weight rather than 
activity or volume 
Measurement of pre- and post-
administration syringe weights (rather 
than syringe weights before and after 
drawing up of doses) 
Use patient/standard dose weight ≥ 140 
times balance precision (e.g. ≥ 0.7 g for a 
precision of 0.005 g)  
Counts If BG = 400, min cts > 2900 
If BG = 1500, min cts > 
4000 
If BG = 3000, min cts > 
5500 
Administration of adequate doses 
Sufficient counting times 
Abbreviations: Min cts, minimum counts; BG, background counts 
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Abstract 
Background: The Modification of Diet in Renal Disease (MDRD) and Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equations are two commonly used formulae 
to estimate glomerular filtration rate (GFR) in adults. The CKD-EPI equation is recommended 
in current international and local guidelines for the diagnosis and management of chronic 
kidney disease (CKD), unless an alternative equation has been shown to have superior 
accuracy. This requires validation and comparison of the equations in local populations. 
Previous studies have reported on the accuracy of these prediction equations in Black South 
Africans and those of Indian ancestry. 
Objectives: The aim of this study was to evaluate the MDRD and CKD-EPI equations in mixed 
ancestry South African adults.  
Methods: In all participants, GFR was measured from the plasma clearance of 99mTc-
diethylenetetraaminepenta-acetic acid (99mTc-DTPA) using a standardised technique. Serum 
creatinine assays were isotope dilution mass spectrometry (IDMS) traceable. GFR was 
estimated (eGFR) using the MDRD and CKD-EPI equations, with and without the Black 
ethnicity factor. The agreement, bias, precision and accuracy of each equation was determined.  
Results: Eighty adults were included (30 male, median age 39 years, median GFR 59 
ml/min/1.73 m2). Sixty had a diagnosis of CKD, 10 were potential kidney donors, and 2 were 
healthy volunteers. Both equations, without the Black ethnicity factor, had good agreement 
with measured GFR. The equations tended to overestimate GFR, with bias of 1.6 and 7.9 
ml/min/1.73 m2 for the MDRD and CKD-EPI, respectively. The interquartile ranges of the 
differences were 15.9 and 20.2 ml/min/1.73 m2, and as a measure of accuracy, the P30 values 
were 80% and 72.5% (p=0.18). For identification of individuals with GFR <60 ml/min/1.73 
m2, the sensitivity of MDRD eGFR was 97.3% and CKD-EPI eGFR was 97.1%.   
Conclusion: The MDRD and CKD-EPI equations have shown satisfactory and comparable 
performance in this South African mixed ancestry adult population, with the MDRD marginally 
less biased than the CKD-EPI equation. 
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Introduction 
Chronic kidney disease (CKD) is defined by the presence of abnormalities of kidney structure 
or function (such as a glomerular filtration rate (GFR) of less than 60 ml/min/1.73 m2), present 
for > 3 months, with implications for health (KDIGO 2013). The Kidney Disease Improving 
Global Outcomes (KDIGO) guideline recommends using a creatinine-based equation to 
estimate GFR in the initial assessment of CKD and for monitoring disease progression (KDIGO 
2013). The two most commonly used equations in adults are the Modification of Diet in Renal 
Disease (MDRD) equation (Levey et al. 1999; Levey et al. 2007), and the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation (Levey et al. 2009). Unless an 
alternative equation has been shown to have superior accuracy, use of the CKD-EPI equation 
is recommended (KDIGO 2013; SARS 2015). 
A 2012 systematic review found that neither the MDRD nor the CKD-EPI equation performed 
well in populations outside North America, Europe or Australia and it concluded that neither 
equation could be used routinely across all populations and all GFR ranges (Earley et al. 2012). 
Studies conducted in various South African populations support this, and although the findings 
varied, the equations tended to have unacceptable bias, precision and/or accuracy (van 
Deventer et al. 2008; van Deventer et al. 2011; Stevens et al. 2011; Madala et al. 2011; Moodley 
et al. 2018). The poor performance of the equations in South African populations is concerning. 
South Africa is a developing country with limited centres that are able to measure GFR. Even 
where the service is available, the large number of CKD patients attending renal clinics 
precludes routine GFR measurement, compelling physicians to rely on estimated GFR. 
Furthermore, GFR estimates are essential in epidemiological studies, specifically to determine 
CKD prevalence. 
The mixed ancestry (Coloured) population group is estimated to comprise 8.8% of South 
Africa’s population (STATS SA 2018) and almost 49% of the Western Cape Province’s 
population (STATS SA 2012). Its origins are Khoisan (32-43%), Bantu-speaking African (20-
36%), European (21-28%), and Asian (9-11%) (de Wit et al. 2010). No previous studies have 
evaluated the GFR estimating equations in this group despite it having a high prevalence of 
CKD (Matsha et al. 2013; Adeniyi et al. 2017). Considering the population group’s genetic 
diversity, it is hypothesized that the accuracy of the commonly used equations will be poor. 
The aim of this study was to evaluate the performance of the MDRD and CKD-EPI equations 
in mixed ancestry South African adults.  
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Methods 
Participants 
Participants were recruited from the outpatient clinics of the Division of Nephrology at 
Tygerberg Hospital, Cape Town, South Africa between June 2015 and October 2018. Patients 
attending routine out-patient appointments or individuals being worked up for potential kidney 
donation were screened by a renal physician to exclude acute renal failure, concurrent illness, 
cancer, expanded extracellular fluid volumes (ascites, oedema, or pleural effusions), pregnancy 
or breastfeeding. After screening, adult patients (≥18 years) who self-classified as South 
Africans of mixed ancestry were invited to participate. All participants provided written, 
informed consent. The study was approved by the Stellenbosch University Health Ethics 
Research Committee (protocol S14/10/217). 
GFR measurement 
GFR was measured in the Nuclear Medicine Division of Tygerberg Hospital following our 
departmental protocol which is based on the methodology in the 2004 British Nuclear Medicine 
Society GFR guideline (Fleming et al. 2004). On arrival, the height and weight of the 
participant was recorded. Approximately 40 MBq of 99mTc-diethylenetetraaminepenta-acetic 
acid (99mTc-DTPA) was injected through an intravenous catheter. Extravasation was excluded 
by imaging the injection site using a gamma camera. A similar dose of 99mTc-DTPA was used 
for preparation of the standard. Patient and standard doses were calibrated accurately by 
weighing the syringes before and after administration of the doses on a Precisa 620C balance 
(precision = 0.005 g) (Precisa Balances Ltd, Milton Keynes, United Kingdom). In order to 
avoid excessively high count rates, a double dilution of the standard was performed, resulting 
in an effective volume of 5 L. Duplicate 1 ml samples of the standard were pipetted into 
counting tubes. Venous blood samples were taken from the contralateral arm at 2, 3 and 4 h 
after 99mTc-DTPA administration. After centrifugation at 1000 g for 10 min, duplicate 1 ml 
plasma samples were pipetted into counting tubes. The plasma and standard samples were 
counted simultaneously in a multichannel well counter (VIDEOGAMMA 4880, l’acn scientific 
laboratories, Italy) together with 2 empty counting tubes for background correction. GFR was 
calculated using the slope-intercept method (Chantler et al. 1969; Fleming et al. 2004). The 
clearance values obtained were corrected for body surface area (BSA) using the Haycock 
formula (Haycock et al. 1978), and to correct for the systematic underestimation of GFR that 
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is inherent to the slope-intercept method, the mean Bröchner-Mortensen correction was applied 
(Bröchner-Mortensen 1972; Bröchner-Mortensen et al. 1974; Fleming et al. 2004). Routine 
quality control checks were performed on each GFR study. Measured GFR is denoted mGFR 
in this text. 
GFR estimation 
A venous blood sample was taken for creatinine measurement immediately prior to 
administration of the 99mTc-DTPA dose. Serum creatinine (Scr) was measured by the National 
Health Laboratory Service (NHLS) of Tygerberg Hospital. Initially a method based on the Jaffé 
reaction was used (Siemens ADVIA 1800, Siemens Healthineers, Munich, Germany). In 
September 2016, the analyser was replaced with a Roche Cobas 6000, c501 module (Roche, 
Basel, Switzerland) where an enzymatic method is applied. Both methods have been 
standardised against isotope dilution mass spectrometry (IDMS) (Myers et al. 2006). The 
analytical imprecision and total error respectively of the Siemens Advia 1800 was 2.0% and 
2.4% at Scr=79 µmol/L; 2.1% and 7.2% at Scr=166 µmol/L; 1.8% and 6.7% at Scr=529 
µmol/L. Values for the Roche Cobas 6000 analyser are 1.9% and 2.4% at Scr=90.5 µmol/L, 
and 1.3% and 4.1% at 327.9 µmol/L. 
Estimated GFR, denoted eGFR, was calculated using the following equations, both of which 
are corrected for BSA: 
1. The re-expressed, 4-variable MDRD equation (Levey et al. 2007):  
eGFR (ml/min/1.73 m2) = 175 × (Scr/88.4)-1.154 × age-0.203 × g × e, 
where Scr is serum creatinine in µmol/L, g is a gender factor (male=1, female=0.742), e is an 
ethnicity factor (African American=1.212, other ethnic groups=1).  
2. The CKD-EPI equation (Levey et al. 2009): 
eGFR = 141 × min(Scr/κ,1)α × max(Scr/κ,1)-1.209 × 0.993age × g × e, 
where Scr is serum creatinine in µmol/L, κ is 61.9 for females and 79.6 for males, α is -0.329 
for females and -0.411 for males, min(x,y) and max(x,y) respectively indicate the minimum 
and maximum of x and y, g is a gender factor (male=1, female=1.108), and e is an ethnicity 
factor (African American=1.159, other ethnic groups=1). 
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Data analysis 
Bias was calculated as the median difference between eGFR and mGFR. Precision was 
expressed as the interquartile range (IQR) of the differences, and as the root mean square error 
of the regression of eGFR vs. mGFR. As measures of accuracy, the RMSE (calculated as the 
square root of mean (log eGFR – log mGFR)2), P30 and P20 were calculated. The P30 and P20 
values are defined as the percentage of GFR estimates within 30% and 20% of measured GFR, 
respectively. Bland-Altman analyses (Bland and Altman 1986) were used to determine the 
agreement between eGFR and mGFR. The sensitivity, specificity and positive predictive value 
for identifying individuals with mGFR < 60 ml/min/1.73 m2 were calculated for each equation. 
The Shapiro-Wilk test was used to test for normality. The McNemar test was used to compare 
proportions. 
Results 
In total, 80 participants were included (30 male; median age 39 years, age range 18 to 68 years) 
(Fig. 4.1). Sixty-eight had a diagnosis of CKD, 10 were potential kidney donors, and 2 were 
healthy volunteers. The median mGFR was 59 ml/min/1.73 m2 (range 10 to 126 ml/min/1.73 
m2 (Table 4.1)Error! Reference source not found.. 
In 46 individuals, serum creatinine (Scr) was measured using the Jaffé (alkaline picrate) 
method and in 34 the enzymatic method on the new analyser was used. There was no significant 
difference in bias or precision of the equations between the alkaline picrate and enzymatic 
groups (data not shown). 
The performance of the GFR estimation equations is given in Table 4.2. The bias of the MDRD 
equation was 1.6 ml/min/1.73 m2 whereas the CKD-EPI equation overestimated GFR by 7.9 
ml/min/1.73 m2 . The RMSE values of the regression of MDRD and CKD-EPI vs. mGFR were 
15.1 and 13.5 ml/min/1.73 m2 respectively, whereas the IQR of the differences was narrower 
for the MDRD equation than the CKD-EPI (15.9 vs. 20.2 ml/min/1.73 m2). The P30 values did 
not differ significantly (MDRD 80.0%, CKD-EPI 72.5%; p=0.18). When the Black ethnicity 
factor was applied, bias, precision and accuracy of both equations deteriorated. The Bland-
Altman analyses are shown in Fig. 4.2. Both equations had non-significantly higher P30 values 
in the subgroup of individuals with GFR ≥ 60 ml/min/1.73 m2 (MDRD 84.6%, CKD-EPI 
82.1%) than in the GFR < 60 ml/min/1.73 m2 subgroup (MDRD 75.6%, CKD-EPI 63.4%). For 
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identification of individuals in whom GFR was < 60 ml/min/1.73 m2 the sensitivities of the 
MDRD and CKD-EPI equations were > 90% in the 3 subgroups analysed (Table 4.3).  
Discussion 
The performance of both equations was satisfactory in this mixed ancestry South African 
population. The MDRD equation was significantly less biased than the CKD-EPI equation, 
overestimating mGFR by 1.6 ml/min/1.73 m2 compared to 7.9 ml/min/1.73 m2 . The IQRs of 
the differences were 15.9 ml/min/1.73 m2 for the MDRD equation and 20.2 ml/min/1.73 m2 for 
the CKD-EPI equation, and the RMSE values were 16.0 and 16.4 ml/min/1.73 m2 respectively. 
Accuracy was not significantly different with P30 values of 80% and 72.5% (p=0.18). In the 
original CKD-EPI study, the CKD-EPI equation was compared to the MDRD equation using 
a large validation set of 6646 individuals (Levey et al. 2009). Although the majority of 
participants were White and had CKD, the population was fairly diverse in terms of ethnicity 
(19% Black, ~4% Asian/Hispanic) and pathology (29% diabetes, 19% transplant recipients, 
14% healthy kidney donors). Its mean GFR was 68 ml/min/1.73 m2. The median difference, 
IQR, and P30 of the MDRD equation were -5.5 ml/min/1.73 m
2, 18.3 ml/min/1.73 m2, and 
80.6%. The CKD-EPI equation performed marginally better with bias of 2.5 ml/min/1.73 m2, 
IQR of 16.6 ml/min/1.73 m2, and P30 of 84.1%. In an earlier study, the MDRD equation was 
evaluated in a large population pooled from 10 studies (mean GFR 68 ml/min/1.73 m2, 32% 
Black, 5% Asian/Native American, 29% diabetes, 5% transplant recipients) (Stevens et al. 
2007a). Median bias was -2.7 ml/min/1.73 m2, IQR 16.4 ml/min/1.73 m2, and P30 83%. The 
results in our study, specifically for the MDRD equation, are comparable to these and some of 
the other large validation studies from North American, European and Australian populations 
(Earley et al. 2012).  
For identification of individuals with GFR < 60 ml/min/1.73 m2, both equations performed 
well, with sensitivities of > 97%, and specificities and positive predictive values of > 80%. 
This is useful information for screening programmes or for researchers conducting 
epidemiological studies on the prevalence of CKD in local communities. Although the 
sensitivity decreased slightly when individuals with GFR < 30 ml/min/1.73 m2 were excluded 
from the analysis, it remained > 90% for both equations. For the GFR subgroups analysed, the 
MDRD equation tended to perform better than the CKD-EPI, however, as expected from the 
small numbers in each group, the differences were not significant.  
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A few investigators have evaluated the MDRD and CKD-EPI equations in other South African 
populations. One consistent finding across all the studies in Black South Africans was that 
incorporation of an African American ethnicity factor resulted in a substantial increase in bias 
and a decrease in precision and accuracy (van Deventer et al. 2008; Stevens et al. 2011; Madala 
et al. 2011; Moodley et al. 2018). It is therefore not surprising that similar results were found 
in this mixed ancestry population (Table 4.2). In a study of 100 Black South Africans with 
CKD the bias, precision and accuracy of the MDRD equation were similar to our values (van 
Deventer et al. 2008). In half of the same population (i.e. 50 Black South Africans) the CKD-
EPI equation had a median bias of 4.9 ml/min/1.73m2 and a P30 of 74%, values also very similar 
to ours (van Deventer et al. 2011). In a separate study of 91 Black South Africans with CKD, 
bias of the MDRD equation was negligible but the precision was poor as reflected by the wide 
95% limits of agreement (LOA) in the Bland-Altman analyses (-37.9 to 40.0 ml/min/1.73m2) 
(Madala et al. 2011). The P30 of the MDRD equation in this study ranged between 36% and 
69% depending on the GFR. In a more recent study of 188 Black South Africans, the P30 value 
of the MDRD equation was 53%-54% and the CKD-EPI equation 53-54%, whereas the P30 
values in 99 Indian South Africans were 49-66% and 54-66% for the MDRD and CKD-EPI 
equations respectively (Moodley et al. 2018). This population included individuals with 
malignancy (58%) and CKD (38%). 
Possible reasons for the poorer performance of eGFR in previous South African studies include 
differences in ethnicity, mean GFR, pathology and/or methodology. Many other studies in 
populations outside the United States, Europe and Australia have shown similarly poor results, 
and in most cases this has been attributed to ethnic differences (Earley et al. 2012). Although 
South Africans of mixed ancestry are genetically diverse with Khoisan (32-43%), Bantu-
speaking African (20-36%), European (21-28%) and Asian (9-11%) ancestral components (de 
Wit et al. 2010), this diversity did not significantly limit eGFR performance in this population. 
Furthermore, that some studies in Black Africans with CKD had similar results, suggests that 
ethnicity may be less important than other factors (van Deventer et al. 2008; van Deventer et 
al. 2011). 
Possibly one of the most important determinants of the effectiveness of eGFR equations is 
patient pathology. The population in our study comprised CKD patients (85%) and healthy 
individuals (15%), similar in composition to the development populations of the MDRD and 
CKD-EPI equations. This is likely to have contributed towards the good performance of the 
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equations in our study. In contrast, in the most recent of the South African studies, 58% of 
patients had cancer (Moodley et al. 2018). A lower average serum creatinine concentration in 
this population may explain the positive bias found for both MDRD and CKD-EPI equations 
as cancer, and other chronic illnesses, are known to reduce creatinine generation through 
muscle wasting (Stevens et al. 2006).  
In the measurement of GFR, factors such as the use of a different filtration marker or method 
to calculate GFR will result in systematic differences in mGFR; however, provided mGFR is 
performed correctly, the impact should be small.  This is because the error on eGFR-mGFR is 
equal to √[(error on eGFR)2 + (error on mGFR)2], so if the error in mGFR << error in eGFR, 
then the latter would contribute little to the error on the difference. In this study, meticulous 
care was paid to methodology for GFR measurement. Our departmental guideline adheres 
strictly to the 2004 British Nuclear Medicine Society GFR guideline (Fleming et al. 2004) and 
we perform rigorous quality control checks on each GFR study. Furthermore, an analysis of 
measurement errors in our unit taking into account error in all aspects of the investigation (e.g. 
measuring patient height and weight, preparation of the standard, measuring of doses, recording 
of time, pipetting technique and counting of samples), revealed an error in mGFR of 
approximately 2 ml/min/1.73 m2 (Holness et al. 2019).  
All participants in this study were screened meticulously by a renal physician, a factor that may 
contribute to the relatively good performance of eGFR. Patients with expanded extracellular 
fluid volumes (ascites, oedema, or pleural effusions), acute renal failure, any acute concurrent 
illness, or any other reason to suspect unstable kidney function were not considered for 
inclusion. Furthermore, GFR and serum creatinine were measured on the same day in every 
patient. Although fluctuations in serum creatinine may, to a degree, mirror fluctuations in GFR, 
with coefficients of variation (CV) for repeat measurements of approximately 8-10% for GFR 
and 6% for serum creatinine (Fleming et al. 2004; Delanaye et al. 2017), measurement of these 
parameters on different days will limit the precision that is attainable. Use of a Jaffe assay 
rather than an enzymatic method for creatinine measurement will further limit the precision 
considering analytical CVs of approximately 5.5% and 2% respectively (Delanaye et al. 2017). 
The main limitation of this study is the sample size; however, the study is sufficiently powered 
to draw conclusions about the performance of the equations in the population. The primary 
outcome variable is the P30 proportion. A sample size of 80 is sufficient to estimate the true 
population value of P30 using a 95% confidence interval to within 10% of the true value (i.e. a 
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confidence interval width of 20%) given P30 is 70-80%. While a better estimation of P30 is 
ideal, an estimation within 10% can be regarded as acceptable. On the other hand, a sample 
size of ~ 150 would be required to detect a significant difference between the MDRD and CKD-
EPI equations at P30 values of 80% and 72.5% respectively. It thus cannot be concluded that 
the MDRD equation out-performed the CKD-EPI equation in this study. Ideally, more patients 
with normal kidney function would have been included. This may have resulted in better 
performance of the CKD-EPI equation as (i) the MDRD equation has been shown to have 
poorer accuracy at higher GFR levels (Stevens et al. 2007a), and (ii) the CKD-EPI equation 
was found to be more accurate than the MDRD in most GFR subgroups (Stevens et al. 2010). 
Based mainly on a CKD population, our results are not necessarily generalisable to other 
populations e.g. patients with cancer. Four of the patients with lupus nephritis that were 
included used trimethoprim chronically. Trimethoprim is known to interfere with the tubular 
secretion of creatinine, thus raising serum creatinine levels (Perrone et al. 1992). However, the 
impact of this on the overall results of this study is thought to be minimal. 
In conclusion, the MDRD and CKD-EPI equations have both shown satisfactory performance 
in this South African mixed ancestry adult population, with comparable accuracy. This 
information is reassuring to physicians treating patients with CKD and to researchers 
conducting epidemiological studies.  
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Tables and figures 
Fig. 4.1 Study enrolment 
 
Abbreviations: GFR, glomerular filtration rate. Scr, serum creatinine. 
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Table 4.1 Participant characteristics (n = 80)  
 Median (range) 
Age (years) 39 (18 – 68) 
Serum creatinine (µmol/L) 92 (66 – 191) 
Serum creatinine (mg/dL) 1.0 (0.5 – 7.9) 
Measured GFR (ml/min/1.73 m2) 59 (10 – 126) 
 n (%) 
Sex (male) 30 (37.5%) 
GFR  
          ≥ 90 ml/min/1.73 m2 27 (33.7%) 
          60 – 89 ml/min/1.73 m2 12 (15.0%) 
          30 – 59 ml/min/1.73 m2 19 (23.8%) 
          < 30 ml/min/1.73 m2 22 (27.5%)  
Diagnosis  
          Glomerular disease 31 (51.3%) 
                  Lupus nephritis 17 (21.3%) 
    Focal segmental glomerulosclerosis 7 (8.7%) 
    IgA nephropathy 4 (5.0%) 
    Membranous nephropathy 3 (3.8%) 
    Other glomerulonephritis 10 (12.5%) 
          CKD of unknown cause 8 (10%) 
          Autosomal dominant polycystic kidney disease 5 (6.2%) 
          Malignant hypertension 4 (5.0%) 
          Solitary kidney 3 (3.8%) 
          Obstructive nephropathy 2 (2.5%) 
          Other specified renal disease 5 (6.2%) 
          Potential kidney donor 10 (12.5%) 
          Healthy volunteer 2 (2.5%) 
Chronic use of trimethoprim 4 (5.0%) 
Abbreviations: GFR, glomerular filtration rate; CKD, chronic kidney disease 
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Table 4.2 Bias, precision, accuracy and 95% limits of agreement of the MDRD and CKD-EPI 
equations 
 
MDRD CKD-EPI 
MDRD with 
Black ethnicity 
factor 
CKD-EPI with 
Black ethnicity 
factor 
Bias 
Median difference*† 
(95% CI) 
1.6 (-0.3 to 7.5) 7.9 (5.4 to 11.5) 15.3 (11.1 to 20.3) 20.3 (14.6 to 24.0) 
Precision 
IQR of the 
differences*† 
15.9 20.2 25.9 28.1 
RMSE*‡ 15.1 13.5 18.2 15.7 
Accuracy 
RMSE§ 0.239 0.257 0.331 0.347 
P30 % (95% CI) 80.0 (69.6 to 88.1) 72.5 (61.4 to 81.9) 51.3 (39.9 to 62.6) 47.5 (36.2 to 59.0) 
P20 % (95% CI) 60.0 (48.4 to 70.8) 55.0 (43.5 to 66.2) 36.3 (25.8 to 47.8) 31.3 (21.4 to 42.6) 
Agreement 
95% LOA* -24.9; 34.4 -17.9; 35.7 -21.6; 60.0 -14.5; 55.2 
*Units ml/min/1.73 m2. †The differences are calculated as eGFR – mGFR. ‡RMSE of the 
regression of eGFR vs. mGFR. §RMSE calculated as the square root of mean (log eGFR – log 
mGFR)2.  
 
Abbreviations: MDRD, Modification of diet in Renal Disease; CKD-EPI, Chronic Kidney 
Disease Epidemiology Collaboration; IQR, interquartile range; RMSE, root mean square 
error; 95% CI, 95% confidence interval; LOA, limits of agreement. 
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Fig. 4.2 Bland-Altman plots of the four equations 
 
Bland-Altman plots of the four equations (i) MDRD, (ii) CKD-EPI, (iii) MDRD with the Black 
ethnicity factor, and (iv) CKD-EPI with the Black ethnicity factor. The solid line represents the 
mean difference between eGFR and mGFR, and the dashed lines represent the upper and lower 
limits of agreement with 95% confidence intervals.  
 
Abbreviations: mGFR, measured glomerular filtration rate; eGFR, estimated glomerular 
filtration rate; MDRD, Modification of Diet in Renal Disease, CKD-EPI, Chronic Kidney 
Disease Epidemiology Collaboration. 
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Table 4.3 Diagnostic performance of the equations to detect patients with GFR < 60 
ml/min/1.73 m2 
 Sensitivity 
% (95% CI) 
Specificity 
% (95% CI) 
PPV 
% (95% CI) 
NPV 
% (95% CI) 
All patients  
(n = 80) 
MDRD 97.3 (91.0 – 99.6) 88.4 (79.3 – 94.5) 87.8 (78.6 – 94.1) 97.4 (91.1 – 99.7) 
CKD-EPI 97.1 (90.7 – 99.6) 82.6 (72.7 – 90.3) 80.5 (70.1 – 88.5) 97.4 (91.1 – 99.7) 
GFR 45-90 ml/min/1.73 m2  
(n = 31) 
MDRD 93.8 (78.9 – 99.3) 73.3 (54.4 – 87.5) 78.9 (60.6 – 91.4) 91.7 (76.1 – 98.5) 
CKD-EPI 92.3 (76.9 – 98.8) 61.1 (42.0 – 78.0) 63.2 (44.1 – 79.7) 91.7 (76.1 – 98.5) 
GFR > 30 ml/min/1.73 m2  
(n = 58) 
MDRD 93.8 (84.2 – 98.4) 90.5 (79.7 – 96.6) 78.9 (66.2 – 88.5) 97.4 (89.4 – 99.8) 
CKD-EPI 92.3 (82.2 – 97.7) 84.4 (72.5 – 92.6) 63.2 (49.5 – 75.5) 97.4 (89.4 – 99.8) 
Abbreviations: GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal 
Disease, CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration, PPV, positive 
predictive value; NPV, negative predictive value. 
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Abstract 
 
Purpose  
Creatinine-based glomerular filtration rate (GFR) estimating equations that were developed for 
chronic kidney disease (CKD) populations tend to perform poorly in cancer patients. The 
Janowitz-Williams model is a new equation developed from a large population of White 
patients with cancer. Our study evaluates the performance of this equation and three commonly 
used CKD equations in a genetically and socioeconomically diverse cancer population. It also 
evaluates the utility of a simple tool to improve GFR estimation by adapting the equations’ 
parameters for the patient population.  
Methods 
The records of consecutive adult cancer patients who had GFR measured as part of routine 
clinical management were reviewed. Using serum creatinine levels measured within a week of 
GFR measurement, GFR was estimated (eGFR) using the original Cockcroft-Gault (CG), 
Modification of Diet in Renal Disease (MDRD), Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) and Janowitz-Williams (JW) equations. The population was then 
randomly divided into equal sized development and validation sets. A Microsoft® Excel add-
in (Solver) was used to optimise the equations’ parameters using the development set data. The 
bias, precision, accuracy and agreement of all original and adapted equations was determined 
using the validation set data. The impact of using eGFR on management decisions was also 
assessed. 
Results 
The data of 435 patients were included. Of the original equations, the JW equation was least 
biased and most precise. The original equations all overestimated GFR by 7.9 to 16.0 
ml/min/1.73 m2. Bias of the adapted equations was significantly lower (-2.2 to 3.4 ml/min/1.73 
m2, p<0.0001). The original equations had interquartile ranges (IQRs) of 21.8-30.4 
ml/min/1.73 m2 but adapting the equations reduced the IQRs to 21.2-24.0 ml/min/1.73 m2. The 
accuracy, reflected by the P30 values, improved from 57.1%-73.7% to 78.3%-82.9% after 
adapting the equations (p≤0.0001). The 95% confidence intervals (CI) were ± 42.3, 34.4, 32.9 
and 33.3 ml/min/1.73 m2 for the adapted CG, MDRD, CKD-EPI and JW equations 
respectively. Using eGFR with a CI allows for reliable exclusion of patients with impaired 
renal function, however eGFR remains equivocal in a significant proportion of patients. 
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Conclusions 
The JW equation provides the most accurate unadapted estimate. Adapting the equations for 
this population improved their performance. While reliable to exclude low GFR, when eGFR 
is normal to high, in the GFR range where most critical clinical decisions are made,  GFR 
estimates are equivocal. In these cases, there is no alternative to GFR measurement. 
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Introduction 
 
Nephrotoxicity is a serious adverse effect of certain chemotherapeutic drugs e.g. the platinum-
based agents, yet because of their efficacy, many of these drugs are widely used for the 
treatment and palliation of many types of cancer. Patients receiving potentially nephrotoxic 
chemotherapy require accurate determination of kidney function both prior to starting and 
during treatment (Launay-Vacher et al. 2008).  
Glomerular filtration rate (GFR) is generally accepted as the best measure of kidney function 
but its measurement is associated with several real and perceived challenges including being 
inconvenient for the patient, comparatively expensive, and only available in specialized units. 
Consequently, many oncologists rely on an estimation of GFR. The most commonly used 
equations for this purpose are the Cockcroft-Gault (Cockcroft and Gault 1976), the 
Modification of Diet in Renal Disease (MDRD) (Levey et al. 1999), and the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) (Levey et al. 2009) equations. These 
equations were developed from the data of patients with chronic kidney disease (CKD) and 
healthy individuals, and while the formulae correct for various demographic and/or 
physiological characteristics (e.g. age, sex, ethnicity, weight), they do not take pathology into 
account.  
Many studies have evaluated the performance of these GFR estimating equations in cancer 
patients, and although the results have varied, their accuracy was consistently poor with values 
for the mean/median absolute percentage error (APE) ranging between 10% and 18% (Wright 
et al. 2001; Poole et al. 2002; Marx et al. 2004; de Lemos et al. 2006; Barraclough et al. 2008a; 
Ainsworth et al. 2011; Hartlev et al. 2012; Lauritsen et al. 2014; Janowitz et al. 2017). One of 
the more recent studies found that carboplatin doses would have been acceptable in only one-
fifth of patients (Lauritsen et al. 2014). However, CKD derived equations remain the most used 
in clinical oncology practice. 
There are some GFR estimating equations that have been derived from cancer patient data. 
Three of these were developed prior to the era of routine standardization of serum creatinine 
assays (Jelliffe 1973; Martin et al. 1998; Wright et al. 2001). The recently described Janowitz-
Williams equation was developed and validated in a White population from the United 
Kingdom (Janowitz et al. 2017). While it achieved improved results, the authors point out the 
need to validate its performance in oncology patients of different ethnicities. It is well known 
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that in non-oncology populations outside Europe, North America and Australia, GFR 
estimating equations do not perform well, most likely due to genetic differences in muscle mass 
and diet (Stevens et al. 2006; Earley et al. 2012). It is thus hypothesized that similarly, the 
Janowitz-Williams equation will perform less well in a cancer population that is ethnically 
diverse with many patients coming from poor socioeconomic backgrounds. 
The aims of this study were (i) to evaluate the performance of the Cockcroft-Gault, MDRD, 
CKD-EPI and Janowitz-Williams equations in this population, and (ii) to adapt the parameters 
of the equations using a simple Microsoft® Excel-based tool, and evaluate the performance of 
the adapted equations. 
Methods 
Study population 
This was a retrospective case review of all adult (age ≥ 18 years) cancer patients who had GFR 
measured in the Nuclear Medicine Division of Tygerberg Hospital, Cape Town, between 
January 2011 and June 2016. GFR is measured prior to initiating therapy as part of routine 
clinical practice in all patients receiving platinum-based chemotherapy, and repeat 
measurements are performed in cases where there has been a significant increase in serum 
creatinine (Scr). Cases were included if Scr was measured within 7 days of the GFR study and 
no treatment was administered between the two measurements. Cases with missing information 
or methodological errors were excluded, as were cases of patients with documented ascites, 
pleural effusions, or any other source of expanded extracellular fluid volume. Ethical approval 
was granted by the institutional Health Research Ethics Committee (reference number 
S15/05/121).  
GFR measurement 
GFR was measured from the plasma clearance of 99mTc-diethylenetriaminepenta-acetic acid 
(99mTc-DTPA) following the methodology in the 2004 British Nuclear Medicine Society 
(BNMS) guideline (Fleming et al. 2004). This is an established and accepted reference method 
for GFR measurement in clinical practice. Three venous blood samples were taken at 2, 3 and 
4 hours after administration of radiotracer. The clearance values obtained using the slope-
intercept method (Chantler et al. 1969; Fleming et al. 2004) were corrected for body surface 
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area (BSA) using the Haycock formula (Haycock et al. 1978). Thereafter, the mean Bröchner-
Mortensen equation was used to correct for the systematic error arising from use of a mono-
exponential clearance model (Bröchner-Mortensen 1972; Bröchner-Mortensen et al. 1974; 
Fleming et al. 2004). This is referred to in the text as measured GFR (mGFR). Various quality 
assurance checks, as recommended in the BNMS guideline, were performed for all GFR studies 
(Fleming et al. 2004). 
GFR estimation 
Serum creatinine was measured by the Tygerberg Hospital National Health Laboratory Service 
(NHLS) using a Jaffe kinetic alkaline picrate assay with blank rate correction (Siemens Advia 
1800, Siemens Healthineers, Erlangen, Germany). The analytical imprecision was 2% at 79 
µmol/L, 2.1% at 166 µmol/l and 1.8% at 529 µmol/l. Total error at these levels was 2.4%, 7.2% 
and 6.7%. This assay is traceable to the reference method, isotope dilution mass spectrometry 
(IDMS) (Myers et al. 2006). Estimated GFR, denoted eGFR, was estimated using the following 
equations (Table 5.1): 
1. The Cockcroft-Gault equation (Cockcroft and Gault 1976) 
2. The re-expressed, 4-variable MDRD equation (Levey et al. 2007) 
3. The CKD-EPI equation (Levey et al. 2009) 
4. The Janowitz-Williams equation (Janowitz et al. 2017) 
The MDRD and CKD-EPI equations have additional correction factors that are applied for 
African American individuals. However, because previous studies in Black South Africans 
have concluded that the accuracy of the equations is better without this correction, and because 
the population in this study is ethnically diverse, these corrections were omitted (van Deventer 
et al. 2008; Stevens et al. 2011; Madala et al. 2011). 
Data analysis 
The bias, precision and accuracy of each equation was calculated based on previous 
recommendations (Stevens et al. 2007b; Earley et al. 2012). Bias was measured as the median 
difference between eGFR and mGFR (eGFR-mGFR), expressed on the raw scale and as a 
percentage of mGFR. Precision was measured using interquartile ranges (IQR) and the root 
mean square error (RMSE) of the regression of eGFR versus mGFR. Accuracy was expressed 
as the percentage of eGFR values that were within 30% of mGFR (P30). The median absolute 
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percentage error (APE) was calculated as an additional metric for purposes of comparison with 
previous studies. Bland-Altman plots were used to determine the agreement between mGFR 
and eGFR (Bland and Altman 1986). The Shapiro-Wilk test was used to test for normality. As 
the CKD-EPI equation is recommended in current, international, chronic kidney disease 
guidelines (KDIGO 2013), it was thus regarded as the reference method against which the other 
equations were compared. The McNemar test was used to compare proportions.  
Adapting the equations 
The population was then randomly divided into two equal groups, a development and a 
validation set. Using the development set data, an iterative non-linear least squares regression 
technique was used to adjust parameters of the equations to better fit the given data. This was 
performed using a readily available and simple tool (Microsoft® Excel Solver Add-in), which 
has been described in detail previously (Brown 2001). Using the validation set data, the bias, 
precision and accuracy of the adapted equations was calculated and compared to that of the 
original equations. Based on previous recommendations, relative reductions in bias of ≥ 50% 
or RMSE of ≥ 20% were regarded as significant improvements (Earley et al. 2012). The 
McNemar test to compare the P30 values of the original and adapted estimates.  
Impact on patient management 
The sensitivities and specificities of the original and adapted equations for identifying 
individuals with mGFR < 60 ml/min/1.73 m2 were calculated using (i) point values, and (ii) 
the 95% confidence intervals for the adapted equations. Replicating the methodology in the 
Janowitz study (Janowitz et al. 2017), hypothetical carboplatin doses were calculated using the 
Calvert formula [dose (mg) = target AUC × (GFR + 25)] (Calvert et al. 1989) based on mGFR 
and the original and adapted equations. The APE in the dose was calculated for each patient. 
Dose deviations > 20% were regarded as significant. 
Statistical analysis was performed using MedCalc Statistical Software for Windows v.18.10.3 
(MedCalc Software bvba, Ostend, Belgium; https://www.medcalc.org; 2019). 
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Results 
A total of 435 patients (340 female) with a median age of 53 years (range 22-78 years) met the 
inclusion criteria. The patient characteristics are summarized in Table 5.2. The majority of 
patients (54%) had a diagnosis of cervical cancer. GFR was normally distributed with a mean 
(SD) of 81 (24) ml/min/1.73 m2. Based on the Kidney Disease: Improving Global Outcomes 
(KDIGO) classification (KDIGO 2013), 155 patients (35.5%) had a normal GFR, in 203 (47%) 
GFR was mildly decreased, and in 77 (17.5%) it was moderately to severely decreased. The 
mean body mass index was 25 kg/m2 with 45% classifying as overweight or obese (WHO 
2018). HIV status and ethnicity were not consistently recorded. 
The bias, precision, accuracy and agreement of the 4 original equations are summarized in 
Table 5.3. All equations overestimated GFR with median bias ranging between 7.7 
ml/min/1.73 m2 (Janowitz-Williams) and 16.5 ml/min/1.73 m2 (Cockcroft-Gault). The biases 
of the CKD-EPI and MDRD equations were similar (12.6 and 13.1 ml/min/1.73 m2 
respectively). The Janowitz-Williams equation was the most precise with a RMSE value of 
13.0 ml/min/1.73 m2 and IQR of 21.4 ml/min/1.73 m2. Accuracy of the Cockcroft-Gault 
equation was poor (< 60%), whereas for the other 3 equations it was moderate (60-80%). The 
P30 value of the Janowitz-Williams equation (77.0%) was significantly higher than all other 
equations (p<0.0001), and the P30 of the CKD-EPI equation (69.7%) was significantly higher 
than both Cockcroft-Gault (58.4%; p=0.0008) and MDRD equations (64.4%; p=0.0165). 
Median APE ranged from 15.3% (Janowitz-Williams) to 24.4% (Cockcroft-Gault).  
The formulae for the adapted equations are listed in Table 5.4 with the original equations 
alongside for comparison. In all four adapted equations bias was reduced by > 50%, with 
absolute values ranging between -2.2 and 3.4 ml/min/1.73 m2. Reductions in RMSE of > 20% 
were found for the Cockcroft-Gault, MDRD and CKD-EPI equations. P30 values of the adapted 
equations ranged between 78.3% and 82.9%; the values all significantly higher than the original 
equations (p=0.0001 for Janowitz-Williams; p<0.0001 for the others) (Table 5.4 and Fig. 5.1). 
There was no significant difference in the P30 values of the different adapted equations.  
Using point values from eGFR equations the specificities for identifying patients with mGFR 
< 60 ml/min/1.73 m2 were 94%-98%. However, the sensitivities ranged between 31% and 50%, 
lowest for the Janowitz-Williams equation, and highest for the MDRD. Adapting the equations 
did not improve the sensitivity to above 50% except in the case of the Cockcroft-Gault formula 
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where it increased to 64%. The 95% predictive confidence intervals (CI) were ± 42.3, 34.4, 
32.9 and 33.3 ml/min/1.73 m2 for the adapted Cockcroft-Gault, MDRD, CKD-EPI and 
Janowitz-Williams equations respectively (Fig. 5.2). Only when eGFR exceeded 
approximately 90 ml/min/1.73 m2 did the 95% confidence intervals not include the value of 60 
ml/min/1.73 m2. This was true for 41-61/217 validation set cases depending on the equation, 
with only 1-3 of these 41-61 cases having mGFR values below 60 ml/min/1.73 m2. Overall, 
applying this threshold to the validation set for excluding patients with low GFR yielded 
sensitivities of 93%-98%, with specificities of 21%-27%. The APE in hypothetical carboplatin 
doses (AUC5) was > 20% in 60-99 (28-46%) for the original equations, lowest using the 
Janowitz-Williams equation, and in 45-57 (21-26%) for the adapted equations. 
Discussion 
In this population the CKD-based equations (Cockcroft-Gault, MDRD and CKD-EPI) all 
overestimated mGFR substantially with biases ranging between 12.6 and 16.5 ml/min/1.73 m2. 
The precision was also poor with RMSE values of 16.4 to 26.8 ml/min/1.73 m2 and IQRs of 
23.5 to 31.8 ml/min/1.73 m2. Despite being significantly more accurate than the Cockcroft-
Gault and MDRD, the CKD-EPI equation had a modest P30 value of 69.7% meaning that almost 
one-third of patients had eGFR values that differed from the true GFR by more than 30%. The 
new Janowitz-Williams equation performed better with median bias of 7.7 ml/min/1.73 m2, 
RMSE of 13.0 ml/min/1.73 m2, IQR of 21.4 ml/min/1.73 m2, and a significantly higher P30 
value of 77.0%.  
The systematic overestimation of GFR implies lower serum creatinine levels on average in this 
population, which is not surprising. Cancer and other chronic illnesses frequently result in 
muscle wasting leading to a decrease in the serum creatinine concentration (Stevens et al. 
2006). Nausea or poor appetite, common symptoms in cancer patients, may perpetuate this by 
reducing a patient’s dietary intake of protein. It is important to note that neither the MDRD nor 
the CKD-EPI development set included oncology patients and that these equations were never 
intended to be used in cancer patients. They were developed in predominantly chronic kidney 
disease (CKD) populations and perform satisfactorily in other populations with similar 
pathology. (Levey et al. 1999; Levey et al. 2009; Earley et al. 2012).  
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The lower bias of the Janowitz-Williams equation is likely to be related to its derivation from 
oncology patient data, yet with a bias of 7.7 ml/min/1.73 m2, it still overestimated GFR. 
Differences in genetics and nutrition are most likely to account for these systematic differences 
in GFR between the two populations. This is supported by the finding in the Janowitz study of 
negligible bias (< 1 ml/min/1.73 m2 and < 1%) for the CKD-EPI equation (Janowitz et al. 
2017). In that study the equations also showed greater precision. In their internal validation set 
the Janowitz-Williams equation had an IQR of 17.7 ml/min whereas in this study population it 
was 21.1 ml/min. Similarly, the CKD-EPI equation had an IQR of 19.3 ml/min/1.73 m2 
compared to 23.5 ml/min/1.73m2 in this study. The poorer precision in our population is 
thought to be due to its greater diversity.   
The poor performance of the unaltered Cockcroft-Gault equation is not unexpected. It was 
originally developed from data limited to men, used non-standardized serum creatinine 
measurements, and as an estimate of creatinine clearance, it systematically overestimates GFR 
due to tubular secretion of creatinine (Cockcroft and Gault 1976; Stevens et al. 2006). Yet it 
remains the most frequently used equation in our and many other oncology departments and 
was thus evaluated in this study. However, even after adapting its parameters, its accuracy was 
not significantly better than that of the unaltered Janowitz-Williams equation.  
Many factors influence the performance of GFR estimating equations. In some populations the 
effect of ethnicity is well documented e.g. African Americans in whom eGFR without 
correction for ethnicity underestimates mGFR (Levey et al. 1999; Levey et al. 2017), and 
Japanese in whom eGFR gives an overestimation (Matsuo et al. 2009). In other populations, 
particularly those of mixed ancestry, the effect of ethnicity is largely unknown. The mean GFR 
of the population studied will also influence the performance of creatinine-based estimations, 
particularly the MDRD equation (Stevens et al. 2010), as may obesity (Verhave et al. 2005). 
Diet, whether due to cultural or socioeconomic factors, is known to influence eGFR through 
its effect on the serum creatinine concentration (Perrone et al. 1992; Stevens et al. 2006). In 
our population 78% were female, 62% of the total population had a gynecological cancer, 45% 
were either overweight or obese by WHO definitions (WHO 2018), the mean GFR was 81 
ml/min/1.73 m2, and the majority fell into a low-income group. The patients were ethnically 
diverse comprising Black African, White and mixed ancestry individuals. Given the numerous 
factors potentially affecting GFR estimating equations, these should ideally be adapted for the 
populations in which they will be used. 
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The Microsoft® Excel Solver add-in is a simple, readily available tool that uses an iterative, 
non-linear, least squares regression technique to adapt parameters to better fit multiple 
variables to development data (Brown 2001). Provided a centre can measure both GFR and 
serum creatinine, it can adapt equations for its own patient population in-house relatively easily 
with the assistance of a medical physicist. Testing the adapted equations (Table 5.4) using 
independent internal validation set data showed significant improvements in bias and accuracy 
of all the equations, and significant improvements in precision in 3/4. Bias was close to zero 
for all equations, RMSE values ranged from 12.2 to 20.0 ml/min/1.73 m2, and the P30 values 
were 78.3% to 82.9%. Various mathematical models (functions) exist to predict GFR from Scr, 
with most showing similar performance once the parameters are adapted to a specific patient 
population. 
When using point values for directing management decisions, none of the equations performed 
well. For detecting patients with mGFR < 60 ml/min/1.73 m2, while specificity was good, the 
sensitivity of all the equations was < 50%. Unfortunately, this is the GFR level at or around 
which critical treatment decisions are made. Using point values will therefore fail to detect 
most patients with reduced renal function, creating a false security for clinicians. Thus, using 
eGFR point values to avoid cisplatin therapy in patients with poor renal function is expected to 
result in inappropriate therapy in more than half of these patients. Extrapolating from these 
data, using the Calvert formula (AUC5) (Calvert et al. 1989) with eGFR point values can be 
predicted to result in inappropriate carboplatin doses in 46-57/217 (21-26%) of patients. 
Using 95% confidence intervals with eGFR yields some improvement in clinical value. The 
main utility would be in cases of normal/high eGFR (eGFR > ~90 ml/min/1.73 m2) where a 
low GFR (false positive) can be reliably excluded when the confidence intervals do not include 
the value of 60 ml/min/1.73 m2. Using this approach, a clinical decision to proceed with 
cisplatin therapy based on adequate GFR can be safely made in about 1/3 of patients in this 
study population using eGFR alone. However, when the confidence interval includes a clinical 
threshold e.g. 60 ml/min/1.73 m2, reliable determination of GFR requires measurement. The 
lack of universal availability of reliable GFR measurement, even in the developed world, is a 
challenge that should be addressed by the oncology community globally, as these 
measurements are not overly sophisticated, especially with the adoption of new simpler single 
sample techniques (Burniston 2018). 
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A limitation of this study is that it was based on a specific local cancer population, and it cannot 
be assumed that its findings can be generalized to cancer populations elsewhere in the world. 
The intention of this study is however to illustrate that estimation equations can be adapted 
locally without high levels of expertise. Furthermore, the number of patients with mGFR < 60 
ml/min/1.73 m2 was relatively small. While this accurately reflects the distribution of GFR in 
our cancer population, it is at this level that critical therapeutic decisions are made. Further 
studies focusing on eGFR in patients with mild to moderately decreased GFR (GFR 45-90 
ml/min/1.73 m2) are required. As a retrospective study there were time lapses between serum 
creatinine and mGFR measurements, which will have reduced the precision of the equations, 
but this probably reflects normal practice where serum creatinine is measured before 
chemotherapy is due to start. However, it is possible that there were a few patients who received 
nephrotoxic chemotherapy between serum creatinine and GFR measurements without this 
being detected during the record review.  
The authors elected not to evaluate other equations developed for oncology patients, 
specifically the Jelliffe (Jelliffe 1973), Martin (Martin et al. 1998) and Wright (Wright et al. 
2001) equations as they are used infrequently having been developed prior to routine 
standardization of serum creatinine assays. In addition, many previous studies that have 
evaluated existing GFR estimating equations in cancer patients exist (Wright et al. 2001; Poole 
et al. 2002; Marx et al. 2004; de Lemos et al. 2006; Barraclough et al. 2008; Ainsworth et al. 
2011; Hartlev et al. 2012; Lauritsen et al. 2014). However, due to significant differences in 
methodology to measure GFR, compounded by non-standardization of creatinine assays in the 
majority, these studies were not compared. Of the numerous equations that have been 
developed for CKD populations, only the MDRD and CKD-EPI were evaluated: the MDRD 
equation as our hospital laboratory service routinely provides an MDRD estimate alongside 
every serum creatinine result, and the CKD-EPI equation as it is recommended in local and 
international CKD guidelines (KDIGO 2013; SARS 2015).   
In conclusion, most GFR estimation equations that were developed in other patient populations 
are suboptimal for use in cancer patients. Adapting these equations for use in a specific 
population of oncology patients is practical and preferable as it improves their performance. 
For centers unable to adapt published equations, the new Janowitz-Williams equation with a 
confidence interval is preferred in oncology patients. However, to ensure correct treatment, in 
a significant proportion of patients GFR measurement is unavoidable. 
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Tables and figures 
Table 5.1 Equations evaluated in this study 
Cockcroft-Gault 
(Cockcroft and 
Gault 1976) 
eGFR (ml/min) = (140 – age) x wt/72 x Scr x g 
where Scr is serum creatinine in mg/dL, age is in years, wt is weight in kilograms, and g is a gender 
factor (male=1, female=0.85). The value obtained was corrected for BSA by multiplying by 
1.73/BSA 
MDRD equation 
(Levey et al. 2007) 
eGFR (ml/min/1.73 m2) = 175 x Scr-1.154 x age-0.203 x g 
where Scr is serum creatinine in mg/dL, g is a gender factor (male=1, female=0.742) 
CKD-EPI (Levey et 
al. 2009) 
eGFR (ml/min/1.73 m2) = 141 x min(Scr/κ,1)α x max(Scr/κ,1)-1.209 x 0.993age x g  
where Scr is serum creatinine in mg/dL, κ is 0.7 for females and 0.9 for males, α is -0.329 for 
females and -0.411 for males, min(x,y) and max(x,y) respectively indicate the minimum and 
maximum of x and y, and g is a gender factor (male=1, female=1.108) 
Janowitz-Williams 
(Janowitz et al. 
2017) 
√GFR (ml/min) = β0 + β1age + β2BSA + β3ln(Scr) + β4ln(Scr)2 + β5ln(Scr)3 +[(β6 + β7) x g] + (β8age 
x BSA) 
where Scr is serum creatinine in mg/dL, BSA is body surface area, age is in years, β0 = 1.8140, β1 
= 0.0191, β2 = 4.7328, β3 = -3.7162, β4 = -0.9142, β5 = 1.0628, β6 =0.0202, β7 = 0.0125, β8 = -
0.0297, g is a gender factor (male=1, female=0). The value obtained was squared and then corrected 
for BSA by multiplying by 1.73/BSA 
Abbreviations: eGFR, estimated glomerular filtration rate; BSA, body surface area 
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Table 5.2 Patient characteristics (n=435) 
Characteristic  Category n (%) 
Gender 
Male 95 (22) 
Female 340 (78) 
Cancer diagnosis  
Gynaecological 269 (62) 
Lung 53 (12) 
Gastrointestinal 48 (11) 
Head and neck 21 (5) 
Urological 18 (4) 
Neuroendocrine 17 (4) 
Other 9 (2) 
GFR category  
> 90 ml/min/1.73m2 155 (35.5) 
60-89 ml/min/1.73m2 203 (47) 
30-59 ml/min/1.73m2 70 (16) 
15-29 ml/min/1.73m2 7 (1.5) 
< 15 ml/min/1.73m2 0 
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Table 5.3 Bias, precision, accuracy, and agreement of the equations 
 
Cockcroft-Gault MDRD CKD-EPI Janowitz-Williams 
Bias  
Median difference* (95% CI) 
(ml/min/1.73 m2) 
16.5 (13.6 to 19.4)  13.1 (11.1 to 16.2) 12.6 (10.0 to 15.0) 7.7 (6.3 to 9.7)  
MPE* (95% CI) 20.0 (17.7 to 25.1)  17.4 (14.5 to 19.8) 16.9 (13.0 to 20.0) 10.8 (7.8 to 13.5)  
Precision  
IQR of the differences* 
(ml/min/1.73 m2) 
31.8 28.3 23.5 21.4 
RMSE† 
(ml/min/1.73 m2) 
26.8 27.0 16.4 13.0 
Accuracy  
P30 % (95% CI) 58.4 (53.6 to 63.1) ‡ 64.4 (59.7 to 68.9) § 69.7 (65.1 to 74.0) 77.0 (72.8 to 80.9) ‡ 
MAPE (%) (95% CI) 24.4 (19.7 to 26.2) 20.7 (19.2 to 23.6) 18.6 (16.6 to 21.6) 15.3 (13.8 to 17.2) 
Agreement  
95% LOA* 
(ml/min/1.73 m2) 
-32.8; -72.2 -36.6; -69.1 -22.5; 48.1 -26.0; 40.5 
*The errors are calculated as eGFR – mGFR. †RMSE of the regression of eGFR vs. mGFR. 
‡P30 value significantly different to the P30 of the CKD-EPI equation.  
Abbreviations: MDRD, Modification of diet in Renal Disease; CKD-EPI, Chronic Kidney 
Disease Epidemiology Collaboration; MPE, median percentage error; IQR, interquartile 
range; RMSE, root mean square error; 95% CI, 95% confidence interval; LOA, limits of 
agreement.
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Table 5.4 Comparison of the original and adapted equations (n=217) 
 
Equation 
Median difference 
(95% CI) 
ml/min/1.73 m2 
Δ bias 
RMSE 
ml/min/1.73 m2 
Δ RMSE IQR of 
differences* 
ml/min/1.73 m2 
P30 p 
Original 
Cockcroft-
Gault 
eGFR = (140-age) x wt/(72 x Scr) x g x 1.73/BSA 
where g=1 (male) or 0.85 (female) 
16.0 
(12.5 to 21.2) 
-86% 
27.1 
-26.2% 
30.4 57.1% 
<0.0001 
Adapted 
Cockcroft-
Gault 
eGFR = (188-age) x wt/(129 x Scr) x g x 1.73/BSA 
where g=1 (male) or 0.75 (female) 
-2.2 
(-5.1 to 0.9) 
20.0 23.5 78.3% 
Original  
MDRD 
eGFR = 175 x Scr-1.154 x age-0.203 x g 
where g=1 (male) or 0.742 (female) 
14.7 
(11.1 to 18.0) 
-77% 
26.7 
-54.3% 
28.2 62.7% 
<0.0001 
Adapted 
MDRD 
eGFR = 274 x Scr-0.533 x age-0.33 x g 
where g=1 (male) or 0.89 (female) 
3.4 
(1.3 to 5.6) 
12.2 24.0 80.6% 
Original  
CKD-EPI 
eGFR = 141 x min(Scr/κ,1)α x max(Scr/κ,1)-1.209 x 0.993age x g 
where g, κ, α = 1, 0.9, -0.411 (male) or 1.108, 0.7, -0.329 (female) 
13.3 
(10.3 to 16.8) 
-84% 
17.2 
-20.3% 
22.9 67.3% 
<0.0001 
Adapted  
CKD-EPI 
eGFR = 108 x min(Scr/κ,1)α x max(Scr/κ,1)-1.365 x 0.993age x g 
where g, κ, α = 1, 1, -0.607 (male) or 1.106, 0.8, -0.318 (female) 
2.1 
(0.3 to 4.5) 
13.7 21.9 80.6% 
Original 
Janowitz-
Williams 
eGFR = {β0 + β1age + β2BSA + β3ln(Scr) + β4ln(Scr)2 + β5ln(Scr)3 +[(β6 + β7) 
x g] + (β8age x BSA)}2 x 1.73/BSA 
where β0 = 1.8140, β1 = 0.0191, β2 = 4.7328, β3 = -3.7162 β4 = -0.9142, β5 = 
1.0628, β6 =0.0202, β7 = 0.0125, β8 = -0.0297, g =1 (male) or 0 (female) 
7.9 
(6.3 to 10.4) 
-77% 
13.8 
- 9.4% 
21.8 73.7% 
0.0001 
Adapted 
Janowitz-
Williams 
eGFR = {β0 + β1age + β2BSA + β3ln(Scr) + β4ln(Scr)2 + β5ln(Scr)3 +[(β6 + β7) 
x g] + (β8age x BSA)}2 x 1.73/BSA 
where β0 = 3.8309, β1 = 0.0027, β2 = 3.1063, β3 = -3.3135 β4 = -0.7315, β5 = 
0.8270, β6 =0.9616, β7 = -0.0157, β8 = -0.0142, g =1 (male) or 0 (female) 
1.8  
(-1.7 to 4.7) 
12.5 21.2 82.9% 
Scr is serum creatinine in mg/dL. The differences are calculated as eGFR – mGFR. RMSE is calculated from the regression of eGFR vs. mGFR.  
Abbreviations: BSA, body surface area; eGFR, estimated glomerular filtration rate; mGFR, measured glomerular filtration rate; MDRD, Modification of Diet in 
Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CI, confidence interval; RMSE, root mean square error; IQR, interquartile range. 
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Fig. 5.1 Bland-Altman plots of the original and adapted equations 
 
 
Bland-Altman plots of the original (1st column) and adapted (2nd column) equations. The differences 
are calculated as eGFR-mGFR, and the mean is the average of eGFR and mGFR. The solid line 
represents the mean difference, the dashed lines represent the 95% upper and lower limits of agreement, 
and the dotted grey line is the zero line.  
Abbreviations: eGFR, estimated glomerular filtration rate; mGFR, measured glomerular filtration rate; 
MDRD, Modification of diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology 
Collaboration. 
Stellenbosch University https://scholar.sun.ac.za
 82 
 
Fig. 5.2 Predictive confidence intervals for the four adapted equations 
 
Predictive confidence intervals for the four adapted equations for each patient in the validation 
set. The patients in the validation set are ordered by eGFR. The overlapping blue points 
represent eGFR and the orange triangles mGFR. The light blue horizontal lines represent the 
95% confidence interval for eGFR for each patient. The solid red vertical lines represent the 
threshold of 60 ml/min/1.73 m2, the level at or around which critical treatment decisions are 
made.  
Abbreviations: GFR, glomerular filtration rate; eGFR, estimated glomerular filtration rate; 
mGFR, measured glomerular filtration rate; MDRD, Modification of diet in Renal Disease; 
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration. 
  
Stellenbosch University https://scholar.sun.ac.za
 83 
 
6. Estimated glomerular filtration rate in children: evaluating 
and adapting existing equations for a specific population 
 
 
JL Holness,1 A Brink,2 MR Davids,3 JM Warwick,1  
 
1Nuclear Medicine Division, Department of Medical Imaging and Clinical Oncology, 
Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa 
2Division of Nuclear Medicine, Department of Paediatrics and Child Health, University of 
Cape Town and Red Cross Children’s Hospital, Cape Town, South Africa 
3Division of Nephrology, Department of Medicine, Stellenbosch University and Tygerberg 
Hospital, Cape Town, South Africa 
 
Publication status: manuscript being finalised for submission 
 
  
Stellenbosch University https://scholar.sun.ac.za
 84 
 
Abstract 
 
Background  
Numerous creatinine-based equations have been developed for estimating glomerular filtration 
rate (GFR) in children. However, these equations frequently do not perform as well in other 
populations that differ in terms of mean GFR, age, pathology, ethnicity and diet. After first 
evaluating the performance of existing GFR estimating equations in non-cancer and cancer 
populations, the aim of this study was to demonstrate the utility of an in-house modification of 
the equations to better fit a specific population. 
Methods 
A total of 256 GFR measurements (mGFR) were performed in 160 children using the plasma 
clearance of 51Cr-ethylenediaminetetra-acetic acid (51Cr-EDTA). Same-day GFR estimations 
(eGFR) were performed using 11 creatinine-based equations. The agreement of eGFR and 
mGFR, and the bias, precision and accuracy of each equation was determined for non-cancer 
and cancer groups independently. The groups were then divided into development and 
validation sets. Using the development set data, the Microsoft® Excel SOLVER add-in was 
used to modify the parameters of 4 equations to better fit the data. Using the validation set data, 
the performance of the original and modified equations was compared. 
Results 
In the non-cancer group, bias was 3.4-22.6 ml/min/1.73 m2. The root mean square error 
(RMSE) was 14.1-30.5 ml/min/1.73 m2, and the P30 values were 48.4-76.1%. In the cancer 
group, bias was 16.8-46.0 ml/min/1.73 m2, RMSE was 13.4-39.5 ml/min/1.73 m2, and the P30 
values were 20.6-67.0%. The Chronic Kidney Disease in Children Study (CKiD) univariate 
equation was the most accurate equation in both groups. Modifying the equations parameters 
resulted in significant improvements in bias and good accuracy (P30 > 80%) in 3/4 of the non-
cancer group. All 4 of the adapted cancer equations demonstrated significant improvements in 
bias and RMSE, with good accuracy in 3/4. 
Conclusions 
Existing paediatric GFR estimating equations performed poorly in both non-cancer and cancer 
populations. However, modifying the equations’ parameters using a simple Excel-based tool 
significantly improved their accuracy.   
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Introduction 
In centres where glomerular filtration rate (GFR) cannot be routinely measured, whether due 
to non-availability, limited capacity or cost, it is frequently estimated from the serum creatinine 
concentration. Numerous creatinine-based equations have been developed for use in children. 
The majority were developed in populations with chronic kidney disease (CKD), with just a 
few developed specifically for cancer populations. However, the performance of the equations 
in subsequent validation studies has been shown to vary widely (Counahan et al. 1976; Léger 
et al. 2002; Mattman et al. 2006; Biörk et al. 2007; Schwartz et al. 2009; Pottel et al. 2010; 
Staples et al. 2010; Bacchetta et al. 2011; Gao et al. 2012; Pottel et al. 2012; Schwartz et al. 
2012; Selistre et al. 2012; De Souza et al. 2012; Blufpand et al. 2013; Hoste et al. 2013; Uemura 
et al. 2014; Deng et al. 2015; Pottel et al. 2016). For example, in CKD populations, values for 
bias of the new bedside Schwartz formula (Schwartz et al. 2009) have ranged between -15 
ml/min/1.73 m2 (underestimation) and 22 ml/min/1.73 m2 (overestimation), and accuracy, 
reflected by P30 values (percentage of estimates within 30% of measured GFR), has ranged 
from good (~90%) to poor (~50%)  (Pottel et al. 2010; Staples et al. 2010; Bacchetta et al. 
2011; Gao et al. 2012; Lee et al. 2012; Pottel et al. 2012; Selistre et al. 2012; De Souza et al. 
2012; Blufpand et al. 2013; Hoste et al. 2013; Uemura et al. 2014; Pottel et al. 2016). There is 
less data on the performance of estimated GFR (eGFR) in children with cancer, but in general, 
the accuracy has been lower (Millisor et al. 2017; Jeong et al. 2018; Llanos-Paez et al. 2018).  
The large discrepancies in estimating equation performance are likely to be due to systematic 
differences in age, kidney function, pathology, genetics, and nutrition between the validation 
population and the population in which the equation was originally developed. The accuracy 
of eGFR in children has been shown to be dependent on both age and GFR (Blufpand et al. 
2013; Hoste et al. 2013). Serum creatinine levels are known to be lower in individuals with 
low-meat or vegetarian diets (Perrone et al. 1992). Ethnicity may also result in differences in 
serum creatinine levels as this has been shown in certain adult populations (Stevens et al. 2006; 
Levey et al. 2009). Ideally, before using estimated GFR in clinical practice, the equations 
should be validated in the population in which they will be used. If no equation with acceptable 
accuracy exists, the only remaining alternatives are to measure GFR in all cases or to develop 
a new equation for that population.  
The development of new estimating equations typically involves the analysis of large data 
series in extensive and costly projects, which is impractical for most paediatric populations, 
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especially outside of the developed world. However, in centres with even limited access to 
GFR measurement, it may be possible to adapt existing equation parameters for use in a 
specific population. This may be possible using a relatively simple and widely available tool 
that requires limited expertise.  
The aims of this study were (i) to evaluate existing GFR estimation equations in diverse, non-
cancer and cancer paediatric populations, and (ii) to evaluate the adaptation of equations using 
a simple spreadsheet-based tool.  
Methods 
Participants 
Children were recruited both prospectively and retrospectively. In the prospective group 
(September 2015 to May 2018), children (<18 years) meeting the following inclusion criteria 
were invited to participate: (i) GFR measured in the Nuclear Medicine Department of the Red 
Cross War Memorial Children’s Hospital, Cape Town, South Africa, (ii) assessed by the 
attending Nuclear Physician to be clinically stable without expanded third spaces (e.g. oedema, 
ascites), and (iii) informed consent signed by a parent or guardian. Prospectively recruited cases 
were excluded if insufficient blood was obtained for serum creatinine measurement. In the 
retrospective group (January 2011 to August 2015), all consecutive studies in children who had 
GFR and serum creatinine measured on the same day were included. In both groups additional 
cases were excluded if the child or his/her parents were not South African, if information in 
the child’s records was missing or inconsistent, or if the GFR measurement failed routine 
quality assurance checks.  
All procedures performed in studies involving human participants were in accordance with the 
ethical standards of the Health Research Ethics Committee of Stellenbosch University 
(reference S14/10/217), the Human Research Ethics Committee of the University of Cape 
Town (reference 184/2015), and with the 1964 Helsinki declaration and its later amendments. 
Informed consent was obtained from the parents or guardians of all individual participants 
included in the study’s prospective group. In addition, assent was obtained from children of 
appropriate age and understanding. For the group of children recruited retrospectively, formal 
consent was not required. 
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GFR and serum creatinine measurement 
GFR was measured following departmental protocol that is based on the 2001 European 
Association of Nuclear Medicine (EANM) guideline for GFR determination in children (Piepsz 
et al. 2001). There was no change in protocol during the study period. The children’s heights 
and weights were measured, and body surface area (BSA) was calculated using the DuBois and 
DuBois formula (Du Bois and Du Bois 1989). The dose of 51Cr-ethylenediaminetetraacetic 
acid (51Cr-EDTA), calculated as 2.8 x BSA (MBq), was administered intravenously. Venous 
blood samples were taken from the contralateral arm at 2 h and 4 h after administration. The 
plasma clearance was calculated using the slope-intercept method (Chantler et al. 1969). This 
value was adjusted for BSA, and the Jodal Bröchner-Mortensen (Jodal and Bröchner‐
Mortensen 2009) correction was applied. The measured GFR value is referred to in the text as 
mGFR. Serum creatinine (Scr) was measured using an enzymatic method (Beckman Coulter 
AU480 analyzer) with calibration that is isotope dilution mass spectrometry (IDMS) traceable 
(Myers et al. 2006). 
Evaluation of existing equations 
GFR was estimated using 11 paediatric, creatinine-based equations (Table 6.1). Equations that 
were developed prior to IDMS-standardization of serum creatinine assays were not evaluated. 
The estimated GFR value is referred to in the text as eGFR. Previous studies point to the need 
to develop separate estimation equations for patients with cancer (Millisor et al. 2017; Llanos-
Paez et al. 2018).  As all evaluated equations were developed almost exclusively from chronic 
kidney disease (CKD) populations, the children in the current study were divided into cancer 
and non-cancer groups. Bland-Altman analyses were used to determine the agreement between 
eGFR and mGFR. The performance of the equations in each group was quantified in terms of 
bias, precision and accuracy, calculated based on previous recommendations (Stevens et al. 
2007b; Earley et al. 2012). Bias was measured as the median difference between eGFR and 
mGFR (eGFR – mGFR), expressed on the raw scale (ml/min/1.73 m2). As a measure of 
precision, the root mean square error (RMSE) of the regression of eGFR vs. mGFR was 
calculated. Accuracy was expressed as the percentage of eGFR values that fell within 30% of 
mGFR (P30).  
Stellenbosch University https://scholar.sun.ac.za
 88 
 
Modification of the equations 
In the second part of this study, the cancer and non-cancer populations were randomly divided 
into equally sized development and validation sets. A spreadsheet-based tool applying an 
iterative least squares technique (Excel Solver add-in, Microsoft® Corporation, Albuquerque, 
New Mexico, United States) was used to adjust parameters of three of the equations to optimize 
the fit of the development set data, following methodology described previously (Brown 2001). 
Six of the equations were not adapted as these require normalization of the children’s serum 
creatinine concentrations to the median or average, age-matched, serum creatinine 
concentrations in their populations. These values are denoted Q-values in the simple-height 
independent (SHI) (Pottel et al. 2012), Q (age), Q (height) (Hoste et al. 2013), FAS (age) and 
FAS (height) (Pottel et al. 2016) equations, and reference serum creatinine in the Japanese 
equation (Uemura et al. 2014). These values are population-specific and are not available for 
our patient population. The Schwartz-Lyon variation of the Schwartz equation (De Souza et al. 
2012) was also not assessed due to the paucity of males ≥ 13 years.  
The performance of each modified equation was evaluated and compared to the original using 
the validation set data. Cancer and non-cancer groups were analyzed separately. The changes 
in bias (Δbias) and RMSE (ΔRMSE) were calculated, and Bland-Altman analyses were 
performed to compare the agreement of the original and calibrated equations.  
Statistical analysis was performed using MedCalc Statistical Software for Windows v.19 
(MedCalc Software bvba, Ostend, Belgium; https://www.medcalc.org; 2019). Normality was 
tested using the Shapiro-Wilk test. The McNemar and chi-squared tests were used to compare 
proportions within groups and between groups respectively.  
Results 
A total of 256 GFR measurements in 160 children were included (median age 8.9 years; age 
range 0.1-17.9 years). The diagnosis was cancer in 97 (37.9%) and non-cancer conditions in 
the remaining 159: CKD in 63 (24.6%), vasculitis (Takayasu’s arteritis or polyarteritis nodosa) 
in 52 (20.3%), and liver transplant in 44 (17.2%). Mean (SD) GFR was 88.9 (29.9) ml/min/1.73 
m2. The characteristics of the children are summarized in Table 6.2. One hundred and fifty-
five (61%) children were recruited prospectively. 
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In the non-cancer group, median bias ranged between 3.4 ml/min/1.73 m2 for the Chronic 
Kidney Disease in Children Study univariate equation (CKiD) and 22.6 ml/min/1.73 m2 for the 
Q(age) equation (Table 6.3). RMSE ranged between 14.1 (Gao’s quadratic formula (QF)) and 
30.5 (Q(age) equation) ml/min/1.73 m2. The P30 values ranged between 76.1% (CKiD) and 
48.4% (Q(age) equation) (Fig. 6.1). The P30 of the CKiD equation was not significantly 
different to the Japanese equation P30 (p=0.21) but was significantly higher than all the other 
equations. The 95% limits of the Bland-Altman analyses were narrowest for Gao’s QF and 
widest using the Q(age) equation.  
In the cancer group, bias of every equation was systematically greater. Median bias ranged 
between 16.8 ml/min/1.73 m2 (CKiD) and 46.0 ml/min/1.73 m2 (Schwartz) (Table 6.3). 
Similarly, RMSE increased in the cancer group for all equations with the single exception of 
Gao’s QF. With a RMSE of 13.4 ml/min/1.73 m2, Gao’s QF was most precise, and the 
Q(height) the least precise (RMSE = 39.5 ml/min/1.73 m2). Only the CKiD equation and Gao’s 
QF had P30 values > 50% (67.0% and 62.9% respectively) (Fig. 6.1). There was no significant 
difference between the two (p=0.5), but the CKiD was significantly more accurate than the 
other equations. The P30 values of the CKiD and Gao’s QF equations were also not different 
for cancer patients compared to non-cancer patients (p=0.1138 and p=0.7590 respectively). In 
the remaining 9/11 equations the P30 values were significantly lower in the cancer group 
compared to the non-cancer group (p-values <0.0001 to 0.0008). 
For modification of the equations, the development and validation sets respectively included 
79 and 80 cases (non-cancer), and 48 and 49 cases (cancer). The optimized equations are listed 
in Table 6.4. On testing with validation set data, in both non-cancer and cancer groups there 
was a reduction in bias of > 50% in all cases, with the exception of the CKiD in non-cancer 
patients which showed a reduction of only 5% (Table 6.5). None of the non-cancer group 
showed reductions in RMSE that exceeded 20%. However, the RMSE decreased by >20% in 
all four cancer-adapted equations, with the greatest reduction in the refitted CKiD equation 
(38%). The P30 values of the refitted non-cancer equations ranged from 70.0% to 83.8%, in 
comparison to 53.8% to 71.3% for the original equations, significantly improving for the 
Schwartz formula ( p<0.0001), Flanders metadata equation (p=0.002) and Gao’s QF  
(p=0.019). The P30 values of the refitted cancer equations increased from 14.3%-67.3% to 
77.6%-89.8%, significantly improving for the Schwartz formula (p<0.0001), Flanders 
metadata equation (p<00001), and Gao’s QF (p=0.003) (Fig. 6.2). Bland-Altman plots 
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illustrate the difference between the original and adapted versions of the 4 equations (Fig. 6.3). 
The 95% confidence intervals (CI) in ml/min/1.73 m2 for the adapted non-cancer equations 
were: Schwartz ± 44.7, Flanders metadata ± 42.4, CKiD ± 41.7 and Gao’s QF ± 36.3. For the 
adapted cancer equations, the 95% CIs were Schwartz ± 57.8, Flanders metadata ± 57.8, CKiD 
± 41.5 and Gao’s QF ± 41.5. 
The adapted Flanders metadata equation had the highest P30 in the non-cancer group (83.8%) 
and the adapted Schwartz formula had the highest P30 in the cancer group (89.8%). When 
compared to the original CKiD equation, the best performing original equation in both groups, 
the P30 of the adapted equations was significantly improved (non-cancer p=0.013; cancer 
p=0.001). 
Discussion 
In this study, paediatric GFR estimating equations generally performed poorly in non-cancer 
patients. GFR was consistently overestimated with biases ranging between 3.4 and 22.6 
ml/min/1.73 m2. Only Gao’s QF, the CKiD and Japanese equations had RMSE values < 20 
ml/min/1.73 m2. The accuracy, reflected by the P30 values, was moderate (60-80%) for 7 of the 
equations and low (< 60%) for the remaining 4 equations. 
Previous validation studies have shown variable results although, in general, the accuracy of 
all the equations was lower in our non-cancer population. Using the Schwartz formula, some 
studies found good accuracy (> 80%), while in others it was moderate to poor, with P30 values 
similar to the 58% found in this study (Pottel et al. 2010; Bacchetta et al. 2011; Pottel et al. 
2012; Selistre et al. 2012; De Souza et al. 2012; Uemura et al. 2014; Deng et al. 2015; Pottel 
et al. 2016). The Schwartz-Lyon equation was found to have P30 values consistently > 77% in 
comparison to our 68% (Bacchetta et al. 2011; Selistre et al. 2012; Hoste et al. 2013), and the 
SHI equation had P30 values of 64% and 77% in two separate studies compared to our 54% 
(Blufpand et al. 2013; Deng et al. 2015). In a study that evaluated the Flanders metadata 
equation, results were presented in age and GFR categories. However, in 4/6 groups the P30 
values were > 80% compared to the 67% in our study (Hoste et al. 2013). Having been 
developed relatively recently, Gao’s QF and the FAS equation have not been evaluated in many 
independent validation studies, although one found Gao’s QF to have a P30 of 72%, marginally 
higher than the 65% in this study (Deng et al. 2015).  
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The consistent overestimation of GFR in our non-cancer population reflects systematically 
lower serum creatinine levels in comparison to the populations in which the equations were 
developed and validated. Lower dietary protein intake, which is likely in this population due 
to poor socio-economic conditions, possibly combined with ethnic/genetic differences are 
likely causative factors (Stevens et al. 2006). The poor precision of eGFR is unsurprising 
considering the population’s diversity. In the non-cancer group, the children fell into one of 
three main ethnic groups. The kidney function and ages of the children also varied widely, with 
25% of children having a GFR of < 60 ml/min/1.73 m2, 45% > 90 ml/min/1.73 m2, half under 
10 years in age, approximately one-third between 10 and 14 years, and the remaining 15% > 
14 years. Such diversity places a limit on the precision that can be achieved with any GFR 
estimating equation.  
In the cancer group, there was consistently poorer performance in terms of bias, precision and 
accuracy. Bias ranged between 16.8 ml/min/1.73 m2 (CKiD) and 46.0 ml/min/1.73 m2 
(Schwartz formula), and 9 of the 11 evaluated equations had RMSEs of > 30 ml/min/1.73 m2. 
Interestingly, Gao’s QF had a RMSE of 13.4 ml/min/1.73 m2, which is similar to the value in 
the non-cancer group. No equations demonstrated good accuracy, and at 63% and 67%, Gao’s 
QF and the CKiD were the only equations with P30 values > 50%.  
Although the cancer and non-cancer groups differed significantly in terms of age (median 5.9 
vs. 9.7 years) and mGFR (mean 95 vs. 85 ml/min/1.73 m2), the poorer performance of eGFR 
in the cancer group likely mostly reflects differences in pathology. The greater overestimation 
of GFR in this group is not unexpected as chronic illnesses such as cancer are known to 
decrease the serum creatinine concentration (Stevens et al. 2006). This is likely compounded 
by a reduced dietary protein intake due to the symptoms of cancer or its treatment, further 
reducing the serum creatinine concentration (Stevens et al. 2006). The poor precision of eGFR 
may in part reflect a diversity of cancer types, stages of disease and timing of the GFR 
determination in relation to treatment.  
In comparison to other studies in paediatric cancer populations, the accuracy in our population 
was lower. In 124 GFR measurements in 73 children with cancer, Llanos-Paez et al (Llanos-
Paez et al. 2018) evaluated 22 equations, 8 of which were also evaluated in our study. In 7/8 
the accuracy was substantially lower in our study with differences in P30 values of 14.5-48.9% 
between the two studies. Millisor et al (Millisor et al. 2017) found a P30 value of 55% for the 
Schwartz formula. Although this is considered low, it was more than double the value in our 
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study. Jeong et al (Jeong et al. 2018) found values of 64% and 66% for the Schwartz formula 
and FAS(age) equations respectively, again much higher than our values of 21% and 33%. 
Similar to the non-cancer population, systematically lower Scr levels may be attributable to 
differences in diet and ethnicity. It is also possible that our population included patients who 
presented later with more advanced disease. The population’s greater diversity may again 
account for the poorer precision. 
Ideally, GFR should be measured in all children, but as mGFR remains unavailable in many 
centres, clinicians may be compelled to rely on eGFR. However, eGFR should not be used 
without initial confirmation of its validity in the patient population. This is particularly relevant 
for children with cancer. Furthermore, within the same hospital, separate equations are likely 
to be required for children with and without cancer. When performance of published equations 
is unsatisfactory, adapting the equations provides a practical option without the need for large 
expensive studies. This still requires at least limited availability of mGFR, but it then allows 
for population-specific adaptation of the equations to be performed. A simple tool, the 
Microsoft® Excel Solver add-in, is readily available for this purpose, with a step-by-step guide 
for its use (Brown 2001).  
It must be noted that while the Schwartz formula could be adapted using a simple linear 
regression, Solver allows fitting of non-linear functions with multiple variables, allowing for 
numerical adaptations of all 4 estimating equations. When adapting equations, there must be 
an internal validation set with independent data, to avoid overfitting. For an adapted eGFR 
equation to be valid it is essential for the adaptation to be derived from a similar patient 
population with renal function over the same range. The minimum number of cases required to 
successfully adapt equations is expected to depend on the number of equation parameters and 
the diversity of the population being modelled. If the population were to have a wide range of 
heights, GFRs, or ages, larger numbers would be required, whereas in a more homogeneous 
population fewer would suffice. In order to get an indication of the minimum number of cases 
required for a satisfactory adaptation we studied the effect of development set size on bias, 
precision and P30 for an independent validation set. Bias and P30 changed little after surprisingly 
few cases (~40), while precision continued to improve after a large number of cases (data not 
shown). Based on this we used development sets of at least 40-50 cases, but we would use as 
many cases as possible when these were available. 
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Before being put into clinical practice, a new equation needs to be shown to sufficiently 
improve the accuracy of GFR estimates compared to existing equations (Earley et al. 2012; 
KDIGO 2013). Relative reductions in bias of > 50% or RMSE of > 20% have been proposed 
(Earley et al. 2012). In 3/4 adapted non-cancer equations in this study, there were significant 
improvements in bias. Based on the P30 values, accuracy of 3/4 was good (> 80%) and 1/4 was 
moderate. All 4 of the adapted cancer equations demonstrated significant improvements in both 
bias and RMSE, with good accuracy (> 80%) in 3/4 and moderate accuracy in 1/4.  
As the GFR estimating equations were modified to fit specific non-cancer and cancer 
populations, the adapted versions cannot be assumed to work well in other populations that 
differ in terms of age or GFR range, pathology, genetics and nutrition. Rather, the intention of 
this study was to demonstrate the utility of modifying the equations. Another limitation of this 
study is that the performance of the modified equations should ideally have been assessed in 
different age and GFR categories; however, the small numbers in each group precluded this. 
Specifically, there were very few children in the cancer group with mGFR < 60 ml/min/1.73 
m2. A development dataset should ideally include a representative range of GFRs to ensure its 
validity for the full range of renal function (KDIGO 2013). 
A limitation of eGFR in general is that the decision to use it in the clinic should always be 
made with a good understanding of the inherent uncertainty associated with these estimates. 
For example, for an eGFR of 100 ml/min/1.73 m2 the P30 represents values between 70 and 130 
ml/min/1.73 m2. This in itself is a wide range, but for a P30 of 80%, which is often considered 
acceptable, 1 in 5 children will have a true GFR that is beyond even this range. If a specific 
clinical context permits a certain amount of uncertainty in the GFR value obtained, then it may 
be acceptable to use an eGFR with a P30 of 80%. In support of it, the Chronic Kidney Disease 
Improving Global Outcomes (KDIGO) guideline recommends use of eGFR for diagnosing and 
monitoring CKD in adults and children (KDIGO 2013). However, if the clinical context 
requires a high degree of certainty, eGFR should probably only be used to place the value 
within a 95% confidence interval, making it useful in only a limited proportion of patients, 
typically those with high eGFR values. For example, in oncology where GFR must be above a 
specific value (typically 60 ml/min/1.73 m2) for a child to receive chemotherapy, only a very 
high eGFR result is useful to reliably exclude a reduced GFR, with eGFR expected to 
misclassify a large proportion of cases. 
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Inclusion of children < 2 years of age in this study (10%) may have contributed to the original 
equations’ poor overall performance as under 2-year-olds were excluded from many of the 
development datasets; however, the impact of this on the overall results is likely to be small. 
Six of the equations require normalization the child’s Scr to the population’s mean or median 
Scr (Pottel et al. 2012; Hoste et al. 2013; Uemura et al. 2014; Pottel et al. 2016). Had this data 
been available for our local population, it is expected that the accuracy of the relevant equations 
would have been better.  
In conclusion, existing paediatric GFR estimating equations performed poorly in this specific 
population that differed from the development populations in terms of age, GFR, pathology, 
ethnicity and diet. Modifying the equations’ parameters using a simple Excel-based tool is 
achievable in any department that has at least some access to GFR measurement, and 
significantly improved their accuracy. However, in specific clinical settings that require high 
degrees of certainty with GFR values, GFR measurement is essential.  
Conflicts of interest 
None 
Author contributions 
JL Holness: data analysis, manuscript preparation 
A Brink: participant recruitment, manuscript review 
MR Davids: co-supervisor, manuscript review 
JM Warwick: supervisor, manuscript review 
Sources of funding 
James Warwick received funding from the National Research Foundation, South Africa (grant 
number 93471). Jennifer Holness received funding from the South African Medical Research 
Council (SAMRC), through its Division of Research Capacity Development, under the 
Clinician Researcher Development PhD Scholarship Programme. The funding is provided by 
the South African National Treasury. The content hereof is the sole responsibility of the authors 
and does not necessarily represent the official views of the SAMRC or the funders. 
 
Stellenbosch University https://scholar.sun.ac.za
 95 
 
Tables and figures 
 
Table 6.1 The GFR estimating equations evaluated in this study 
Equation name Formula (ml/min/1.73m
2) Units 
New bedside Schwartz 
formula  
(Schwartz et al. 2009) 
eGFR = k(ht/Scr) 
k = 0.413 
Scr: mg/dL 
ht: cm 
Flanders Metadata 
formula  
(Pottel et al. 2010) 
eGFR = k(ht/Scr) 
k = [0.0414 x ln(age) + 0.3018]  
Scr: mg/dL 
ht: cm 
Schwartz-Lyon formula 
(De Souza et al. 2012) 
eGFR = k(ht/Scr) 
k = 32.5 all females and males < 13y 
k = 36.5 males ≥ 13y  
Scr: µmol/L 
ht: cm 
Simple height-
independent equation 
(Pottel et al. 2012) 
eGFR = 107.3/(Scr/Q) 
Q = (0.0270 x age) + 0.2329 
Scr: mg/dL 
age: years 
Q(age) equation  
(Hoste et al. 2013) 
eGFR = 107.3/(Scr/Q) 
Boys: Q = 0.21 + (0.057 x age) – (0.0075 x age2) + (0.00064 x age3) – 0.000016 x age4)  
Girls: Q = 0.23 + (0.034 x age) – (0.0018 x age2) + (0.00017 x age3) – (0.0000051 x age4)  
Scr: mg/dL 
age: years 
 
Q(height) equation  
(Hoste et al. 2013) 
eGFR = 107.3/(Scr/Q) 
Q = 3.94 – (13.4 x L) + (17.6 x L2) – (9.84 x L3) + (2.04 x L4) for boys and girls 
Scr: mg/dL 
L: cm 
CKiD univariate equation 
(Schwartz et al. 2012) 
eGFR = a(ht/Scr)b 
a = 42.3 
b = 0.780 
Scr: mg/dL 
ht: m 
Gao’s quadratic formula 
(Gao et al. 2012) 
Boys: eGFR = 0.68 x (Ht/Scr) – 0.0008 x (Ht/Scr)2 + (0.48 x age) – 21.53  
Girls: eGFR = 0.68 x (Ht/Scr) – 0.0008 x (Ht/Scr)2 + (0.48 x age) – 25.68  
Scr: mg/dL 
ht: cm 
Japanese equation 
(Uemura et al. 2014) 
eGFR = 110.2 x (ref Scr/pt Scr) + 2.93 
Boys: ref Scr = (-1.259 x L5) + (7.815 x L4) – (18.57 x L3) + (21.39 x L2) – (11.71 x L) + 2.628 
Girls: ref Scr = (-4.536 x L5) + (27.16 x L4) – (63.47 x L3) + (72.43 x L2) – (40.06 x L) + 8.778 
Scr: mg/dL 
L: m 
Full age spectrum (FAS) 
equation (age)  
(Pottel et al. 2016) 
eGFR = 107.3/(Scr/Q) 
See original papers for Q value table (Hoste et al. 2013; Pottel et al. 2016) 
Scr: * 
Full age spectrum (FAS) 
equation (height)  
(Pottel et al. 2016) 
eGFR = 107.3/(Scr/Q) 
See original papers for Q value table (Hoste et al. 2013; Pottel et al. 2016) 
Scr: * 
*Scr units must correspond to the units of the Q value 
Abbreviations: CKiD, Chronic Kidney Disease in Children study; eGFR, estimated glomerular 
filtration rate; ht, height; Scr, serum creatinine; L, length; ref, reference; pt, patient  
Stellenbosch University https://scholar.sun.ac.za
 96 
 
Table 6.2 Patient characteristics (n = 256) 
Age (years)  8.9 (4.3 to 12.6) 
Sex Male 117 (46%) 
GFR (ml/min/1.73 m2)  90.6 (69.9 to 108.6) 
Weight (kg)  23.9 (14.2 to 37.7) 
Height (cm)  120.8 (99.6 to 145.0) 
Scr (mg/dL)  0.43 (0.32 to 0.57) 
Scr (µmol/L)  38 (28 to 51) 
Height/Scr Non-cancer 220 
Cancer 328 
GFR categories ≥ 90 ml/min/1.73m2 131 (51.2%) 
60 – 89 ml/min/1.73m2 81 (31.6%) 
45 – 59 ml/min/1.73m2 24 (9.4%) 
< 45 ml/min/1.73m2 20 (7.8%) 
Diagnoses Non-cancer 159 (62.1%) 
        Vasculitis          52 (32.7%) 
        Liver transplant drug monitoring         44 (27.7%) 
        Neurogenic bladder         12 (7.5%) 
        Posterior urethral valves         6 (3.8%) 
        Uteropelvic junction obstruction         6 (3.8%) 
        Solitary kidney         6 (3.8%) 
        Fibromuscular dysplasia         5 (3.1%) 
        Cystic diseases         4 (2.5%) 
        Glomerular disease         3 (1.9%) 
        Other causes of CKD (congenital and medical)         21 (13.2%) 
Cancer 97 (37.9%) 
        Neuroblastoma         33 (34.0%) 
        Osteosarcoma         17 (17.5%) 
        Lymphoma         11 (11.3%) 
        Wilms tumor         9 (9.3%) 
        CNS tumors         8 (8.3%) 
        Other         19 (19.6%) 
Ethnicity Mixed ancestry 148 (57.8%) 
Black African 74 (28.9%) 
Caucasian 34 (13.3%) 
Values are either median (IQR) or n (%).  
Abbreviations: GFR, glomerular filtration rate; Scr, serum creatinine; CKD, chronic kidney 
disease; CNS, central nervous system.
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Table 6.3 Summary statistics for the 11 original estimating equations 
 
 
Non-cancer (n=159) Cancer (n=97) 
 
Median 
GFR* 
Median 
difference 
(95% CI)* 
RMSE* 
P30  (%) 
(95% CI) 
Mean 
difference  
(95% LOA)* 
Median 
GFR* 
Median 
difference 
(95% CI)* 
RMSE* 
P30  (%) 
(95% CI) 
Mean 
difference 
(95% LOA)* 
mGFR (51Cr-EDTA plasma 
clearance) 
85.5 NA NA NA NA 95.1 NA NA NA NA 
New bedside Schwartz 
formula  
103.5 
18.4 
(15.7 to 21.4) 
23.4 
57.9 
(49.8 to 65.7) 
19.4 
(-27.3; 66.1) 
141.1 
46.0 
(37.3 to 58.2) 
35.8 
20.6 
(13.1 to 30.3) 
51.7 
(-18.1; 121.5) 
Flanders metadata 
formula  
99.5 
12.8 
(9.9 to 16.0) 
21.6 
67.3 
(59.4 to 74.5) 
13.5 
(-29.3; 56.3) 
123.4 
31.1 
(24.5 to 37.9) 
33.9 
42.3 
(32.3 to 52.8) 
35.2 
(-30.8; 101.3) 
Schwartz-Lyon formula 92.4 
9.6 
(6.7 to 12.7) 
21.0 
67.9 
(60.0 to 75.1) 
9.2 
(-33.9; 52.3) 
125.7 
35.0 
(25.5 to 42.2) 
31.6 
34.0 
(24.7 to 44.3) 
36.6 
(-25.1; 98.3) 
Simple height-
independent equation 
105.5 
17.8 
(15.0 to 25.3) 
29.6 
54.1 
(46.0 to 62.0) 
23.3 
(-34.6; 81.1) 
133.7 
39.5 
(31.0 to 44.0) 
33.1 
27.8 
(19.2 to 37.8) 
41.9 
(-23.0; 106.7) 
Q(age) equation 107.6 
22.6 
(17.1 to 28.1) 
30.5 
48.4 
(40.4 to 56.4) 
26.8 
(-33.0; 86.5) 
137.7 
42.3 
(34.5 to 48.7) 
33.3 
23.7 
(15.7 to 33.4) 
45.5 
(-19.5; 110.5) 
Q(height) equation 98.0 
13.8 
(8.7 to 17.2) 
21.2 
64.2 
(56.2 to 71.6) 
13.3 
(-29.4; 56.0) 
134.9 
42.8 
(32.4 to 48.8) 
39.5 
25.8 
(17.4 to 35.7) 
47.9 
(-30.1; 125.9) 
CKiD univariate 
equation 
86.6 
3.4 
(0.5 to 7.2) 
15.0 
76.1 
(68.7 to 82.5) 
1.3 
(-39.1 to 41.7) 
110.3 
16.8 
(14.1 to 20.5) 
21.3 
67.0 
(56.7 to 76.2) 
17.7 
(-27.4; 62.8) 
Gao’s quadratic formula 101.8 
9.9 
(6.1 to 17.1) 
14.1 
64.8 
(56.8 to 72.2) 
10.1 
(-27.4; 47.6) 
116.5 
19.3 
(16.2 to 22.9) 
13.4 
62.9 
(52.5 to 72.5) 
16.8 
(-24.0; 57.7) 
Japanese equation 90.2 
5.4 
(1.8 to 10.3) 
18.6 
71.7 
(64.0 to 78.6) 
5.2 
(-34.0; 44.5) 
121.3 
28.2 
(22.4 to 34.1) 
30.3 
49.5 
(39.2 to 59.8) 
31.6 
(-27.8; 91.1) 
FAS (age) equation 105.1 
17.8 
(14.3 to 23.2) 
28.6 
54.7 
(46.6 to 62.6) 
22.5 
(-33.4; 78.5) 
131.8 
37.0 
(29.3 to 42.2) 
32.3 
33.0 
(23.8 to 43.3) 
39.8 
(-23.7; 103.3) 
FAS (height) equation 96.6 
12.9 
(7.3 to 15.1) 
20.9 
63.5 
(55.5 to 71.0) 
11.6 
(-30.8; 54.1) 
129.9 
36.3 
(28.7 to 44.4) 
33.9 
32.0 
(22.9 to 42.2) 
40.9 
(-25.5; 107.2) 
*Units are ml/min/1.73 m2. Median and mean differences are calculated as eGFR – mGFR. RMSE is calculated from the regression of eGFR vs. mGFR.  
Abbreviations: GFR, glomerular filtration rate; mGFR, measured glomerular filtration rate; eGFR, estimated glomerular filtration rate; LOA, limits of 
agreement; CI, confidence interval; RMSE, root mean square error; NA, not applicable; CKiD, Chronic Kidney Disease in Children study; FAS, full age 
spectrum. 
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Fig. 6.1 Comparison of the P30 values of the non-cancer and cancer groups 
 
Bar chart of the P30 values of the non-cancer (blue) and cancer (orange) groups for each 
equation. The equations have been arranged from left to right in descending order of average 
P30. The error bars represent the 95% confidence intervals.  
Abbreviations: CKiD, Chronic Kidney Disease in Children study; FAS, full age spectrum.  
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Table 6.4 Original and adapted equations 
Schwartz formula 
Original eGFR = 0.413(ht/Scr) 
Adapted non-cancer eGFR = 0.333(ht/Scr) 
Adapted cancer eGFR = 0.254(ht/Scr) 
Flanders metadata 
equation 
Original 
eGFR = k(ht/Scr)   
k = [0.0414 x ln(age) + 0.3018]  
Adapted non-cancer 
eGFR = k(ht/Scr) 
 k = [0.0518 x ln(age) + 0.2198] 
Adapted cancer 
eGFR = k(ht/Scr) 
 k = [0.0117 x ln(age) + 0.2366] 
CKiD univariate 
equation 
Original 
eGFR = a(ht/Scr)b 
a = 42.3; b = 0.780 
Adapted non-cancer  
eGFR = a(ht/Scr)b 
a = 45.0; b = 0.728 
Adapted cancer 
eGFR = a(ht/Scr)b 
a = 69.3; b = 0.280 
Gao’s quadratic 
formula 
Original 
Boys: eGFR = 0.68(Ht/Scr) – 0.0008(Ht/Scr)2 + (0.48 x age) – 21.53  
Girls: eGFR = 0.68(Ht/Scr) – 0.0008(Ht/Scr)2 + (0.48 x age) – 25.68  
Adapted non-cancer  
Boys: eGFR = 0.61(Ht/Scr) – 0.0006(Ht/Scr)2 + (1.68 x age) – 37.03  
Girls: eGFR = 0.61(Ht/Scr) – 0.0006(Ht/Scr)2 + (1.68 x age) – 43.29  
Adapted cancer 
Boys: eGFR = 0.12(Ht/Scr) – 0.00004(Ht/Scr)2 + (0.64 x age) + 58.92  
Girls: eGFR = 0.12(Ht/Scr) – 0.00004(Ht/Scr)2 + (0.64 x age) + 51.69 
Height in units m for the CKiD equation, and cm for the others. Scr in units mg/dL for all 
equations.  
Abbreviations: CKiD, Chronic Kidney Disease in Children study; eGFR, estimated 
glomerular filtration rate; ht, height; Scr, serum creatinine.
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Table 6.5 Evaluation of the adapted non-cancer and cancer equations 
 Non cancer (n=80) Cancer (n=49) 
 
Median 
difference 
(95% CI)* 
Δ bias 
(%) 
RMSE* Δ RMSE 
P30 (%)  
(95% CI) 
p-value 
Median 
difference 
(95% CI)* 
Δ bias 
(%) 
RMSE* Δ RMSE 
P30 (%)  
(95% CI) 
p-value 
Original Schwartz 
18.3 
(12.2 to 24.3) 
-93% 
22.0 
-19% 
53.8 
(42.3 to 65.0) 
<0.0001 
46.0 
(36.8 to 62.3) 
-88% 
28.6 
-38% 
14.3 
(6.0 to 27.3) 
<0.0001 
Adapted Schwartz 
1.3 
(-3.9 to 8.2) 
17.8 
80.0 
(69.6 to 88.1) 
-5.3 
(-8.9 to -0.8) 
17.6 
89.8 
(77.8 to 96.6) 
Original Flanders 
11.5 
(7.3 to 16.3) 
-82% 
20.2 
-14% 
67.5 
(56.1 to 77.6) 
0.0023 
31.1 
(24.5 to 50.5) 
-82% 
28.1 
-36% 
34.7 
(21.7 to 49.6) 
<0.0001 
Adapted Flanders 
-2.1 
(-5.6 to 1.6) 
17.4 
83.8 
(73.9 to 91.1) 
-5.5 
(-7.9 to 1.3) 
17.9 
87.8 
(75.3 to 95.4) 
Original CKiD univariate 
5.7 
(0.7 to 10.2) 
-5% 
14.3 
-6% 
71.3 
(60.1 to 80.9) 
1.0000 
16.4 
(13.3 to 21.9) 
-63% 
17.2 
-67% 
67.3% 
(52.4 to 80.0) 
0.2668 
Adapted CKiD 
univariate 
5.4 
(0.7 to 11.7) 
13.5 
70.0 
(58.7 to 79.7) 
6.0  
(-1.7 to 14.1) 
5.6 
77.6% 
(63.4 to 88.3) 
Original Gao 
11.3 
(5.7 to 18.8) 
-85% 
14.6 
5% 
58.8 
(47.2 to 69.7) 
0.0192 
21.1 
(16.6 to 26.3) 
-79% 
12.0 
-44% 
61.2% 
(46.2 to 74.8) 
0.0034 
Adapted Gao  
1.7 
(-3.1 to 6.6) 
15.3 
72.5 
(61.4 to 79.7) 
4.4 
(-1.8 to 10.0) 
6.7 
83.7% 
(70.4 to 92.7) 
*Units are ml/min/1.73 m2. Median and mean differences are calculated as eGFR – mGFR. RMSE is calculated from the regression of eGFR vs. 
mGFR.  
Abbreviations: CKiD, Chronic Kidney Disease in Children study; CI, confidence interval; RMSE, root mean square error.
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Fig. 6.2 Comparisons of the P30 values of the original and adapted equations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bar graphs showing the P30 values of the original (solid) and adapted (shaded) equations for 
the (a) non-cancer and (b) cancer groups. The error bars represent the 95% confidence intervals. 
Abbreviations: CKiD, Chronic Kidney Disease in Children study; Gao’s QF, Gao’s quadratic 
formula  
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Fig. 6.3 Bland-Altman plots of the original and modified equations  
 
 
Bland-Altman plots of the original and modified equations for non-cancer (blue; NC) and 
cancer (orange; C) groups.  
Abbreviations: CKiD, Chronic Kidney Disease in Children study. 
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Discussion    
Optimising mGFR methodology 
In paper 1, a post-hoc evaluation of the contribution of two deviations from the 2004 BNMS 
guideline (low counts and lack of decay correction) to the overall variability in VD and GFR 
was performed. The resultant combined errors in GFR and VD were small relative to the 
physiological variation of these parameters.  
In paper 3, a more exhaustive evaluation of the effect of measurement errors on GFR was 
performed. We compared 2-point SI-GFR, 3-point SI-GFR, SS-GFR and SO-GFR. After 
introducing realistic, random errors to all measurements, the median absolute error for all 
methods/variations was low. The error in GFR, expressed as the CV, increased sharply for all 
methods when GFR decreased to below 60 ml/min/1.73 m2. For normal or high GFR values, 
the mean CV of SS-GFR was the lowest, whereas for GFR values < 50 ml/min/1.73 m2 the 
CVs for 3-point SI-GFR and 2-point SI-GFR (2 and 4 h) were the lowest.  
Based on data from repeat GFR measurements, in cases of normal clearance, the CV of 
measurement errors was found to be small in relation to the CV of biological variation. 
However, for lower rates of clearance the CV of measurement errors approaches or even 
exceeds the CV of biological variation and would therefore contribute significantly to repeat 
GFR measurement variability. 
In a sensitivity analysis of GFR to individual measurement errors, the effect of measurement 
errors on three-point SI-GFR and SS-GFR was found to be similar. Both methods were 
relatively insensitive to errors in pipetting volume, flask volume, height, weight and time 
measurements. On the other hand, errors in the administered dose measurements were found 
to be most significant. Of the measurements made, this therefore requires the most attention to 
avoid error. 
Supporting the results of paper 1, GFR was found to be surprisingly robust with low counts. A 
minimum of 2500 counts for each sample (background-corrected) was shown to be adequate 
to avoid a significant error in GFR. 
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The first conclusion drawn from paper 3 is that in most patients the measurement errors that 
occur on a day-to-day basis in an ordinary nuclear medicine department are unlikely to result 
in significant errors in GFR. In fact, it is very unlikely that the resultant error in GFR will be > 
5 ml/min/1.73 m2, which in turn means that patient management is unlikely to be affected. This 
is useful information for individuals undergoing once-off GFR measurement e.g. for potential 
kidney donors, or for previously healthy patients prior to receiving nephrotoxic chemotherapy 
for cancer. 
However, frequently GFR is measured in patients with known or suspected poor kidney 
function, or is required to detect a deterioration in kidney function. In these cases, the 
repercussions of measurement errors are far more significant. Below a value of 25 ml/min/1.73 
m2 the effect of measurement errors becomes too great to meaningfully interpret changes in 
GFR over serial measurements. However, this conclusion applies to SI-GFR, SO-GFR and SS-
GFR using the methodologies described here, and in the case of SS-GFR the equation 
developed by Fleming et al (Fleming et al. 2005a), whereas the current BNMS guideline 
recommends an alternative SS-GFR equation when GFR is < 25 ml/min/1.73 m2 (Gref and 
Karp 2009; Burniston 2018). As the study for paper 3 was developed prior to the 2018 
guideline, it did not evaluate whether measurement errors would have the same effect on GFR 
measurements using this method. Perhaps more importantly, it did not assess the effect of 
measurement errors on SI-GFR, SO-GFR and SS-GFR based on later sampling times and/ or 
prolonged sampling intervals, as are recommended in the latest BNMS guidelines. This would 
be an area for further research. 
Some of the recommended measurement error limits listed in paper 3 are more strict than those 
in the 2018 BNMS guideline (Burniston 2018; Holness et al. 2019). For the majority of 
indications for GFR measurement, these stricter limits are not necessary. However, as stated in 
the paper, one may not know at the outset whether patients will have reduced kidney function. 
It is in these cases that a high level of precision of every measurement is ideal. 
The 2004 BNMS guideline stated that a minimum of 10 000 counts should be obtained for all 
samples to avoid statistical counting error (Fleming et al. 2004). The effect of counts was 
explored further in paper 3 and all methods were found to be surprisingly robust to low counts 
(Holness et al. 2019). Accordingly, a lower value for minimum counts could be recommended. 
This is consistent with the 2018 BNMS guidelines’ recommendation of a precision of less than 
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2% for background corrected counts. This is particularly relevant to departments that use 51Cr-
EDTA as lower doses of activity are administered.    
When using the 2-point SI-GFR, paper 3 provided clear evidence that taking the blood samples 
at 2 h and 4 h is optimal (Holness et al. 2019). Ideally, if the first sample is delayed for whatever 
reason, the second sample should be delayed by the same amount of time. 
As discussed, based on two studies by McMeekin et al (McMeekin et al. 2016a; McMeekin et 
al. 2016b), SS-GFR became the recommended technique in the updated BNMS guideline 
(Burniston 2018). The findings of paper 3 support this conclusion as SS-GFR was found to be 
the least susceptible to measurement errors in the majority of patients. A change to SS-GFR is 
likely to be welcomed by nuclear medicine departments. For the patient, it is less invasive and 
generally requires less time in the department, and for the technologist the procedure is 
simplified, which may translate into an increase in capacity. 
QC checks for mGFR 
In paper 1, as a primary aim, we defined reference data for 99mTc-DTPA T½ and VD in a healthy 
adult population. The ranges represent 2 SD of the mean. For T½, this was derived from the 
regression of T½ vs. the inverse of BM-GFRcorr. No published data with similar methodology 
was available for comparison. 
For VD, the reference data was derived from the regression of VD vs. BSA. For uncorrected 
and corrected VD, the values obtained in our study were systematically higher than the 
reference data that was available at the time (Fleming et al. 2004; Fleming et al. 2009). 
Uncorrected VD will always overestimate true VD, but the degree of overestimation is 
dependent on GFR. Being a healthy population of potential kidney donors, the mean GFR in 
our population is expected to be higher than the BNMS guideline population, thus providing a 
plausible explanation for the higher uncorrected VD values. However, our values for corrected 
VD fell within the 2 SD error limits of the published reference data, and vice versa (Fleming et 
al. 2009). The apparent systematic differences therefore may not be significant. Supporting this 
was the finding of very similar values for ECV to those found in a study of 1878 healthy kidney 
donors from the United Kingdom (Peters et al. 2012). The values for VD in our study also 
showed greater variability than the published reference data. This was thought to be largely 
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due to the greater ethnic/genetic diversity in our population, with a smaller contribution from 
experimental error.  
During GFR measurement, ensuring that values obtained for T½ and VD are within defined 
reference ranges was regarded as an important QC check in the original (2004) BNMS 
guideline (Fleming et al. 2004). Subsequent to the publication of paper 1, questions have been 
raised about the utility of GFR QC parameters. McMeekin et al. evaluated the effectiveness of 
various commonly used QC checks, including VD (McMeekin et al. 2016b). In this study 
measurement errors were classified into 3 categories: (1) model failure errors (failure of the 
simplified, single-compartment method e.g. in a patient with ascites); (2) whole curve errors 
(measurement errors that affect the whole curve in the same way e.g. due to an error in the 
standard or inaccuracy in measuring the administered activity); and (3) individual point errors 
(errors in the plasma samples e.g. due to inaccurate recording of time or inaccurate pipetting). 
The conclusion was that all conventional QC checks have poor sensitivity and positive 
predictive value for detecting clinically significant errors in SI-GFR and SS-GFR (McMeekin 
et al. 2016b). However, the authors point out that due to its design, it was unable to detect type 
2 (whole curve) errors, and only 1 out of 412 GFR tests had a type 3 (individual point) error.  
In 2018, an updated GFR guideline was released by the BNMS (Burniston 2018). Based on the 
findings of the McMeekin paper (McMeekin et al. 2016b) and another paper published by the 
same authors in parallel (McMeekin et al. 2016a), SS-GFR is recommended as the preferred 
method in the new guideline. Thus, QC checks such as VD would fall away in the majority of 
GFR measurements. In 2019 Klein et al (Klein et al. 2019) provided a SI-GFR spreadsheet as 
a useful tool with many embedded QC checks, however, VD was not included. 
While there is evidence that as a QC measure VD can be both non-specific and insensitive 
(McMeekin et al. 2016b), we are of the opinion that in specific scenarios and if interpreted 
optimally, VD may still contribute to QC of SI-GFR. We are unaware of work addressing gross 
human errors, e.g. mixing up of patient samples or misinjections. These mishaps, or ‘blunders’, 
frequently result in grossly erroneous GFR results that may be difficult to detect using SS-
GFR. Our experience in a busy clinical department where GFR measurements are performed 
by one of several generically functioning radiographers or by trainees under supervision is that 
despite attempts to eliminate them, infrequent but clinically potentially catastrophic type 2 and 
3 errors still occur. When this happens, the causes are typically related to significant procedural 
Stellenbosch University https://scholar.sun.ac.za
 107 
 
or patient identification errors that are often large and clearly detected using the battery of QC 
checks that are in place, including VD. 
The reference ranges that were defined for T½ and VD were based on the mean ± 2 SD (Holness 
et al. 2013). As for any reference range, the use of 2 SD error limits will result in 5% of normal 
studies falling outside of the range. One in twenty GFR measurements would thus fail this QC 
test and would need to be repeated, an unacceptably high proportion. The specificity can be 
increased by increasing the error limits to 2.5 SD or 3 SD, but this would come at the expense 
of sensitivity, with the risk of providing a false sense of security to the nuclear medicine 
physician. Further research would be useful to define an optimal threshold. 
A further potential criticism of the reference ranges defined in paper 1 (Holness et al. 2013) is 
that they were derived from a healthy population with normal kidney function. A concern raised  
by Klein et al (Klein et al. 2019) is whether these reference ranges are valid for QC of GFR 
tests performed for patients with serious disease e.g. cancer, or in individuals with reduced 
kidney function. Current work in our unit is attempting to address these questions. Using the 
dataset of paper 3 (786 3-sample SI-GFR measurements in individuals with various pathologies 
and GFR values across the full range), the reference range for VD using 2.5 SD error limits was 
found to be applicable with only 1.9% of studies giving false positive results for VD 
(unpublished data). These results require confirmation however. 
In the 2004 BNMS guideline the T½ was noted to be ‘typically within’ 100-120 min in a person 
with normal GFR (Fleming et al. 2004), but no guidance was provided on the use of T½ as a 
QC test if GFR was decreased. Paper 1 provided a GFR-dependent reference range for T½. 
However, the usefulness of this as a QC test is yet to be evaluated. 
99mTc-DTPA vs 51Cr-EDTA 
As a secondary aim in paper 1, we defined reference data for 99mTc-DTPA GFR. For adults < 
40 years, mean GFR was 108 ml/min/1.73 m2. Thereafter, it decreased at a rate of 1.55 
ml/min/1.73 m2 per year. 
In paper 2, we performed a mini meta-analysis of the data of 3 previous studies directly 
comparing the plasma clearance of 99mTc-DTPA and 51Cr-EDTA (Holness et al. 2015). The 
methods were found to agree well, with median bias < 1%, P30 = 93%, and P10 = 72%.  
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The 99mTc-DTPA GFR reference range defined in paper 1 (Holness et al. 2013) agreed 
reasonably well with the reference data that was available at that time (Granerus and Aurell 
1981; Hamilton et al. 2000; Grewal and Blake 2005a). Limitations of our study though were 
the small sample size and the lack of individuals > 40 years. In 2017, the data from paper 1 
was included in a meta-analysis comprising 5482 healthy, potential kidney donors from 12 
independent studies (Pottel et al. 2017). GFR was measured using a variety of tracers (51Cr-
EDTA 3667, iothalamate 1305, inulin 332, 99mTc-DTPA 126, and iohexol 52). Mean GFR was 
found to be ~107 ml/min/1.73 m2 in individuals < 40 years, and decreased at a rate of 0.89 
ml/min/1.73 m2 per year in individuals > 40 years. Differences in mean GFR were observed in 
the 12 included studies, and were thought to be due to a combination of systematic differences 
in the clearance of the various filtration markers and major differences in methodology and/or 
calculation method.   
Although already in the 2004 BNMS guidelines 99mTc-DTPA was stated to be an acceptable 
radiopharmaceutical for GFR measurement, there are still members of the Nuclear Medicine 
and wider clinical community that question its reliability over alternatives such as 51Cr-EDTA. 
Furthermore, doubts were raised about the use of 99mTc-DTPA to measure GFR in a systematic 
review that compared the plasma and urinary clearance of various exogenous filtration markers 
to urinary inulin clearance (Soveri et al. 2014). The plasma clearance of 99mTc-DTPA was 
concluded to be an inaccurate method. However, this was based on the results of two relatively 
old and methodologically questionable studies that compared plasma 99mTc-DTPA clearance 
to urinary inulin clearance head to head (the requirement for inclusion in the review). Its 
conclusions were reached without considering literature supporting the use of 99mTc-DTPA, 
based on studies that compared 99mTc-DTPA with other tracers. The results of our mini meta-
analysis of data from 3 published studies comparing plasma clearance of 99mTc-DTPA and 
51Cr-EDTA confirmed that there is excellent agreement between them (Holness et al. 2015). 
This has become particularly relevant recently as production of 51Cr-EDTA has been 
discontinued by the major global supplier forcing departments to find an alternative. Given its 
availability, relatively low cost, and the methodology being identical to that of 51Cr-EDTA, it 
is a simple adaptation for affected centres to change to 99mTc-DTPA. The availability of 
reference data for 99mTc-DTPA plasma clearance (Holness et al. 2013), combined more 
importantly with the demonstrated comparability with 51Cr-EDTA (Holness et al. 2015; Pottel 
et al. 2017), provides evidence in support of this transition.  
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mGFR as the ground truth 
In studies that validate the performance of eGFR equations, mGFR serves as the reference 
technique against which eGFR is compared. Irrespective of the tracer or method used, mGFR 
is regarded as the gold standard. Consequently, there is an assumption that errors in eGFR are 
solely due to failure of the estimating equations in that population. The contribution of errors 
in mGFR and biological variation are seldom considered. A reason for this may be that eGFR 
validation studies are frequently conducted by clinicians who may have limited understanding 
of the intricacies of GFR measurement.  
As GFR cannot be measured directly in humans, ‘true’ GFR is never known (Levey and Inker 
2016). Thus, whether GFR is assessed using clearance methods (mGFR) or estimating 
equations (eGFR), the error compared to true GFR cannot be quantified. It is well known that 
the urinary clearance of inulin provides the most accurate measure of GFR (Brenner and Levine 
2008), and that there are systematic differences in the clearance of other tracers compared to 
inulin (Soveri et al. 2014). The use of a simplified technique (e.g. SI-GFR or SS-GFR) is likely 
to result in a further deviation from true GFR. It follows that in studies developing new 
estimating equations, in order to approximate true GFR as closely as possible, the most accurate 
mGFR method available should be selected, and the measurements performed with the utmost 
precision. However, even with the most accurate technique, there will always be some 
systematic and random error against the ground truth.  
In eGFR validation studies, error is measured as eGFR-mGFR. This difference, typically used 
as a proxy for eGFR error, overestimates eGFR errors relative to the ground truth and is really 
a combination of 3 independent sources of error: 
1. eGFR error (relative to the true GFR) 
2. mGFR error (relative to the true GFR) 
3. biological variation of the true GFR 
There are two components to eGFR error: (i) error in Scr measurement and (ii) error in the  
model. Error in Scr measurement is both systematic and random, however it is relatively small 
in magnitude. Routine standardization of Scr assays has minimised the large systematic 
differences that existed previously between different laboratories (Myers et al. 2006). Random 
errors vary depending on the method (enzymatic vs. Jaffe), however these are quantifiable and 
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values are readily available from the laboratory (Delanaye et al. 2017). For example, the 
analytical imprecision of the Roche Cobas 6000 analyser (enzymatic) used in our laboratory is 
1.9% at Scr=90.5 µmol/L, and 1.3% at 327.9 µmol/L. On the other hand, the error in the model 
is difficult to quantify and an estimate can only be made after consideration of all other sources 
of error. 
There are also two main components to error in mGFR: (i) measurement errors and (ii) errors 
inherent to the method. In paper 3 measurement errors were found to have a relatively small 
impact on GFR, however they had an increasingly significant effect as GFR decreased. In a 
prospective eGFR validation study, it is plausible to keep measurement errors to a minimum. 
This is achieved by strict adherence to protocols, use of high-precision equipment and, in 
particular, use of a dedicated, well-trained research team. In contrast, there is frequently little 
control over mGFR methodology in retrospective studies or in validation studies initiated by a 
department that does not perform the GFR measurements itself.  
Errors inherent to the method include the choice of tracer and calculation technique. At this 
point it must be emphasized that the importance of these errors lies in the differences in tracer 
or technique between the validation and development studies, rather than deviations from true 
GFR. For the development of the existing eGFR equations a variety of tracers and techniques 
were used. Those assessed in this dissertation are listed in Table 7.1. Use of a tracer different 
to the tracer used in the development study will result in systematic errors. In most cases, this 
bias has been quantified previously, either by direct comparison, or indirectly as in the 
systematic review by Soveri et al (Soveri et al. 2014). 
Use of a different calculation technique will introduce both systematic and random errors. The 
errors will vary in magnitude depending on the technique used. In paper 5, the results of 
previous studies conducted in adult cancer patients were not compared for this reason. For 
example, in two of the more recent papers (Lauritsen et al. 2014; Hartlev et al. 2012) the single-
sample technique described by Groth and Aasted was used (Groth and Aasted 1981). 
Subsequently, this technique has been shown to be inaccurate when compared to GFR 
measured from the full area under the plasma clearance curve with median bias of 11 
ml/min/1.73 m2, and 24% of measurements differing from the reference GFR values by > 20% 
(McMeekin et al. 2016a).  
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Other differences in mGFR methodology between development and validation studies, such as 
the method to calculate BSA or to correct for the missing first exponential (SI-GFR), will also 
result in systematic and random errors. These errors would best be modelled using full AUC 
reference data. However, use of the dataset of paper 3 provides an idea of their magnitude. 
Three-point SI-GFR (2, 3, 4 h), using the Haycock formula to correct for BSA (Haycock et al. 
1978) and the mean Bröchner-Mortensen equation to correct for the one-pool assumption 
(Fleming et al. 2004), served as the reference for each of the 786 GFR measurements. A widely 
used alternative BSA formula, the DuBois and DuBois equation (DuBois and DuBois 1989), 
resulted in small, insignificant systematic and random errors in GFR, with a median error of -
1.0 ml/min/1.73 m2 and IQR of 0.3 ml/min/1.73 m2. Use of alternative formulae to correct for 
the one-pool assumption (Bröchner-Mortensen 1972; Bröchner-Mortensen et al. 1974; Jodal 
and Bröchner-Mortensen 2009) also resulted in small systematic errors ranging between -1.5 
and 1.1 ml/min/1.73 m2. However, the random errors were larger (IQRs ranging from 1.9 to 
13.6 ml/min/1.73 m2). 
The third component of the error in eGFR-mGFR is the intra-individual biological variation 
between Scr and GFR measurements. It contributes to the imprecision of GFR estimates. For 
Scr the CV for biological variation is 4.3-6.0% (Delanaye et al. 2017). For GFR the biological 
variation is not known. Values of 7.5-12.2% reported in the literature are measures of 
repeatability (Bröchner-Mortensen and Rödbro 1976; Wilkinson et al. 1990; Blake et al. 1997; 
Grewal and Blake 2005; Delanaye et al. 2008a; Bird et al. 2008). However, in paper 3, using 
the calculated values for measurement error, the biological variation of GFR was estimated to 
be 2.8-11.0%. The contribution of biological variation to error in eGFR is applicable only to 
studies in which Scr and GFR are measured on different days, as in paper 5. Ideally, in 
validation studies GFR and Scr should be measured simultaneously. However, this is not 
always feasible and is impossible to ensure in retrospective studies. 
Like many studies in the literature, papers 4, 5 and 6 made the assumption that errors in GFR 
estimation are solely due to errors in the model (eGFR equation). The contribution of errors in 
mGFR, biological variation, and Scr measurement was not quantified in these papers. 
Supporting this assumption are the results of paper 6. The errors in mGFR, biological variation 
and Scr measurement are expected to be similar in magnitude for the non-cancer and cancer 
groups, therefore the finding of significant differences in bias and precision between the groups 
is consistent with poor performance of the model in the cancer group. However, it would be a 
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useful adjunct to existing literature to perform a more rigorous evaluation of the effects of error 
in mGFR, biological variation and Scr measurement in eGFR evaluations. 
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Table 7.1 Methods for measuring GFR in equation development studies 
Equation Filtration marker Sampling and calculation algorithm 
MDRD Iothalamate urinary 
clearance 
Subcutaneous injection without epinephrine 
1 h equilibration period 
4 consecutive urine samples & 5 plasma samples 
CKD-EPI Iothalamate urinary 
clearance 
Various (multiple databases) 
Cockcroft-Gault Creatinine clearance 24-hour urine collection 
Creatinine measured using continuous flow analysis 
Janowitz Williams 51Cr-EDTA plasma 
clearance 
3 plasma samples 
Details not specified 
Schwartz formula Iohexol plasma 
clearance 
Full AUC 
Sample times: 10, 30, 120, 300 min (Schwartz et al. 
2006) 
HPLC to measure plasma concentrations 
Flanders metadata 
equation 
51Cr-EDTA plasma 
clearance 
SS-GFR (Ham and Piepsz 2008) 
Sample time: 120 min 
Schwartz-Lyon equation Inulin urinary 
clearance 
Priming dose, then continuous infusion 
3-4 urine and plasma samples 
Enzymatic method to measure plasma & urinary 
concentrations (Dubourg et al. 2010) 
Simple height 
independent equation 
51Cr-EDTA plasma 
clearance 
SS-GFR (Ham and Piepsz 2008) 
Sample time: 120 min 
Q(age) and Q(height) 51Cr-EDTA plasma 
clearance 
SS-GFR (Ham and Piepsz 2008) 
Sample time: 120 min 
CKiD univariate 
equation 
Iohexol plasma 
clearance 
Group 1: full AUC 
Sample times: 10, 30, 120, 300 min (Schwartz et al. 
2006) 
Group 2: Technique described by Ng (Ng et al. 2011) 
Sample times: 120, 240, 300 min  
Gao’s quadratic formula Inulin urinary 
clearance 
Details not specified 
Anthrone test to measure plasma & urinary 
concentrations 
Japanese equation Inulin urinary 
clearance 
Priming dose, then continuous infusion 
2 urine samples: 60, 120 min  
Enzymatic method to measure plasma & urinary 
concentrations 
FAS(age) and 
FAS(height) 
(i) Iohexol plasma 
clearance* 
(ii) Inulin urinary 
clearance 
(i) SI-GFR with Brochner-Mortensen correction* 
Sample times: 120, 180, 240 min 
(ii) Technique described by Dubourg (Dubourg et al. 
2010) 
*Tracers and methods used in the paediatric databases only. 
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Abbreviations: MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease 
Epidemiology Collaboration; CKiD, Chronic Kidney Disease in Children; FAS, full age spectrum;  
AUC, area under the curve;  HPLC,  high performance liquid chromatography; SS-GFR, single-
sample glomerular filtration rate;  SI-GFR, slope-intercept glomerular filtration rate.
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eGFR in South African populations 
In paper 4, the performance of the MDRD and CKD-EPI equations was evaluated in a mixed 
ancestry adult population comprising healthy individuals and patients with CKD. Both 
equations performed reasonably well, with no significant difference between the two. The P30 
of the MDRD equation was 80% and the CKD-EPI 72.5%.  
Consistent with previous publications (van Deventer et al. 2008; Stevens et al. 2011; Madala 
et al. 2011), inclusion of the ethnicity factors derived for African Americans resulted in a 
decrease in accuracy of both equations.   
In paper 5, the performance of four creatinine based GFR estimating equations was evaluated 
in 435 adults with cancer. The agreement of all the equations with measured GFR was poor, 
and all the equations over-estimated mGFR. The over-estimation suggests lower Scr levels on 
average in this population, which is largely secondary to the cancer itself. However, the degree 
of over-estimation which is greater than that found in previous non-South African studies, is 
likely to reflect poorer nutrition (lower protein intake), possibly combined with greater muscle 
wasting due to more advanced disease. Three of the equations had moderate accuracy (60-80%) 
in this population, while the accuracy of the fourth was poor (< 60%). The Janowitz-Williams 
equation, developed specifically for cancer patients, was the most accurate.  
In paper 6, eleven GFR estimating equations were evaluated in non-cancer and cancer 
paediatric populations. In both groups all the equations over-estimated GFR, with a larger bias 
in the cancer group. None of the equations had good (> 80%) accuracy. In the non-cancer 
group, the accuracy of 7/11 equations was moderate, while in 4/11 it was poor. In the cancer 
group 9/11 equations had poor accuracy.  
It was hypothesized that the GFR estimating equations would perform poorly in all the studied 
populations and that ethnicity would be the major predictive factor. Consequently, the results 
of paper 4 were surprising. The MDRD and CKD-EPI equations performed reasonably well in 
this population. The accuracy of the MDRD equation was in fact comparable to some of the 
largest international validation studies (Levey et al. 2009; Earley et al. 2012). It is clear that in 
some populations ethnicity is important. The most well-established of these is in African-
Americans in whom ethnicity has been shown to be an independent predictor of higher GFR 
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(Levey et al. 1999). However, for our mixed ancestry adult population the results suggest that 
despite their diverse ethnicity, equations derived from pathologically similar, largely White 
populations are still useful. This is interesting in light of the generally poorer results in Black 
and Indian South Africans (Madala et al. 2011; Moodley et al. 2018). 
Pathology and mean GFR are two factors that have been shown to affect the performance of 
eGFR (Stevens et al. 2010). Ideally, a multivariate analysis looking at the accuracy of eGFR in 
various categories (e.g. GFR, pathology, and BMI) would have been performed, but this was 
not possible due to the relatively small sizes of each of the subgroups. The fact that the 
population in paper 4 closely resembled the original MDRD equation development set, with 
mean GFR < 60 ml/min/.73 m2 and CKD being present in the majority of participants, is the 
most likely reason for the good performance of the MDRD equation in particular.  
In general, the performance of eGFR in adults and children with cancer was worse than in the 
non-cancer groups. Reasons for the greater bias and poorer precision in the cancer groups have 
been discussed in the respective papers. If pathology was the only contributing factor, it is 
likely that all the equations derived from non-cancer populations would have performed better 
in populations without cancer. However, this was not the case, and in both adult and paediatric 
populations, there were some exceptions. In the adult non-cancer population (paper 4), the 
CKD-EPI equation was found to have a P30 value of 72.5%, similar to the 69.7% found in the 
adult cancer population (paper 5) (p=0.6). Similarly, in children (paper 6), the P30 values of 
Gao’s QF and the CKiD equation did not differ significantly between the non-cancer and 
cancer groups (p=0.8 and p=0.1 respectively). While differences may have become apparent 
with greater statistical power, it is likely that there are other factors that these three equations 
are better able to correct for. In our populations differences in mean GFR is the most likely 
secondary cause. The mean GFRs were significantly higher in the adult and paediatric cancer 
groups compared to the non-cancer groups. Looking at the origins of these equations may 
explain why they are better suited than other equations. The CKD-EPI and CKiD equations are 
modifications that were developed to improve the performance of the MDRD and Schwartz 
equations respectively, in individuals with normal or high GFR (Stevens et al. 2007a; Levey et 
al. 2009; Pottel et al. 2010; Schwartz et al. 2012). Likewise, Gao et al (Gao et al. 2012) 
developed their equation to improve performance across the entire GFR range.  
A recurring message in papers 4-6 is that interpreting an eGFR is not necessarily 
straightforward and is highly dependent on the clinical setting. In some settings, such as in the 
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management of patients with CKD, an eGFR result based on an equation with P30 = 80% is 
adequate (KDIGO 2013). Based on the results of paper 4, for detection of individuals with GFR 
< 60 ml/min/1.73m2, both equations had sensitivities of 97% and specificities 83-88%. 
However, the same degree of uncertainty would be unacceptable in a potential kidney donor. 
Similarly, in cancer patients binary decisions are frequently made based on the GFR result. For 
example, cisplatin is usually only administered if the GFR exceeds 60 ml/min/1.73 m2. Based 
on the data from these studies, relying on eGFR will result in a large proportion of patients 
being misclassified and either being exposed to high risk of nephrotoxicity, or being denied 
potentially life-saving treatment. In these cases, there is no satisfactory alternative to measuring 
GFR. It can be argued that providing a 95% CI alongside every GFR estimate would provide 
more clarity on the information it provides. However, clinicians are unlikely to find this useful. 
The 95% CIs in two of our populations were extremely wide, which means for example that 
only when the eGFR result is high (> 90 ml/min/1.73 m2) can impaired kidney function reliably 
be excluded.  
Estimated GFR is also frequently used in epidemiological studies to determine the prevalence 
of CKD in a population. Based on the adult non-cancer study (paper 4), the sensitivity of eGFR 
for detecting low GFR (< 60 ml/min/1.73 m2) was > 97%. However, these values were based 
on a population with a high prevalence of CKD, whereas epidemiological studies are conducted 
in populations with low prevalence. In this context, the result of the adult non-cancer study 
thus needs to be interpreted with caution. To determine the true utility of eGFR as a screening 
test for CKD, a large study comparing eGFR to mGFR in a healthy, non-hospital population 
would be required. However, logistically this would be very difficult. Pooling CKD patients 
with potential kidney donors, while controlling for confounders, would be a more practical 
alternative. 
Adapting eGFR for local populations 
In paper 4, where the existing MDRD and CKD-EPI equations both provided reasonable 
estimates of mGFR, the equations were not adapted.  
Adapting the equations for adults with cancer significantly improved their accuracy. The P30 
values improved from 57-74% to 78-83%, with 3/4 of the adapted equations having good (> 
80%) accuracy. However, despite adaptation, all equations still had poor sensitivity (< 50%) 
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for detecting individuals with GFR < 60 ml/min/1.73 m2, an important requirement in the 
clinical management of these patients. The 95% confidence intervals of the adapted estimates 
were wide. Using the original equations, 28-46% of patients would have received carboplatin 
doses that were incorrect, with only a modest improvement using the adapted estimates. 
Adapting the equations for paediatric populations resulted in significant reductions in bias in 
3/4 equations in non-cancer patients, and 4/4 equations in cancer patients. In both patient 
groups, accuracy of 3/4 adapted equations was good, and moderate in 1/4. 
Before using eGFR in clinical practice, the performance of the equation/s should be validated 
in that population. In some of the larger independent validation studies, or in their own 
validation populations, the P30 values of the MDRD, CKD-EPI and CKiD equations ranged 
between 80% and 84% (Stevens et al. 2007a; Levey et al. 2009; Stevens et al. 2011; Schwartz 
et al. 2012). It is not expected that the accuracy will exceed these values in populations 
elsewhere, but it is reasonable to use them as an indication of optimal performance. If the 
accuracy of the tested equation is found to be inadequate, adapting the parameters of the 
equation can be reasonably easily achieved using a Microsoft® Excel-based tool. The 
methodology for this has been described in papers 5 and 6. In paper 4, where the original 
MDRD and CKD-EPI equations were found to perform adequately, adaptation offered no 
advantage (results not given in the published paper). However, in the adult cancer, paediatric 
non-cancer and paediatric cancer groups, adaptation offered a significant improvement and 
resulted in good accuracy of 3/4 equations in each group.  
The use of unvalidated and potentially invalid eGFR equations is unacceptable in populations 
in which published equations are unlikely to perform well. However, in many such centres the 
routine use of mGFR or the setting up of large studies to develop local versions of eGFR 
equations is unrealistic. In this scenario a relatively simple adaptation requiring modest 
amounts of data may provide a practical alternative. In our cancer population, the minimum 
number of cases required for a satisfactory adaptation was found to be 40-50 (unpublished 
data). Unfortunately, the centres that rely on eGFR exclusively are frequently also those 
without any access to GFR measurement, and validating and adapting equations requires at 
least some access. A solution may be collaboration between state and private institutions 
serving similar patient populations.  
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Conclusion and future directions 
The intention of GFR measurement or estimation is to provide a value that is as close to the 
patient’s true GFR as possible. Many factors, including the tracer used, the choice of 
calculation method, and errors in measurements, may cause deviations from true GFR.  
GFR measurement 
The first part of this dissertation focused on improving GFR measurement. 
Reference data were defined for two QC parameters that may be used to check the result of SI-
GFR. However, the low sensitivity of all conventional post-calculation QC tests shown by 
McMeekin et al (McMeekin et al. 2016)has raised the question of whether QC tests should be 
used at all and if so, which ones?  
Reference data for 99mTc-DTPA GFR were defined. The data from this study were included in 
a subsequent meta-analysis (Pottel et al. 2017). 
Re-analysis of data from direct comparisons of 51Cr-EDTA and 99mTc-DTPA demonstrated 
good agreement, thus providing evidence to support a change from 51Cr-EDTA to 99mTc-
DTPA. This is particularly relevant currently considering to the global unavailability of 51Cr-
EDTA. 
Paper 3 provided a comprehensive assessment of the impact of measurement errors on GFR: 
• The sources of measurement errors that occur during GFR measurement were 
identified, and their relative importance was assessed.  
• The overall impact of measurement errors on the GFR result was determined and 
compared to expected biological variation in GFR.  
• Practical guidance was provided in the form of recommendations for maximum 
allowable measurement errors, and ways to minimise measurement error. 
• The most robust GFR calculation methods were identified, under different 
circumstances. 
• The interpretation of changes in GFR over serial studies was discussed. 
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These results, in conjunction with the BNMS guideline recommendations (Burniston et al. 
2018), are likely to improve the precision of GFR measurements. However, it must again be 
noted that this study did not assess the systematic errors, often larger in magnitude, that arise 
from use of a simplified method to calculate GFR, as opposed to calculation of GFR from the 
area under the full plasma clearance curve, as this has been addressed previously (Bird et al. 
2007; McMeekin et al. 2016a).  
Estimated GFR 
The performance of estimated GFR is known to be population specific. The second part of this 
dissertation evaluated eGFR in local populations and demonstrated a simple technique for 
adapting the estimating equations to improve performance: 
The need to first validate eGFR in a population before using it clinically was highlighted.  
Estimated GFR was shown to perform adequately in a local, mixed ancestry renal population. 
This study was instigated in response to a request from nephrologists to validate eGFR locally 
as it is used routinely in their clinics. The results are therefore reassuring. 
In local adult cancer and paediatric populations eGFR was shown to perform poorly. These 
papers are yet to be submitted for publication, but the intention is to disseminate the results to 
local oncologists and paediatricians who use eGFR, with the intention of improving local 
practice. 
A technique for adapting existing estimation equations was demonstrated with an improvement 
in performance being shown in most cases. This methodology may offer a realistic alternative 
to developing new equations in other centres where existing equations are shown to be invalid.  
Practical suggestions were provided for interpreting an eGFR result taking cognisance of the 
inherent uncertainty associated with GFR estimates.  
A limitation of the three eGFR studies is that being based in specific local populations limits 
the generalisability of the results. However, these studies were initiated in response to questions 
raised by clinicians about the validity of eGFR in their populations. The results are therefore 
likely to influence and enhance local practice. 
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Future research 
This work raises new questions that require further research. 
1. QC of mGFR 
Klein et al (Klein et al. 2019) recommended a series of QC checks, that are not biologically 
based, that their department has found useful. These include an assessment of duplicate sample 
count differences, the correlation coefficient, and the counts-activity-ratio (CAR), as well as a 
batch of range checks for measurements such as BSA, injected activity, residual activity in 
syringes etc. Initially, local normal ranges for these QC parameters need to be defined using a 
departmental GFR database. This would be expected to further improve the accuracy of the 
GFR measurements being performed in a department. Thereafter, it would be useful to establish 
the sensitivity of these tests for detecting significant errors in GFR. 
When defining a reference range for any QC parameter, practical consideration needs to be 
given as to what the optimal range should be. Broader ranges (e.g. 2.5 or 3 SD of the mean) 
tend to increase the specificity of the test but at the expense of sensitivity. An approach 
suggested by Klein et al (Klein et al. 2019) is a two-tiered system of warning and error ranges. 
The ranges for their QC parameters were based on false positive rates of 1:20 for a warning 
and 1:1000 for an error. A GFR measurement in which one of the QC parameters falls outside 
its error range requires repeating, whereas a QC parameter that falls outside the warning range 
requires review but is accepted if no error can be found. This may be a useful approach but 
requires further validation. 
A well-designed study analysing the sensitivity of VD, T½ and other ancillary QC checks 
specifically for detecting type 2 (whole curve) and type 3 (individual point) measurement errors 
is required. The results may assist nuclear physicians/physicists in deciding what method to 
use in their departments for measuring GFR. If for QC purposes, they do indeed prove to have 
poor sensitivity, this would provide further support for the decision to switch to methodologies 
that do not provide these QC parameters.  
We have begun to address this issue in a post-hoc analysis of VD. Using the dataset of paper 3 
(786 3-sample GFR measurements), we introduced errors of varying size to (i) the standard 
counts (type 2) or (ii) one of the sample counts (type 3). Only “plausible” studies (i.e. GFR 
between 0 and 160 ml/min/1.73 m2 and sample counts progressively decreasing with time) 
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were included. GFR errors > 20% were considered significant. Cases in which VD in litres was 
beyond our 2.5 SD reference range (Holness et al. 2013) were considered positive. GFR 
changed significantly for type 2 errors > 20%. For gross errors in the standard (< -50% or > 
120%) VD had a sensitivity of > 80%. For significant type 3 errors, the correlation coefficient 
(r < 0.985) was an excellent QC check, far more sensitive than VD. For the 2-sample SI-GFR 
(where the correlation coefficient cannot be used), VD had a sensitivity of > 80% for large 
errors of the 2- or 3-hour samples (< -50% or > 40%). These early findings suggest that for SI-
GFR measurements based on only 2 samples, or performed without injection site imaging, VD 
is of some value for the detection of large type 2 and type 3 errors that may not be detectable 
by other means (unpublished data). While this preliminary work suggests that VD may only be 
sensitive for larger errors, this may not equate to VD being of little utility as a QC check as, in 
our experience at least, the real world blunders that give rise to type 2 and 3 errors are often 
crude enough to be flagged by an abnormal VD, without being detectable from looking at the 
incorrect mGFR result. While these events should be infrequent, they are probably impossible 
to completely eliminate, and can be potentially devastating for the affected patient. 
The 2004 BNMS guideline (Fleming et al. 2004) suggested a minimum value of 0.985 for the 
correlation coefficient, whereas McMeekin et al (McMeekin et al. 2016) in a receiver operating 
curve (ROC) analysis found no cut-off value to be adequate for detecting inaccurate SI-GFR 
values. However, Klein et al (Klein et al. 2019) highlighted the dependence of the correlation 
coefficient on GFR and suggested further work to define a GFR-dependent lower limit. This 
would be worth exploring. 
In the updated BNMS guideline (Burniston 2018) the possibility was raised of using eGFR as 
a QC check for GFR measurements. An advantage of this interesting approach is that eGFR is 
independent of mGFR and can therefore be used to check any method.  Further research could 
provide insights into how to use it optimally, and how effective it would be.  
2. Measurement error at low GFR (< 50 ml/min/1.73 m2) 
The 2018 guideline suggests taking blood samples for SS-GFR at 6 h (when GFR is 25 to 50 
ml/min/1.73 m2) or at 24 h (when GFR < 25 ml/min/1.73 m2) (Burniston 2018). In paper 3, 
measurement errors were found to have a significant effect on SS-GFR when GFR fell below 
50 ml/min/1.73 m2. However, SS-GFR based only on earlier sampling times (3 h and 4 h) was 
assessed in this study. It is possible that sampling at the recommended times will address the 
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significant errors in SS-GFR, but this will require further research. Similarly, later blood 
sampling has been recommended for SI-GFR in cases of low GFR (Fleming et al. 2004). 
Whether this would reduce the impact of measurement errors on the GFR result would also 
require further research. 
Although the radiochemical purity of a 99mTc-DTPA preparation is usually very high (> 97%), 
one of the impurities that exists is free pertechnetate (99mTcO4
-). Its presence in a plasma sample 
in these low levels is unlikely to have a significant effect on the final GFR result. Sampling at 
24 h assumes in-vivo stability of the radiopharmaceutical in which case the effect of free 
pertechnetate will remain negligible, particularly in cases of poor kidney function. Modern 
99mTc-DTPA kits are likely to be stable, however it is prudent to prove this as there were reports 
of instability of some earlier kits (Millar 1983). This is also applicable to GFR measurements 
for patients with normal kidney function but expanded ECV (e.g. due to oedema or ascites) as 
the methodology requires 24 h blood sampling (Burniston 2018; Wickham et al. 2013; 
Wickham et al. 2015). 
3. Repeatability of GFR 
In paper 3, the CV of repeat GFR measurements was explored. Values ranging between 7.5% 
and 12% were found in the literature (Bröchner-Mortensen and Rödbro 1976a; Wilkinson et 
al. 1990; Blake et al. 1997a; Grewal and Blake 2005b; Delanaye et al. 2008b; Bird et al. 2008). 
A consequence of these high values is that GFR has to decrease by > 20% before the change 
can be regarded as significant (Fleming et al. 2004), and decreases of < 20% necessitate repeat 
measurements after a few months for confirmation. However, this recommendation and the 
evidence on which it was based raises a couple of issues. Firstly, a 20% change translates to a 
decrease of only 5 ml/min/1.73 m2 if the GFR is 25 ml/min/1.73 m2, whereas for a GFR of 100 
ml/min/1.73 m2, it would be 20 ml/min/1.73 m2. It may be more useful to express significant 
changes in absolute terms. Secondly, in one study exercise and a lack of fasting were found to 
increase the variability of repeat GFR measurements (Wilkinson et al. 1990). In South Africa, 
transport to and from the hospital is a challenge for the majority of patients, and frequently 
entails waking up early and walking many kilometres. Restricting exercise and food prior to 
GFR measurement as recommended in the guidelines is thus often difficult to implement. A 
study measuring the intra-patient variability of GFR in a South African population, without 
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restricting diet or exercise, and expressing the variability in absolute terms, may therefore be a 
useful contribution to local practice at least. 
4. Analysis of error in eGFR  
A study quantifying and/or reviewing the contribution of errors in mGFR and Scr measurement 
to the observed systematic and random errors in GFR estimates would allow more meaningful 
interpretation of eGFR validation study results and possibly also lead to an improvement in the 
quality of GFR measurement in validation studies. More sophisticated assessments of eGFR 
performance, incorporating our knowledge of mGFR errors and biological variation, would be 
expected to provide better measures of eGFR error. Development of these techniques is an area 
of potential future research. 
5. Utilisation of eGFR as a clinical tool: 
In some clinical settings the use of eGFR is well established e.g. in the follow-up of patients 
with CKD, however there are specific clinical scenarios where further research is required to 
critically evaluate the use of eGFR given the uncertainty that accompanies the estimates, even 
for equations that are well suited to the population in which they are applied. The first of these 
is when binary treatment decisions are made based on whether eGFR is above or below 60 
ml/min/1.73 m2 e.g. for the administration of cisplatin in cancer patients. Another scenario is 
in the follow-up of cancer patients being treated with nephrotoxic chemotherapy. Previous 
studies have shown eGFR to be insensitive for detecting changes in kidney function (Hartlev 
et al. 2012; Lauritsen et al. 2014). Further work is required to confirm or refute this in local 
populations, and to determine the sensitivity of locally adapted equations for detecting changes. 
Finally, although the MDRD and CKD-EPI equations were shown to perform reasonably well 
in adults with CKD, further work is required to determine the sensitivity of eGFR as a screening 
test for CKD and its accuracy for determining the prevalence of CKD in community-based 
epidemiological studies. 
6. Local adaptation of eGFR equations: 
A relatively simple technique for adaptation of eGFR to local populations was introduced in 
papers 5 and 6 that was able to provide improved performance in independent data. However, 
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it requires more extensive and statistically rigorous evaluation of its potential limitations and 
practical implementation e.g. minimum patient numbers. 
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